Pyridone modulators of DCN-1 and methods of use thereof

Pyridone modulators of DCN-1 are developed to treat hemoglobin-related disorders by modulating DCN-1 activity and inducing fetal hemoglobin production, effectively addressing the underlying causes of sickle cell disorders and thalassemia.

WO2026236356A1PCT designated stage Publication Date: 2026-11-12CELLARITY INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026892
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a need for therapeutic agents and methods to treat hemoglobin-related disorders such as sickle cell disorders and thalassemia, as existing treatments are inadequate in addressing the underlying causes of these conditions.

Method used

Development of pyridone modulators of DCN-1, which can modulate DCN-1 activity and induce fetal hemoglobin production, thereby addressing the root cause of these disorders.

Benefits of technology

The pyridone modulators effectively treat hemoglobin-related disorders by increasing fetal hemoglobin levels, improving oxygen delivery and reducing complications associated with sickle cell disease and thalassemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026892_12112026_PF_FP_ABST
    Figure US2026026892_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides DCN-1 modulating compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions, and their use for treating sickle cell disorders, diseases, and conditions. Such compounds are of Formula I: or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

PYRIDONE MODULATORS OF DCN-1 AND METHODS OF USE THEREOFCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U. S. C. §119(e) of U. S. Provisional Application No. 63 / 801,484 filed on May 7, 2025, the entirety of which is incorporated herein by reference.TECHNICAL FIELD OF THE INVENTION

[0002] The present disclosure relates generally to various compounds and compositions useful in the treatment of hemoglobin-related disorders including sickle cell disorders, diseases, and conditions, and thalassemia.BACKGROUND OF THE INVENTION

[0003] Hemoglobinopathies are diseases that affect hemoglobin that include sickle cell disease and thalassemia. Sickle cell disease or disorder is a group of inherited red blood cell disorders that affect hemoglobin and can block blood flow to the body. Specifically, a defective beta hemoglobin chain in sickle cell patients twists and changes the shape of each red blood cell from a doughnutlike shape into a “sickled” or croissant shape that can clog small blood vessels and prevent the delivery of oxygen around the body. Sickle-cell disease is characterized by various acute and chronic complications, which are associated with significant morbidity and mortality in an afflicted subject. Thalassemia is also an inherited red blood cell disorder that is caused by a defect in the beta-globin gene, controlling the production of the beta-globin chains of hemoglobin. Accordingly, a patient suffering from thalassemia can’t make enough normal hemoglobin and thus has relatively fewer red blood cells and lower blood oxygen levels than people who do not suffer from the disease. Thalassemia patients may not make enough of either or both of the alpha or beta proteins in hemoglobin.

[0004] The cullin family of ubiquitination E3s are the most well-characterized substrates of neddylation. Upon neddylation, the cullins constellate the cullin-RING E3 UB ligase family (CRLs), which has approximately 300 members. The CRLs regulate diverse biological processes including cell cycle, signal transduction, DNA replication, and viral modulation. CRL dysfunction 1335853366 CENC-015 / 01WO 360899-2048is implicated in a number of human diseases, including cancer. Drug discovery efforts targeting the CRLs and the associated proteasomal protein degradation machinery have been extensive and continue to grow. The neddylation pathway has been successfully targeted by MLN4924 (Pevonedistat), an inhibitor of NEDD8’s El enzyme, that completely blocks NEDD8 ligation to substrates. MLN4924 is currently being tested in oncology clinical trials. An inhibitor of the COP9 signalosome, responsible for de-neddylation of the CRLs, has been reported and also displays antitumor activity. Defective in cullin neddylation 1 (DCN-1) is a protein that interacts with cullins and is required for neddylation. DCN-1 is also known as DCUN1D1, DCNL1 or Squamous Cell Carcinoma-related Oncogene (SCCRO). DCN-1 is the most well characterized isoform due to its common amplification as part of a large 3q26.3 amplicon in squamous cell carcinomas (SCC) and other tumors. DCN-1 amplification in SCC negatively correlates with cause-specific survival, suggesting that targeting DCN-1 may be of clinical utility in cancers. Its role in other diseases remains under-explored.

[0005] There remains a need to find therapeutic agents, methods, and therapies for the treatment of hemoglobin-related disorders including sickle cell disorders, diseases and conditions and thalassemia. The present invention fulfils this need and provides other related advantages.DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS1. General Description of Certain Embodiments of the Invention; Definitions

[0006] It has now been found that the compounds and compositions of the disclosure can modulate DCN-1, induce fetal hemoglobin and are useful in treating hemoglobin-related disorders including sickle cell disorders, diseases and conditions and thalassemia.

[0007] In one aspect, the present disclosure provides a compound of Formula I:Ior a pharmaceutically acceptable salt thereof, wherein:2335853366 CENC-015 / 01WO 360899-2048Ring A is phenyl or a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;R1is a Ci-6 aliphatic group, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- 6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R1is optionally substituted with halogen, -CN, - C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, - N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or-NRS(O)2R, phenyl, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen or an optionally substituted group selected from C1-6 aliphatic or a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring;each occurrence of R3is independently a halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, - S(O)R, -S(O)2R, -S(O)2N(R)2, -NRS(O)2R, or an optionally substituted C1-6 aliphatic;R4is phenyl, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 3- 8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a C1-6 aliphatic; wherein R4is optionally substituted with p instances of R7;R5is a substituent comprising a warhead group;R6is hydrogen or an optionally substituted C1-6 aliphatic group;each occurrence of R7is independently a halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, - S(O)R, -S(O)2R, -S(O)2N(R)2, -NRS(O)2R, or an optionally substituted C1-6 aliphatic;3335853366 CENC-015 / 01WO 360899-2048each occurrence of R is independently hydrogen or an optionally substituted group selected from Ci-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;n is 0, 1, 2, 3, 4, or 5; andp is 0, 1, 2, 3, 4, or 5.

[0008] As defined generally above, Ring A is selected from phenyl and a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0009] In some embodiments, Ring A is phenyl. In some embodiments, Ring A is a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0010] In some embodiments, Ring A is phenyl.

[0011] In some embodiments, Ring A is selected from those depicted in Table 1, below.

[0012] As defined generally above, R1is a Ci-6 aliphatic group, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R1is optionally substituted with halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, -NRS(O)2R, phenyl, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.4335853366 CENC-015 / 01WO 360899-2048

[0013] In some embodiments, R1is a Ci-6 aliphatic group. In some embodiments, R1is a substituted Ci-6 aliphatic group. In some embodiments, R1is phenyl. In some embodiments, R1is a 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, R1is a 3-8 membered partially unsaturated monocyclic carbocyclic ring. In some embodiments, R1is a 3-8 membered saturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R1is a 3-8 membered partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R1is a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0014] In some embodiments, R1is a Ci-6 aliphatic group substituted with halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or -NRS(O)2R. In some embodiments, R1is a phenyl substituted with halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or -NRS(O)2R. In some embodiments, R1is a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring substituted with halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or -NRS(O)2R. In some embodiments, R1is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur substituted with halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or -NRS(O)2R. In some embodiments, R1is a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur substituted with halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or -NRS(O)2R.

[0015] In some embodiments, R1is a Ci-6 aliphatic group substituted with phenyl. In some embodiments, R1is a Ci-6 aliphatic group substituted with a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and 5335853366 CENC-015 / 01WO 360899-2048sulfur. In some embodiments, R1is a C1-6 aliphatic group substituted with -OR. In some embodiments, R1is a C1-6 aliphatic group substituted with a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R1is a C1-6 aliphatic group substituted with a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.some embodiments, R1is selected from propyl, methyl, benzyl,and

[0017] In some embodiments, R1is selected from those depicted in Table 1, below.

[0018] As defined generally above, R2is hydrogen or an optionally substituted group selected from Ci-6 aliphatic or a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring.

[0019] In some embodiments, R2is hydrogen. In some embodiments, R2is a Ci-6 aliphatic group. In some embodiments, R2is a substituted Ci-6 aliphatic group. In some embodiments, R2is a 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, R2is a 3-8 membered partially unsaturated monocyclic carbocyclic ring. In some embodiments, R2is a substituted 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, R2is a substituted 3-8 membered partially unsaturated monocyclic carbocyclic ring.

[0020] In some embodiments, R2is hydrogen. In some embodiments, R2is ethyl.

[0021] In some embodiments, R2is selected from Ci-6 alkyl optionally substituted with 1, 2, 3, 4, 5, or 6 halogen or deuterium atoms.

[0022] In some embodiments, R2is selected from methyl, -CD3, -CF3, ethyl, -CH2CF3, n-propyl, isopropyl, n-butyl, and s-butyl.

[0023] In some embodiments, R2is ethyl.

[0024] In some embodiments, R2is selected from those depicted in Table 1, below.

[0025] As defined generally above, each occurrence of R3is independently a halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, - 6335853366 CENC-015 / 01WO 360899-2048N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, -NRS(O)2R, or an optionally substituted Ci-6 aliphatic.

[0026] In some embodiments, R3is halogen. In some embodiments, R3is -CN. In some embodiments, R3is -C(O)R. In some embodiments, R3is -C(O)OR. In some embodiments, R3is -OC(O)R. In some embodiments, R3is -C(O)N(R)2. In some embodiments, R3is -N(R)C(O)R. In some embodiments, R3is -N(R)C(O)N(R)2. In some embodiments, R3is -OC(O)N(R)2. In some embodiments, R3is -N(R)C(O)OR. In some embodiments, R3is -OR. In some embodiments, R3is -N(R)2. In some embodiments, R3is -NO2. In some embodiments, R3is -SR. In some embodiments, R3is -S(O)R. In some embodiments, R3is -S(O)2R. In some embodiments, R3is -S(O)2N(R)2. In some embodiments, R3is -NRS(O)2R. In some embodiments, R3is a Ci-6 aliphatic group. In some embodiments, R3is a substituted Ci-6 aliphatic group.

[0027] In some embodiments, R3is selected from Ci-6 alkyl optionally substituted with 1, 2, 3, 4, 5, or 6 halogen or deuterium atoms.

[0028] In some embodiments, R3is selected from methyl, -CDs, -CF3, ethyl, -CH2CF3, n-propyl, isopropyl, n-butyl, and s-butyl.

[0029] In some embodiments, R3is selected from Cl, F or -CF3.

[0030] In some embodiments, R3is -CF3.

[0031] In some embodiments, R3is selected from those depicted in Table 1, below.

[0032] As defined generally above, R4is phenyl, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a C1-6 aliphatic; wherein R4is optionally substituted with p instances of R7

[0033] In some embodiments, R4is phenyl. In some embodiments, R4is a 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, R4is a 3-8 membered partially unsaturated monocyclic carbocyclic ring. In some embodiments, R4is a 3-8 membered saturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R4is a 3-8 membered partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R4is a 5-6 membered monocyclic heteroaromatic ring having 1-47335853366 CENC-015 / 01WO 360899-2048heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R4is a C1-6 aliphatic.

[0034] In some embodiments, R4is selected from phenyl substituted with p instances of R7and cyclopropyl substituted with p instances of R7.

[0035] In some embodiments, R4is selected from;cyclopropyl and phenyl.

[0036] In some embodiments, R4is selected from those depicted in Table 1, below.

[0037] As defined generally above, R5is a substituent comprising a warhead group.

[0038] In some embodiments, the warhead group comprises an electrophilic group capable of reacting with a nucleophile under biological conditions to form a covalent bond to the nucleophile. In some embodiments, the warhead group comprises an electrophilic group capable of reacting with the thiol group of a cysteine under biological conditions to form a covalent bond to the cysteine. In some embodiments, the warhead group comprises an epoxide, a Michael acceptor (e.g., substituted or unsubstituted acrylamide, substituted or unsubstituted acrylate, substituted or unsubstituted alpha halo acetamide), an alkyl chloride, alkyl bromide, alkyl iodide, a sulfonyl halide, an alpha-halo ketone, an alpha-halo amide, an aldehyde, an aminonitrile, an N-cyanamide, a nitrile, a vinyl sulfone, a vinyl sulfonamide, or an anhydride.

[0039] In some embodiments, the warhead group is -L2-Y, wherein:L2is a covalent bond or a bivalent Ci-s saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three methylene units of L2are optionally and independently replaced by cyclopropylene, — NR —, — N(R)C(O) —, — C(O)N(R) —, — N(R)SO2 —, — SO2N(R)—, — O—, — C(O)—, — OC(O)—, — C(O)O—, — S—, —SO—, — SO2—, -O- P(O)(OR)O-, — C(=S)—, — C(=NR)—, — N=N—, or — C(=N2)—;Y is hydrogen, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0- 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 Regroups; andeach Reis independently selected from -Q-Z, oxo, NO2, halogen, CN, a suitable leaving group, or a C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, wherein:Q is a covalent bond or a bivalent C1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced 8335853366 CENC-015 / 01WO 360899-2048by — N(R)—, — S—, — O—, — C(O)—, — OC(O)—, — C(O)O—, —SO— or — SO2—, — N(R)C(O)—, — C(O)N(R)—, — N(R)S02— or — SO2N(R)—; andZ is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN.

[0040] In certain embodiments, L2is a covalent bond. In certain embodiments, L2is a bivalent C1-8 saturated or unsaturated, straight or branched, hydrocarbon chain. In certain embodiments, L2is — CH2—.

[0041] In certain embodiments, L2is a covalent bond, — CH2 —, — NH —, — CH2NH —, — NHCH2—, — NHC(O)—, — NHC(O)CH2OC(O)—, — CH2NHC(O)—, — NHSO2—, — NHSO2CH2—, — NHC(O)CH2OC(O)—, or— SO2NH—.

[0042] In some embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and one or two additional methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SCh —, — SO2N(R)—, — S—, — S(O)—, — SO2—, — OC(O)—, — C(O)O—, cyclopropylene, — O—, — N(R)—, -O-P(O)(OR)O-, or — C(O)—.

[0043] In certain embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O)—, — NRC(O)—, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, — S(O)—, — SO2—, — OC(O) —, or — C(O)O —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, or — C(O) —.

[0044] In some embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O) —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, -O-P(O)(OR)O-, or — C(O) —. In some embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O) —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, -O-P(O)(OR)O-, or — C(O) —, wherein at least one double bond is located in an alpha-beta position relative to a — C(O) —.

[0045] As described above, in certain embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond. One of ordinary skill in the art will recognize that such a double bond may exist within the hydrocarbon chain backbone or may be 9335853366 CENC-015 / 01WO 360899-2048“exo” to the backbone chain and thus forming an alkylidene group. By way of example, such an L2group having an alkylidene branched chain includes — CH2C(=CH2)CH2 —. Thus, in some embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one alkylidenyl double bond. In some embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one alkylidenyl double bond located in an alpha-beta position relative to a — C(O) —. Exemplary L2groups include — NHC(O)C(=CH2)CH2 —.

[0046] In certain embodiments, L2is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O)—. In certain embodiments, L2is — C(O)CH=CH(CH3)—, — C(O)CH=CHCH2NH(CH3)—, C(O)CH=CH(CH3) —, C(O)CH=CH —, — CH2C(O)CH=CH— CH2C(O)CH=CH(CH3)—, — CH2CH2C(O)CH=CH—, — CH2CH2C(O)CH=CHCH2—, — CH2CH2C(O)CH=CHCH2NH(CH3)—, — CH2CH2C(O)CH=CH(CH3)—, or — CH(CH3)OC(O)CH=CH—.

[0047] In certain embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — OC(O)—.

[0048] In some embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — NRC(O)—, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, — S(O)—, — SO2—, — OC(O) —, or — C(O)O —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, or — C(O) —. In some embodiments, L2is — CH2OC(O)CH=CHCH2—, — CH2— OC(O)CH=CH—, or — CH(CH=CH2)OC(O)CH=CH—.

[0049] In certain embodiments, L2is — NRC(O)CH=CH —, — NRC(O)CH=CHCH2N(CH3)—, — NRC(O)CH=CHCH2O—, — CH2NRC(O)CH=CH—, — NRSO2CH=CH—, — NRSO2CH=CHCH2—, — NRC(O)(C=N2)C(O)—, — NRC(O)CH=CHCH2N(CH3)—, — NRSO2CH=CH— — NRSO2CH=CHCH2— — NRC(O)CH=CHCH2O— — NRC(O)C(=CH2)CH2—, — CH2NRC(O)—, — CH2NRC(O)CH=CH —, — CH2CH2NRC(O) —, or — CH2NRC(O)cyclopropylene-, wherein each R is independently hydrogen or optionally substituted C1-6 aliphatic.

[0050] In certain embodiments, L2is — NHC(O)CH=CH —, —10335853366 CENC-015 / 01WO 360899-2048NHC(O)CH=CHCH2N(CH3)— — NHC(O)CH=CHCH2O—, — CH2NHC(O)CH=CH—, — NHSO2CH=CH— — NHSO2CH=CHCH2— — NHC(O)(C=N2)C(O)—, — NHC(O)CH=CHCH2N(CH3)—, — NHSO2CH=CH— — NHSO2CH=CHCH2— — NHC(O)CH=CHCH2O— — NHC(O)C(=CH2)CH2— — CH2NHC(O)—, — CH2NHC(O)CH=CH— — CH2CH2NHC(O)—, or — CH2NHC(O)cyclopropylene-.

[0051] In some embodiments, L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein L2has at least one triple bond. In certain embodiments, L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein L2has at least one triple bond and one or two additional methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR —, — S—, S(O), SO2, — C(=S)—, C(=NR), O—, — N(R)—, or C(O). In some embodiments, L2has at least one triple bond and at least one methylene unit of L2is replaced by — N(R)—, — N(R)C(O)—, — C(O)—, — C(O)O—, or — OC(O)—, or — O— In some embodiments, L2has at least one triple bond and at least one methylene unit of L2is replaced by — N(R) —, — N(R)C(O) —, — C(O) —, — C(O)O —, or — OC(O) —, or — O —, wherein at least one triple bond is located in an alpha-beta position relative to a — C(O) —.

[0052] Exemplary L2groups include — C=C —, — C=CCH2N(isopropyl)-, — NHC(O)C=CCH2CH2—, — CH2— C=C=CH2—, — C=CCH2O—, — CH2C(O)C=C—, — C(O)C=C— or — CH2OC(=O)C=C—.

[0053] In certain embodiments, L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein one methylene unit of L2is replaced by cyclopropylene and one or two additional methylene units of L2are independently replaced by — C(O) —, — NRC(O) —, — C(O)NR —, — N(R)SO2—, or — SO2N(R) —. Exemplary L2groups include — NEIC(O)-cyclopropylene-SO2— and — NEIC(O)-cyclopropylene-.

[0054] In certain embodiments, L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein one methylene unit of L2is replaced by -O-P(O)(OR)O-.

[0055] As defined generally above, Y is hydrogen, Ci-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with at 1-4 Regroups, each Reis independently selected from -Q-Z, oxo, NO2, halogen, CN, a suitable leaving group, or Ci-6 aliphatic, wherein Q is a covalent bond or a bivalent Ci-6 saturated or unsaturated, straight or branched, hydrocarbon chain,11335853366 CENC-015 / 01WO 360899-2048wherein one or two methylene units of Q are optionally and independently replaced by — N(R) —, — S—, — O—, — C(O)—, — OC(O)—, — C(O)O— —SO—, or — SO2—, — N(R)C(O)—, — C(O)N(R) —, — N(R)S02 —, or — SO2N(R) —; and, Z is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN.

[0056] In certain embodiments, Y is hydrogen. In some embodiments, when L is a covalent bond, Y is other than hydrogen.

[0057] In certain embodiments, Y is C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN. In some embodiments, Y is C2-6 alkenyl optionally substituted with oxo, halogen, NO2, or CN. In other embodiments, Y is C2-6 alkynyl optionally substituted with oxo, halogen, NO2, or CN. In some embodiments, Y is C2-6 alkenyl. In other embodiments, Y is C2-4 alkynyl.

[0058] In other embodiments, Y is C1-6 alkyl substituted with oxo, halogen, NO2, or CN. Such Y groups include — CH2F, — CH2CI, — CH2CN, and — CH2NO2.

[0059] In certain embodiments, Y is a saturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Y is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y.

[0060] In some embodiments, Y is a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group is -L2-Y. Exemplary such rings are epoxide and oxetane rings, wherein each ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group is -L2-Y.

[0061] In other embodiments, Y is a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y. Such rings include piperidine and pyrrolidine, wherein each ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group is -L2-Y. In certain embodiments, Y iswherein each R, Q, Z, and Reis as defined above in warhead group -L2-Y.

[0062] In some embodiments, Y is a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2- 12335853366 CENC-015 / 01WO 360899-2048Y. Tn certain embodiments, Y is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein each ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y. In certain embodiments,wherein Reis as defined above in warhead group -L2-Y.

[0063] In certain embodiments, Y is cyclopropyl optionally substituted with halogen, CN or NO2.

[0064] In certain embodiments, Y is a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y.

[0065] In some embodiments, Y is a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group - L2-Y. In some embodiments, Y is cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl wherein each ring is substituted with 1-4 Regroups, wherein each Reis as definedwherein each Reis as defined above in warhead group -L2-Y.

[0066] In certain embodiments, Y is a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y. In certain embodiments, Y is selected from:

[0067] wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y.

[0068] In certain embodiments, Y is a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead 13335853366 CENC-015 / 01WO 360899-2048group - L2-Y. In certain embodiments, Y is phenyl, pyridyl, or pyrimidinyl, wherein each ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y.

[0069] In some embodiments, Y is selected from:wherein each Reis as defined above in warhead group -L2-Y.

[0070] In other embodiments, Y is a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y. In some embodiments, Y is a 5 membered partially unsaturated or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y. Exemplary such rings are isoxazolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, thienyl, triazole, thiadiazole, and oxadiazole, wherein each ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y. In certain embodiments, Y is selected from:wherein each R is as defined above and described herein and Reis as defined above in warhead group - L2-Y.

[0071] In certain embodiments, Y is an 8-10 membered bicyclic, saturated, partially 14335853366 CENC-015 / 01WO 360899-2048unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group -L2-Y. According to another aspect, Y is a 9-10 membered bicyclic, partially unsaturated, or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group -L2-Y. Exemplary such bicyclic rings include 2,3-dihydrobenzo[d]isothiazole, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group - L2-Y.

[0072] As defined generally above, each Regroup is independently selected from -Q-Z, oxo, NOz, halogen, CN, a suitable leaving group, or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, wherein Q is a covalent bond or a bivalent C1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by — N(R) —, — S —, — O —, — C(O) —, — OC(O) —, — C(O)O —, — SO—, or — SO2—, — N(R)C(O)—, — C(O)N(R)—, — N(R)SO2—, or — SO2N(R)—; and Z is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN.

[0073] In certain embodiments, Reis C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN. In other embodiments, Reis oxo, NO2, halogen, or CN.

[0074] In some embodiments, Reis -Q-Z, wherein Q is a covalent bond and Z is hydrogen (i.e., Reis hydrogen). In other embodiments, Reis -Q-Z, wherein Q is a bivalent C1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by — NR —, — NRC(O) —, — C(O)NR —, — S —, — O —, — C(O) —, — SO —, or — SO2—. In other embodiments, Q is a bivalent C2-6 straight or branched, hydrocarbon chain having at least one double bond, wherein one or two methylene units of Q are optionally and independently replaced by — NR —, — NR. C(O) —, — C(O)NR —, — S —, — O —, — C(O) —, — SO —, or — SO2—. In certain embodiments, the Z moiety of the Regroup is hydrogen. In some embodiments, -Q-Z is — NHC(O)CH=CH2 or — C(O)CH=CH2.

[0075] In certain embodiments, each Reis independently selected from oxo, NO2, CN, fluoro, chloro, — NHC(O)CH=CH2, — C(O)CH=CH2, — CH2CH=CH2, — C=CH, — C(O)OCH2C1, — C(O)OCH2F, — C(O)OCH2CN, — C(O)CH2C1, — C(O)CH2F, — C(O)CH2CN, or — CH2C(O)CH3.15335853366 CENC-015 / 01WO 360899-2048

[0076] In certain embodiments, Reis a suitable leaving group, i.e., a group that is subject to nucleophilic displacement. A “suitable leaving” is a chemical group that is readily displaced by a desired incoming chemical moiety such as the thiol moiety of a cysteine of interest. In some embodiments, the warhead group modifies a cysteine of DCN-1. In some embodiments, the cysteine of DCN-1 is Cysll5. Suitable leaving groups are well known in the art, e g., see, “Advanced Organic Chemistry,” Jerry March, 5thEd., pp. 351-357, John Wiley and Sons, N. Y. Such leaving groups include, but are not limited to, halogen, alkoxy, sulfonyloxy, optionally substituted alkylsulfonyloxy, optionally substituted alkenyl sulfonyloxy, optionally substituted aryl sulfonyloxy, acyl, and diazonium moieties. Examples of suitable leaving groups include chloro, iodo, bromo, fluoro, acetoxy, methanesulfonyloxy (mesyloxy), tosyloxy, triflyloxy, nitrophenyl sulfonyloxy (nosyloxy), and bromo-phenylsulfonyloxy (brosyloxy).

[0077] In certain embodiments, the following embodiments, and combinations of -L2-Y apply:(a) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and one or two additional methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SO2 —, — SO2N(R) —, — S —, — S(O)—, — SO2—, — OC(O)—, — C(O)O—, cyclopropylene, — O—, — N(R)—, -O- P(O)(OR)O-, or — C(O) —; and Y is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety; or(b) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O) —, — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, — S(O)—, — SO2—, — OC(O)—, or — C(O)O —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, or — C(O) —; and Y is hydrogen or Ci- 6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety; or(c) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O) —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, or — C(O) —; and Y is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, beta- 16335853366 CENC-015 / 01WO 360899-2048unsaturated carbonyl moiety; or(d) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O) —; and Y is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2- Y comprises an alpha, beta-unsaturated carbonyl moiety; or(e) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — OC(O) —; and Y is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2- Y comprises an alpha, beta-unsaturated carbonyl moiety; or(f) L2is — NRC(O)CH=CH—, NRC(O)CH=CHCH2N(CH3), NRC(O)CH=CHCH2O—, — CH2NRC(O)CH=CH—, — NRSO2CH=CH—, — NRSO2CH=CHCH2—, — NRC(O)(C=N2)—, — NRC(O)(C=N2)C(O)—, — NRC(O)CH=CHCH2N(CH3)—, — NRSO2CH=CH—, — NRSO2CH=CHCH2—, — NRC(O)CH=CHCH2O—, — NRC(O)C(=CH2)CH2—, — CH2NRC(O)—, — CH2NRC(O)CH=CH—, — CH2CH2NRC(O)—, or — CH2NRC(O)cyclopropylene-; wherein R is H or optionally substituted C1-6 aliphatic; and Y is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, betaunsaturated carbonyl moiety; or(g) L2is — NHC(O)CH=CH—, — NHC(O)CH=CHCH2N(CH3)—, — NHC(O)CH=CHCH2O—, — CH2NHC(O)CH=CH— — NHSO2CH=CH—, — NHSO2CH=CHCH2—, — NHC(O)(C=N2)—, — NHC(O)(C=N2)C(O)—, — NHC(O)CH=CHCH2N(CH3)—, — NHSO2CH=CH—, — NHSO2CH=CHCH2—, — NHC(O)CH=CHCH2O—, — NHC(O)C(=CH2)CH2—, — CH2NHC(O)—, — CH2NHC(O)CH=CH—, — CH2CH2NHC(O)—, or — CH2NHC(O)cyclopropylene-; and Y is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2- Y comprises an alpha, beta-unsaturated carbonyl moiety; or(h) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one alkylidenyl double bond and at least one methylene unit of L2is replaced by — C(O) —, — NRC(O)—, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, — S(O)—, — SO2—, — OC(O) —, or — C(O)O —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, or — C(O) —; and Y is 17335853366 CENC-015 / 01WO 360899-2048hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2- Y comprises an alpha, beta-unsaturated carbonyl moiety; or(i) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one triple bond and one or two additional methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SO2—, — SO2N(R) —, — S —, — S(O) —, — SO2—, — OC(O) —, or — C(O)O —, and Y is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, beta- unsaturated carbonyl moiety; or(j) L2is — C=C—, — C=CCH2N(isopropyl)-, — NHC(O)C=CCH2CH2—, — CH2— C=C=CH2, — C=CCH2O—, — CH2C(O)C=C—, — C(O)C=C— or — CH2OC(=O)C=C—; and Y is hydrogen or Ci-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety; or(k) L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein one methylene unit of L2is replaced by cyclopropylene and one or two additional methylene units of L2are independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SO2—, — SO2N(R) —, — S —, — S(O) —, — SO2—, — OC(O) —, or — C(O)O —; and Y is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, betaunsaturated carbonyl moiety; or(l) L2is a covalent bond and Y is selected from:(i) C1-6 alkyl substituted with oxo, halogen, NO2, or CN;(ii) C2-6alkenyl optionally substituted with oxo, halogen, NO2, or CN; or (iii) C2-6alkynyl optionally substituted with oxo, halogen, NO2, or CN; or (iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group -L2-Y.; or(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or335853366Reis as defined above in warhead group -L2-Y; or(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Rcis as defined above in warhead group -L2-Y; or (viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(x) ' wherein each Reis as defined above in warhead group -L2- Y; or(xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead groupwherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y; or(xiv)19335853366 CENC-015 / 01WO 360899-2048each Reis as defined above in warhead group -L2-Y; or(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Rcgroups, wherein each Regroup is as defined above in warhead group -L2-Y; or(xvi)wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group -L2-Y;(m) L2is — C(O) — and Y is selected from:(i) Ci-6 alkyl substituted with oxo, halogen, NO2, or CN; or(ii) C2-ealkenyl optionally substituted with oxo, halogen, NO2, or CN; or(iii) C2-salkynyl optionally substituted with oxo, halogen, NO2, or CN; or(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or20335853366 CENC-015 / 01WO 360899-2048defined above in warhead group -L -Y; or(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or (viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(x), wherein each Reis as defined above in warhead group -L -Y; or (xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; orwherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group -L2- Y; or21335853366 CENC-015 / 01WO 360899-2048wherein each Reis as defined above in warhead group -L2-Y; or(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y; or(xvi)wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group -L2-Y;(n) L2is — N(R)C(O) — and Y is selected from:(i) Ci-6 alkyl substituted with oxo, halogen, NO2, or CN; or(ii) C2-ealkenyl optionally substituted with oxo, halogen, NO2, or CN; or(iii) C2-salkynyl optionally substituted with oxo, halogen, NO2, or CN; or(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or22335853366 CENC-015 / 01WO 360899-2048(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or■wherein each R, Q, Z, and Reis as defined above in warhead group -L2-Y; or(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or (viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; orwherein each Reis as defined above in warhead group -L2-Y; or (xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -(xii), wherein each R and Reis as defined above in warhead group -L2-Y; or(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group -L2- Y; or23335853366 CENC-015 / 01WO 360899-2048wherein each Reis as defined above in warhead group -L2-Y; or(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y; or(xvi)wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group - L2-Y;(o) L2is a bivalent Ci-s saturated or unsaturated, straight or branched, hydrocarbon chain; and Y is selected from:(i) Ci-6 alkyl substituted with oxo, halogen, NO2, or CN;(ii) C2-6alkenyl optionally substituted with oxo, halogen, NO2, or CN; or(iii) C2-salkynyl optionally substituted with oxo, halogen, NO2, or CN; or(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or24335853366 CENC-015 / 01WO 360899-2048(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; orwherein each R, Q, Z, and Reis as defined above in warhead group -L2-Y; or(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or (viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(x), wherein each Reis as defined above in warhead group -L2-Y; or (xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; oreach R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or25335853366 CENC-015 / 01WO 360899-2048(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group -L2- Y; orwherein each Reis as defined above in warhead group -L2-Y; or(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y; or(xvi)wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group - L2-Y;(p) L2is a covalent bond, — CH2—, — NH—, — C(O)—, — CH2NH—, — NHCH2—, — NHC(O)—, — NHC(O)CH2OC(O)—, — CH2NHC(O)—, — NHSO2—, — NHSO2CH2— — NHC(O)CH2OC(O) —, or — SO2NH —; and Y is selected from:(i) Ci-6 alkyl substituted with oxo, halogen, NO2, or CN; or(ii) C2-6alkenyl optionally substituted with oxo, halogen, NO2, or CN; or26335853366 CENC-015 / 01WO 360899-2048(iii) C2-salkynyl optionally substituted with oxo, halogen, NO2, or CN; or (iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; orwherein each R, Q, Z, and Reis as defined above in warhead group -L2-Y; or(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or (viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; orwherein each Reis as defined above in warhead group -L2-Y; or (xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or27335853366 CENC-015 / 01WO 360899-2048R and Reis as defined above in warhead group -L2-Y; or(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group -L2- Y; orwherein each Reis as defined above in warhead group -L2-Y; or(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y; or(xvi)wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group -L2-Y;28335853366 CENC-015 / 01WO 360899-2048(q) L2is a bivalent Ci-8 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three methylene units of L2are optionally and independently replaced by cyclopropylene, —NR—, — N(R)C(O)—, — C(O)N(R)—, — N(R)SO2—, — SO2N(R)—, — O—, — C(O)—, — OC(O)—, — C(O)O—, — S—, —SO—, — SO2—, -O-P(O)(OR)O-, — C(=S) —, — C(=NR) —, — N=N —, or — C(=N2) —; and Y is hydrogen or Ci-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety;(r) L2is a bivalent Ci-s saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three methylene units of L2are optionally and independently replaced by cyclopropylene, NR —, N(R)C(O) —, C(O)N(R) —, N(R)SO2—, SO2N(R) —, O-, — C(O)—, — OC(O)—, — C(O)O—, — S—, —SO—, — SO2—, -O-P(O)(OR)O-, — C(=S) —, — C(=NR) —, — N=N —, or — C(=N2) —; and Y is hydrogen or Ci-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, wherein -L2-Y comprises an alpha halo carbonyl moiety.

[0078] In certain embodiments, a Y group is selected from those set forth in Table la, below.

[0079] In certain embodiments, R5is L2-Y. In certain embodiments, the following embodiments, and combinations of -L2-Y apply:L2is a covalent bond or a bivalent C2-s straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COOR, -CN, -CON(R)2, -NRCN, NO2, -N(R)2, optionally substituted Ci- 29335853366 CENC-015 / 01WO 360899-20488 aliphatic, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide.

[0080] In certain embodiments, R5is L2-Y. In certain embodiments, the following embodiments, and combinations of -L2-Y apply:L2is a covalent bond or a bivalent C2-8 straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COORf, -CN, -CONRf2, -NRfCN, NO2, -NR*2, Ci-s aliphatic optionally substituted with halogen, NO2, or CN, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide; and wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.30335853366 CENC-015 / 01WO 360899-2048

[0081] In certain embodiments, R3is L2-Y In certain embodiments, the following embodiments and combinations of -L2-Y apply:L2is a covalent bond or a bivalent C2-8 straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, — S(O)—, — SO2—, -C(O)-, — OC(O)—, or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by a ring-NRfCN, NO2, -NRf2, epoxide, C1-8 aliphatic optionally substituted with halogen, NO2, or CN,; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, C2-6 alkynyl group, sulfonyl group, or epoxide; wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms; and wherein each occurrence of Rgand Rhis independently H, halogen, or OH, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 331335853366 CENC-015 / 01WO 360899-2048halogen atoms.

[0082] In certain embodiments, R5is L2-Y, wherein the following definitions of -L2-Y apply: L2is a covalent bond or a bivalent optionally substituted C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O)—, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S— -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched, hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN or -OR group; and additionally one methylene unit of L2is optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COOR, -CN, -CON(R)2, -CONRCN, -NRCN, NO2, -N(R)2, optionally substituted Ci-s aliphatic, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide.

[0083] In certain embodiments, R5is L2-Y. In certain embodiments, the following definitions of -L2-Y apply:32335853366 CENC-015 / 01WO 360899-2048L2is a covalent bond or a bivalent optionally substituted C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O)—, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2 —, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN or -OR group; and additionally one methylene unit of L2is optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COORf, -CN, -CONRf2, -CONRfCN, -NRfCN, NO2, -NRf2, Ci-s aliphatic optionally substituted with halogen, NO2, or CN, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide; and wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

[0084] In certain embodiments, R5is L2-Y. In certain embodiments, the following definitions of -L2-Y apply:L2is a covalent bond or a bivalent C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR— — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN or -OR group; and additionally one methylene unit of L2is optionally replacedby a ring selected from335853366 CENC-015 / 01WO 360899-2048hydrogen, halogen, -COORf, -CN, -CONRf2, -CONRfCN, -NRfCN, NO2, -NRf2, epoxide, Ci- s aliphatic optionally substituted with halogen, NO2, or CN, or a ring selected froman alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, C2-634335853366 CENC-015 / 01WO 360899-2048alkynyl group, sulfonyl group, or epoxide; wherein each occurrence of Rfis independently H, or straight or branched Ci-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms; and wherein each occurrence of Rgand Rhis independently H, halogen, or OH, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

[0085] In certain embodiments, R5is L2-Y, wherein the following definitions of -L2-Y apply: L2is a covalent bond or a bivalent optionally substituted C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O)—, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2 —, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched, hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2 or -OR group; and additionally one or two methylene units of L2are optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COOR, -CN, -CON(R)2, -CONRCN, -NRCN, NO2, -N(R)2, optionally substituted Ci-s aliphatic, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic 35335853366 CENC-015 / 01WO 360899-2048heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide.

[0086] In certain embodiments, R5is L2-Y. In certain embodiments, the following definitions of -L2-Y apply:L2is a covalent bond or a bivalent optionally substituted C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O)—, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2or -OR group; and additionally one or two methylene units of L2are optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COORf, -CN, -CONRf2, -CONRfCN, -NRfCN, NO2, -NRf2, Ci-s aliphatic optionally substituted with halogen, NO2, or CN, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide; and wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

[0087] In certain embodiments, R5is L2-Y. In certain embodiments, the following definitions of -L2-Y apply:L2is a covalent bond or a bivalent C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched hydrocarbon chain is optionally 36335853366 CENC-015 / 01WO 360899-2048substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2or -OR group; and additionally one methylene unit of L2is optionallyNRfCN, NO2, -NRf2, epoxide, C1-8 aliphatic optionally substituted with halogen, NO2, or CN,or a ring selected fromwherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, C2-6 alkynyl group, sulfonyl group, or epoxide; wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms. In some embodiments, -L2-Y is selected from those set forth in Table lg

[0088] In certain embodiments, a L2-Y group is selected from those set forth in Table 1c, Table Id, Table le and Table If below. In certain embodiments, a warhead group is selected from 37335853366 CENC-015 / 01WO 360899-2048those set forth in Table 1c, Table Id, Table le, and Table If belowTable la. Exemplary Y groups38335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048wherein each Reis independently a suitable leaving group, NO2, CN or oxo.

[0089] In certain embodiments, a warhead group is — C=CH, — C=CCH2NH(isopropyl), — NHC(O)C=CCH2CH3, — CH2— OOCt, — OCCH2OH, — CH2C(O)C=CH, — C(O)C=CH, or — CH2C(=0)C=CH. In some embodiments, a warhead group is selected from — NHC(O)CH=CH2, — NHC(O)CH=CHCH2N(CH3)2, or — CH2NHC(O)CH=CH2.

[0090] In certain embodiments, a warhead group is selected from those set forth in Table lb, below, wherein each wavy line indicates the point of attachment to the rest of the molecule. In certain embodiments, R? is selected from those set forth in Table lb.Table lb. Exemplary Warhead Groups335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-204844335853366 CENC-015 / 01WO 360899-2048wherein each Reis independently a suitable leaving group, NO2, CN, or oxo.

[0091] In some embodiments, Y of a warhead group is an isoxazoline compound or derivative capable of covalently binding to serine. In some embodiments, Y of a warhead group is an isoxazoline compound or derivative described in WO 2010135360, the entire content of which is incorporated herein by reference. As understood by one skilled in the art, an isoxazoline compound or derivative described in WO 2010135360, as Y of a warhead group, can covalently connect to L2of the warhead group at any reasonable position of the isoxazoline compound or derivative. Insome embodiments, Y of a warhead group is: Rawherein G, Ra, and Rcare:45335853366 CENC-015 / 01WO 360899-204846335853366 CENC-015 / 01WO 360899-204847335853366 CENC-015 / 01WO 360899-204848335853366 CENC-015 / 01WO 360899-204849335853366 CENC-015 / 01WO 360899-2048

[0092] In some embodiments, a warhead group is selected from those set forth in Table 1c, below, wherein each wavy line indicates the point of attachment to the rest of the molecule. In some embodiments, R? is selected from those set forth in Table 1c.50335853366 CENC-015 / 01WO 360899-2048Table 1c. Exemplary Warhead Groups51335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-204854335853366 CENC-015 / 01WO 360899-204855335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048

[0093] In some embodiments, R3is selected from those set forth in Table 1c.335853366 CENC-015 / 01WO 360899-2048

[0094] In some embodiments, a warhead group is selected from those set forth in Table Id, below, wherein each wavy line indicates the point of attachment to the rest of the molecule. In some embodiments, R5is selected from those set forth in Table Id.Table Id. Exemplary Warhead Groups

[0095] In some embodiments, R5is selected from those set forth in Table Id.

[0096] In some embodiments, a warhead group is selected from those set forth in Table le, below, wherein each wavy line indicates the point of attachment to the rest of the molecule. In some embodiments, R5is selected from those set forth in Table le.Table le. Exemplary Warhead Groups59335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048

[0097] In some embodiments, R is selected from those set forth in Table le.

[0098] In some embodiments, a warhead group is selected from those set forth in Table If, below, wherein each wavy line indicates the point of attachment to the rest of the molecule. In some embodiments, R5is selected from those set forth in Table If.Table If. Exemplary Warhead Groups61335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048

[0099] In some embodiments, a warhead group is selected from those set forth in Table 1g, below, wherein each wavy line indicates the point of attachment to the rest of the molecule. In some embodiments, R5is selected from those set forth in Table 1g.Table 1g. Exemplary Warhead Groups65335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048

[0100] In some embodiments, R5is selected from those depicted in Table 1, below.

[0101] As defined generally above, R6is hydrogen or an optionally substituted Ci-6 aliphatic group.

[0102] In some embodiments, R6is hydrogen. In some embodiments, R6is an unsubstituted Ci-6 aliphatic group. In some embodiments, R6is a substituted Ci-6 aliphatic group.

[0103] In some embodiments, R6is hydrogen.

[0104] In some embodiments, R6is selected from those depicted in Table 1, below.

[0105] As defined generally above, each occurrence of R7is independently a halogen, -CN, - C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, - N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, -NRS(O)2R, or an optionally substituted Ci-6 aliphatic.

[0106] In some embodiments, R7is halogen. In some embodiments, R7is -CN. In some embodiments, R7is -C(O)R. In some embodiments, R7is -C(O)OR. In some embodiments, R7is -OC(O)R. In some embodiments, R7is -C(O)N(R)2. In some embodiments, R7is -N(R)C(O)R. In 69335853366 CENC-015 / 01WO 360899-2048some embodiments, R7is -N(R)C(O)N(R)2. In some embodiments, R7is -OC(O)N(R)2. In some embodiments, R7is -N(R)C(O)OR. In some embodiments, R7is -OR. In some embodiments, R7is -N(R)2. In some embodiments, R7is -NO2. In some embodiments, R7is -SR. In some embodiments, R7is -S(O)R. In some embodiments, R7is -S(O)2R. In some embodiments, R7is -S(O)2N(R)2. In some embodiments, R7is -NRS(O)2R. In some embodiments, R7is C1-6 aliphatic group. In some embodiments, R7is substituted C1-6 aliphatic group.

[0107] In some embodiments, R7is halogen. In some embodiments, R7is selected from F, Cl or Br. In some embodiments, R7is F.

[0108] In some embodiments, R7is selected from those depicted in Table 1, below.

[0109] As defined generally above, each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0110] In some embodiments, R is hydrogen. In some embodiments, R is a C1-6 aliphatic group. In some embodiments, R is a substituted C1-6 aliphatic group. In some embodiments, R is a 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, R is a 3-8 membered partially unsaturated monocyclic carbocyclic ring. In some embodiments, R is a substituted 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, R is a substituted 3-8 membered partially unsaturated monocyclic carbocyclic ring. In some embodiments, R is phenyl. In some embodiments, R is a substituted phenyl. In some embodiments, R is an 8-10 membered bicyclic aromatic carbocyclic ring. In some embodiments, R is a substituted 8-10 membered bicyclic aromatic carbocyclic ring. In some embodiments, R is a 4-8 membered saturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a 4-8 membered partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a substituted 4-8 membered saturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some 70335853366 CENC-015 / 01WO 360899-2048embodiments, R is a substituted 4-8 membered partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0111] In some embodiments, R is selected from those depicted in Table 1, below.

[0112] As defined generally above, n is 0, 1, 2, 3, 4 or 5. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5.

[0113] In some embodiments, n is selected from those depicted in Table 1, below.

[0114] As defined generally above, p is 0, 1, 2, 3, 4 or 5. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5.

[0115] In some embodiments, p is selected from those depicted in Table 1, below.

[0116] In one aspect, the present disclosure provides a compound of Formula la:or a pharmaceutically acceptable salt thereof, wherein:each of R1, R2, R3, R4, R6, R7, R, n and p are as defined above for Formula I, both singly and in combination; andR5is L2-Y, whereinL2is a bivalent optionally substituted C2-6 straight or branched hydrocarbon chain wherein one methylene unit of L2is optionally replaced by -NR-, -C(O)-, -C(O)N(R)-, -N(R)C(O)-; and335853366 CENC-015 / 01WO 360899-2048additionally one methylene unit of L2is optionally replaced by an optionally substituted ring selected from phenyl, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andYis -CN or -Cl.

[0117] In some embodiments of Formula la, R5is L2-Y, wherein:L2is a bivalent optionally substituted C2-6 straight or branched hydrocarbon chain wherein one methylene unit of L2is optionally replaced by -NR-, -C(O)-, -C(O)N(R)-, -Nadditionally one methylene unit ofL2is optionally replaced by a ring selected from

[0118] In some embodiments, the present disclosure provides compounds of Formula Ila, Formula lib, Formula lie or Formula lid:72335853366 CENC-015 / 01WO 360899-2048He lidor a pharmaceutically acceptable salt thereof, wherein:each of R1, R3, R5, and R7are as defined above and described in embodiments herein, both singly and in combination.

[0119] In some embodiments, the present disclosure provides compounds of Formula Illa, Formula Illb, Formula IIIc or Formula Hid:73335853366 CENC-015 / 01WO 360899-2048IIIc Hidor a pharmaceutically acceptable salt thereof, wherein:each of R1, R3, R5, and R7are as defined above and described in embodiments herein, both singly and in combination.

[0120] In some embodiments, the present disclosure provides compounds of Formula IVa, Formula IVb, Formula IVc or Formula IVd:IVc IVdor a pharmaceutically acceptable salt thereof, wherein:each of R1, R3, and R5are as defined above and described in embodiments herein, both singly and in combination.

[0121] In some embodiments, the present disclosure provides compounds of Formula Va, Formula Vb, Formula Vc or Formula Vd:74335853366 CENC-015 / 01WO 360899-2048Vc Vdor a pharmaceutically acceptable salt thereof, wherein:each of R1, R3, and R5are as defined above and described in embodiments herein, both singly and in combination.

[0122] In some embodiments, the present disclosure provides compounds of Formula Via, Formula VIb, Formula Vic or Formula Vid:Vic Vidor a pharmaceutically acceptable salt thereof, wherein:each of R1, R3, R5and R7are as defined above and described in embodiments herein, both singly and in combination; andR5is L2-Y, whereinL2is a covalent bond or a bivalent optionally substituted C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O)—, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched, hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2or -OR group; and additionally one or two methylene units of L2are optionally replaced by an optionally substituted ring selected from a 3-8 membered 75335853366 CENC-015 / 01WO 360899-2048saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COOR, -CN, -CON(R)2, -CONRCN, -NRCN, NO2, -N(R)2, optionally substituted C1-8 aliphatic, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide.

[0123] In some embodiments of Formula Via, Formula VIb, Formula Vic, and Formula Vid, R5is L2-Y, wherein

[0124] L2is a covalent bond or a bivalent optionally substituted C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SO2—, — SChN(R) —, — S —, -O-, -NR-, — S(O) —, — SO2 —, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2 or -OR group; and additionally one or two methylene units of L2are optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-8 membered 76335853366 CENC-015 / 01WO 360899-2048saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and

[0125] Y is hydrogen, halogen, -COORf, -CN, -CONRf2, -CONRfCN, -NRfCN, NO2, -NRf2, Ci-8 aliphatic optionally substituted with halogen, NO2, or CN, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide; and wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

[0126] In some embodiments of Formula Via, Formula VIb, Formula Vic, and Formula Vid, R5is L2-Y, whereinL2is a covalent bond or a bivalent C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2or -OR group; and additionally one methylene unit of L2is optionallyreplaced by a ring selected from77335853366 CENC-015 / 01WO 360899-2048NRfCN, NO2, -NRf2, epoxide, C1-8 aliphatic optionally substituted with halogen, NO2, or CN,or a ring selected from,; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, C2-6 alkynyl group, sulfonyl group, or epoxide; wherein each occurrence of R1is independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

[0127] In some embodiments, the present disclosure provides compounds of Formula Vila, Formula Vllb, Formula Vile or Formula Vlld:or a pharmaceutically acceptable salt thereof, wherein:78335853366 CENC-015 / 01WO 360899-2048each of R1, R3, R5and R7are as defined above and described in embodiments herein, both singly and in combination; andR5is L2-Y, whereinL2is a covalent bond or a bivalent optionally substituted C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O)—, — C(O)NR— — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2 —, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched, hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2or -OR group; and additionally one or two methylene units of L2are optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COOR, -CN, -CON(R)2, -CONRCN, -NRCN, NO2, -N(R)2, optionally substituted Ci-s aliphatic, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide.79335853366 CENC-015 / 01WO 360899-2048

[0128] In some embodiments of Formula Vila, Formula VIIb, Formula Vile, and Formula Vlld, R5is L2-Y, wherein:L2is a covalent bond or a bivalent optionally substituted C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O)—, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2 or -OR group; and additionally one or two methylene units of L2are optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COORf, -CN, -CONRf2, -CONRfCN, -NRfCN, NO2, -NRf2, Ci-s aliphatic optionally substituted with halogen, NO2, or CN, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide; and wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

[0129] In some embodiments of Formula Vila, Formula Vllb, Formula Vile, and Formula Vlld, R5is L2-Y, wherein:L2is a covalent bond or a bivalent C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2or -OR group; and additionally one methylene unit of L2is optionally80335853366 CENC-015 / 01WO 360899-2048NRfCN, NO2, -NR*2, epoxide, C1-8 aliphatic optionally substituted with halogen, NO2, or CN,or a ring selected fromwherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, C2-6 alkynyl group, sulfonyl group, or epoxide; wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

[0130] In some embodiments, the present disclosure provides compounds of Formula VIIIa, Formula VIIIb, Formula VIIIc, or Formula VIIId:81335853366 CENC-015 / 01WO 360899-2048or a pharmaceutically acceptable salt thereof, wherein:

[0131] Exemplary compounds of the disclosure are set forth in Table 1, below.

[0132] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a disclosed compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0133] In some embodiments, the present disclosure provides a compound shown in Table 1, below, or a pharmaceutically acceptable salt thereof.82335853366 CENC-015 / 01WO 360899-2048Table 1. Exemplary Compounds83335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-204885335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048113335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-20482. Compounds and Related Definitions

[0134] As described generally above, the present invention provides a compound of Formula I:121335853366 CENC-015 / 01WO 360899-2048or a pharmaceutically acceptable salt thereof, wherein the variables are as described above.Definitions

[0135] Compounds of the present invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito: 1999, and March’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M. B. Smith and J. March, 7thEdition, John Wiley & Sons: 2013; the entire contents of each of which are hereby incorporated by reference.

[0136] The term “aliphatic” or “aliphatic group,” as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle,” “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted 122335853366 CENC-015 / 01WO 360899-2048alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0137] As used herein, the term “bicyclic ring” or “bicyclic ring system” refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated, or having one or more units of unsaturation, having one or more atoms in common between the two rings of the ring system. Thus, the term includes any permissible ring fusion, such as or / Ao-fused or spirocyclic. As used herein, the term “spirocyclic” refers to organic compounds that contain at least two rings with one common atom, generally a quaternary carbon. Generally, the number of carbon atoms linked to the spiro atom in each ring is indicated in ascending order in brackets placed between the spiro prefix and thehydrocarbon name. For example,can be represented as spiro[4.5]decane.

[0138] As used herein, the term “heterobicyclic” is a subset of “bicyclic” that requires that one or more heteroatoms are present in one or both rings of the bicycle. Such heteroatoms may be present at ring junctions and are optionally substituted, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc. In some embodiments, a bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated, or partially unsaturated, having at least one bridge. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally, or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bicyclic rings include:123335853366 CENC-015 / 01WO 360899-2048

[0139] Exemplary bridged bicyclics include:

[0140] The term “lower alkyl” refers to a Ci-4 straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0141] The term “lower haloalkyl” refers to a Ci-4 straight or branched alkyl group that is substituted with one or more halogen atoms.

[0142] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2 / -pyrrolyl), NH (as in pyrrolidinyl) or NIC (as in N-substituted pyrrolidinyl)).

[0143] The term “unsaturated,” as used herein, means that a moiety has one or more units of unsaturation.124335853366 CENC-015 / 01WO 360899-2048

[0144] As used herein, the term “bivalent Ci-8 (or Cue) saturated or unsaturated, straight or branched, hydrocarbon chain,” refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.

[0145] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., -(CH2)n-, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0146] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0147] The term “halogen” means F, Cl, Br, or I.

[0148] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present invention, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like. The term “phenylene” refers to a multivalent phenyl group having the appropriate number of open valences to account for groups attached to it. For example, “phenylene” is a bivalent phenyl grouparyl group.

[0149] The terms “heteroaryl” and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 125335853366 CENC-015 / 01WO 360899-20489 ring atoms; having 6, 10, or 14 K electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar- ” as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthal azinyl, quinazolinyl, quinoxalinyl, 4F / -quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3- / >]-l,4-oxazin-3(4 / / )-one. A heteroaryl group may be mono- or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted with a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.

[0150] The term “heteroarylene” refers to a multivalent heteroaryl group having the appropriate number of open valences to account for groups attached to it. For example, “heteroarylene” is a bivalent heteroaryl group when it has two groups attached to it; “heteroarylene” is a trivalent heteroaryl group when it has three groups attached to it. The term “pyridinylene” refers to a multivalent pyridine radical having the appropriate number of open valences to account for groups attached to it. For example, “pyridinylene” is a bivalent pyridineradical when it has two groups attached to it (e.g.,“pyridinylene” is a trivalentpyridine radical when it has three groups attached t

[0151] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated,126335853366 CENC-015 / 01WO 360899-2048and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term “nitrogen” includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-di hydro-2 / / pyrrol yl), NH (as in pyrrolidinyl), or+NR (as in A substituted pyrrolidinyl).

[0152] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, 2-oxa-6-azaspiro[3.3]heptane, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3 7-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. The term “oxo-heterocyclyl” refers to a heterocyclyl substituted by an oxo group. The term “heterocyclylene” refers to a multivalent heterocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “heterocyclylene” is a bivalent heterocyclyl group when it has two groups attached to it; “heterocyclylene” is a trivalent heterocyclyl group when it has three groups attached to it.

[0153] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation but is not intended to include aryl or heteroaryl moieties, as herein defined.

[0154] As described herein, compounds of the invention may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent 127335853366 CENC-015 / 01WO 360899-2048(“optional substituent”) at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0155] Suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen; -(CH2)o 4R0; -(CH2)o 4OR0; -0(CH2)o-4R°, -O-(CH2)O4C(0)0RO; -(CH2)O-4CH(OR0)2; -(CH2)O-4SR°; -(CH2)o-Ph, which may be substituted with R°; -(CH2)o 40(CH2)o iPh which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -(CH2)o-40(CH2)o i-pyridyl which may be substituted with R°; -NO2; -CN; -N3; -(CH2)O-4N(R°)2; -(CH2)O ^N(R°)C(O)R°; -N(R°)C(S)R°; -(CH2)O- 4N(RO)C(O)NR°2; -N(RO)C(S)NR°2; -(CH2)O-IN(R0)C(0)OR°;N(R°)N(R°)C(O)R°; -N(R°)N(R°)C(O)NR°2; -N(R°)N(R°)C(O)OR°; -(CH2)o^C(0)R°; -C(S)R°; -(CH2)o4C(O)ORO; -(CH2)O4C(O)SRO; -(CH2)O 4C(O)OSiR°3; -(CH2)o^OC(0)R°; -OC(0)(CH2)O -4SR-, SC(S)SR°; -(CH2)o^SC(0)R°; -(CH2)o 4C(O)NR°2; -C(S)NR°2; -C(S)SR°; -SC(S)SR°, -(CH2)O4OC(O)NR°2; -C(O)N(OR°)R°; -C(O)C(O)R°; -C(O)CH2C(O)RO; -C(NOR°)R°; -(CH2)o 4SSR0; -(CH2)o4S(O)2RO; (CH2)o 4S(O)2OR°; (CH2)o^OS(0)2R0; S(O)2NR°2; - CH2)O 4S(O)RC; -N(RO)S(O)2NR°2; -N(RO)S(O)2R°; -N(OR°)R°; -C(NH)NRO2; -P(O)2R°; -P(O)RO2; -OP(O)RO2; -OP(O)(ORO)2; SiR°3; -(C1-4 straight or branched alkylene)O-N(R°)2; or — (C1-4 straight or branched alkylene)C(O)O-N(R°)2, wherein each R° may be substituted as defined below and is independently hydrogen, C1-6 aliphatic, -CH2PI1, 0(CH2)o iPh, -CH2-(5-6 membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, which may be substituted as defined below.128335853366 CENC-015 / 01WO 360899-2048

[0156] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, -(CH2)o 2R*, -(haloR*), -(CH2)o 2OH, -(CH2)O2OR*, -(CH2)O2CH(OR*)2; -O(haloR*), -CN, -N3, -(CH2)o2C(O)R*, -(CH2)O2C(O)OH, -(CH2)O2C(O)OR*, -(CH2)O -2SR*, -(CH2)O -2SH, -(CH2)o 2NH2, -(CH2)o2NHR*, -(CH2)O-2NR*2, -NO2, -SiR*3, -OSiR*3, -C(O)SR* -(Ci-i straight or branched alkylene)C(O)OR*, or -SSR* wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from C 1 4 aliphatic, -CH2PI1, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.

[0157] Suitable divalent substituents on a saturated carbon atom of an “optionally substituted” group include the following: =0, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*, =NOR*, — O(C(R2))23O—, or -S(C(R*2))2-3S- wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: -O(CR*2)23O-, wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0158] Suitable substituents on the aliphatic group of R include halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR*), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4 aliphatic, -CH2PI1, 0(CH2)o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0159] Suitable substituents on a substitutable nitrogen of an “optionally substituted” group includef, C(O)CH2; wherein each R:is independently hydrogen, C1-6 aliphatic which may be substituted as defined below,129335853366 CENC-015 / 01WO 360899-2048unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or, notwithstanding the definition above, two independent occurrences of R1', taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0160] Suitable substituents on the aliphatic group of R1' are independently halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR*), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently Ci 4 aliphatic, -CH2PI1, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0161] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate,130335853366 CENC-015 / 01WO 360899-20483-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

[0162] Further, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al., Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al., Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D. C. on their website). These disclosures are incorporated herein by reference.

[0163] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and N+(Ci-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

[0164] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a13C- or14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.

[0165] Compounds containing one or more stereocenters are a mixture of stereoisomers, unless otherwise stated or described (for example, with use of dashed or wedged bonds denoting 131335853366 CENC-015 / 01WO 360899-2048stereochemistry). Generally, enhanced stereochemical representation introduces three types of identifiers that can be attached to a stereogenic center. A stereochemical group label is composed from an identifier and a group number. Each stereogenic center marked with wedge bonds belongs to one (and only one) stereochemical group. Grouping allows to specify relative relationships among stereogenic centers.

[0166] ABS denotes a stereogenic center where the absolute configuration is known. As used herein, “or” denotes a stereogenic center where the relative configuration is known, but the absolute configuration is not known. The structure represents one stereoisomer that is either the structure as drawn (R, S) or the epimer in which the stereogenic centers have the opposite configuration (S, R). One of skill in the art would understand that if a single stereogenic center is present, the designation “or” represents a single isomer for which the absolute configuration is not known. As used herein, “orl”, “or2” denote stereogenic centers where the relative configuration is known, but the absolute configuration is not known when applied to a multi-center stereogroup. The designations “and” and “&” are used interchangeably and denote a mixture of stereoisomers. It can be a pair of enantiomers or all the diastereomers.

[0167] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, such as, for example, by chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Alternatively, a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis. Still further, where the molecule contains a basic functional group (such as amino) or an acidic functional group (such as carboxylic acid) diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers.

[0168] Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. Chiral center(s) in a compound of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. Further, to the extent 132335853366 CENC-015 / 01WO 360899-2048a compound described herein may exist as an atropisomer (e.g., substituted biaryls), all forms of such atropisomers are considered part of this invention.

[0169] Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples, and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.

[0170] The terms “a” and “an” as used herein mean “one or more” and include the plural unless the context is inappropriate.

[0171] The term “alkyl” refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C1-C12 alkyl, C1-C10 alkyl, and Ci-Ce alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3-methyl-1 -butyl, 2-methyl-3 -butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3 -methyl -1 -pentyl, 4-methyl-l -pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l-butyl, 3,3-dimethyl-l -butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.

[0172] The term “cycloalkyl” refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as “C3-C6 cycloalkyl,” derived from a cycloalkane. Exemplary cycloalkyl groups include cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl. The term “cycloalkylene” refers to a bivalent cycloalkyl group.

[0173] The term “haloalkyl” refers to an alkyl group that is substituted with at least one halogen. Exemplary haloalkyl groups include -CH2F, -CHF2, -CF3, -CH2CF3, -CF2CF3, and the like. The term “haloalkylene” refers to a bivalent haloalkyl group.

[0174] The term “hydroxyalkyl” refers to an alkyl group that is substituted with at least one hydroxyl. Exemplary hydroxyalkyl groups include -CH2CH2OH, -C(H)(OH)CH3, -CH2C(H)(OH)CH2CH2OH, and the like.133335853366 CENC-015 / 01WO 360899-2048

[0175] The terms “alkenyl” and “alkynyl” are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively.

[0176] The term “carbocyclylene” refers to a multivalent carbocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “carbocyclylene” is a bivalent carbocyclyl group when it has two groups attached to it; “carbocyclylene” is a trivalent carbocyclyl group when it has three groups attached to it.

[0177] The terms “alkoxy!” or “alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, / c / V-butoxy and the like. The term “haloalkoxyl” refers to an alkoxyl group that is substituted with at least one halogen. Exemplary haloalkoxyl groups include -OCH2F, -OCHF2, -OCF3, -OCH2CF3, -OCF2CF3, and the like. The term “hydroxyalkoxyl” refers to an alkoxyl group that is substituted with at least one hydroxyl. Exemplary hydroxyalkoxyl groups include -OCH2CH2OH, -OCH2C(H)(OH)CH2CH2OH, and the like. The term “alkoxylene” refers to a bivalent alkoxyl group.

[0178] The term “oxo” is art-recognized and refers to a “=O” substituent. For example, a cyclopentane substituted with an oxo group is cyclopentanone.

[0179] The symbol “ T W” indicates a point of attachment. The point of attachment can beA 4drawn at the end of the bond in a chemical structure, for example, N or at the center of4?'the bond in a chemical structure, for example, N

[0180] When a chemical structure containing a ring is depicted with a substituent having a bond that crosses a ring bond, the substituent may be attached at any available position on the ring.For example, the chemical structureRXN encompasses N,, andIn the context of a polycyclic fused ring, when a chemical structure containing a polycyclic fused ring is depicted with one or more substituent(s) having a bond that crosses 134335853366 CENC-015 / 01WO 360899-2048multiple rings, the one or more substituent(s) may be independently attached to any of the ringscrossed by the bond. To illustrate, the chemical structureencompasses, forexample,

[0181] When any substituent or variable occurs more than one time in any constituent or the compound of the invention, its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated.

[0182] The term “warhead” or “warhead group” as used herein refers to a functional group present on a compound wherein that functional group is capable of reversibly or irreversibly participating in a reaction with a protein. Warheads may, for example, form covalent bonds with the protein. For example, the warhead moiety can be a functional group on an inhibitor that can participate in a bond-forming reaction, wherein a new covalent bond is formed between a portion of the warhead and a donor, for example an amino acid residue of a protein. In some embodiments, the warhead is an electrophile and the “donor” is a nucleophile such as the side chain of a cysteine residue.

[0183] One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H2O.

[0184] As used herein, the terms “subject” and “patient” are used interchangeably and refer to organisms to be treated by the methods of the present invention. Such organisms preferably135335853366 CENC-015 / 01WO 360899-2048include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and, most preferably, includes humans.

[0185] The term “ICso” is art-recognized and refers to the concentration of a compound that is required to achieve 50% inhibition of the target. The potency of an inhibitor is usually defined by its ICso value. The lower the IC50 value the greater the potency of the antagonist and the lower the concentration that is required to inhibit the maximum biological response. In certain embodiments, an inhibitor has an IC50 and / or binding constant of less than about 100 pM, less than about 50 pM, less than about 1 pM, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.

[0186] As used herein, the term “inhibitor” is defined as a compound that binds to and / or inhibits the target with measurable affinity. In some embodiments, inhibition in the presence of the inhibitor is observed in a dose-dependent manner. In some embodiments, the measured signal (e.g., signaling activity or biological activity) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% lower than the signal measured with a negative control under comparable conditions.

[0187] The terms “measurable affinity” and “measurably inhibit,” as used herein, means a measurable change or inhibition in target activity between a sample comprising a compound of the present invention, or composition thereof an equivalent sample comprising target, in the absence of said compound, or composition thereof.

[0188] As used herein, the term “effective amount” refers to the amount of a compound sufficient to effect beneficial or desired results (e.g, a therapeutic, ameliorative, inhibitory, or preventative result). An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.

[0189] As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating, or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof. In some embodiments, treatment can be 136335853366 CENC-015 / 01WO 360899-2048administered after one or more symptoms have developed. In other embodiments, treatment can be administered in the absence of symptoms. For example, treatment can be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment can also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.

[0190] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.

[0191] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions e.g., such as an oil / water or water / oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see e.g., Martin, Remington’s Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA

[1975] ,

[0192] For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.

[0193] In addition, when a compound of the invention contains both a basic moiety (such as, but not limited to, a pyridine or imidazole) and an acidic moiety (such as, but not limited to, a carboxylic acid) zwitterions (“inner salts”) may be formed. Such acidic and basic salts used within the scope of the invention are pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts. Such salts of the compounds of the invention may be formed, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

[0194] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that137335853366 CENC-015 / 01WO 360899-2048there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.

[0195] As a general matter, compositions specifying a percentage are by weight unless otherwise specified.3. Methods of Use

[0196] It has now been found that the compounds and compositions of the disclosure can modulate DCN-1 (also referred to herein as DCN1) and are useful in treating disorders, diseases, and conditions associated with DCN-1. In some embodiments, modulating DCN-1 is inhibiting or reducing the activity of DCN-1. Without being limited to a specific mechanism, as shown herein, inhibiting or reducing the activity of DCN-1 results in reduced neddylation and other downstream effects. It has also been found that the compounds and compositions of the disclosure can modulate DCN-2 (also referred to herein as DCN2) and are useful in treating disorders, diseases, and conditions associated with DCN-2. In some embodiments, modulating DCN-2 is inhibiting or reducing the activity of DCN-2. Without being limited to a specific mechanism, as shown herein, inhibiting or reducing the activity of DCN-2 results in reduced neddylation and other downstream effects.

[0197] In one aspect, the present disclosure provides a method of modulating the activity of DCN-1 in vitro or in vivo, comprising contacting DCN-1 with a compound or composition thereof disclosed herein, or a pharmaceutically acceptable salt thereof. In one aspect, the present disclosure provides a method of modulating the activity of DCN-2 in vitro or in vivo, comprising contacting DCN-2 with a compound or composition thereof disclosed herein, or a pharmaceutically acceptable salt thereof.

[0198] In some embodiments, the present disclosure provides a method of modulating the activity of DCN-1 and / or DCN-2 in a subject, comprising administering to the subject a compound or composition thereof disclosed herein, or a pharmaceutically acceptable salt thereof.

[0199] In one aspect, the disease, disorder, or condition associated with DCN-1 or DCN-2 is a hemoglobinopathy such as sickle cell disorder or disease, or thalassemia disorder or disease.

[0200] In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN-2 is selected from one of those described in He et al. (Int Journal of Biological Macromolecules 227, 2024, 134541). In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN-2 is cancer (e.g., non-small cell lung cancer or gastric cancer), liver injury (e.g., non-alcoholic 138335853366 CENC-015 / 01WO 360899-2048fatty liver disease), cardiac remodeling (e.g., atherosclerosis) or neurodegenerative disease (e.g., frontotemporal lobar degeneration). In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN-2 is characterized by overexpression of DCN-1 and / or DCN-2. In some embodiments, the disease, disorder, or condition associated with DCN-1 and / or DCN-2 overexpression is cancer (e.g., non-small cell lung cancer or gastric cancer).

[0201] In one aspect, the disclosure provides compounds and compositions for the treatment of of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. In one aspect, the compounds and compositions described herein induce HbF (fetal hemoglobin; expressed by the gamma globin genes HBG1 and HBG2). It should be appreciated that induction of HbF allows for the treatment of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. Thus, in one aspect, the disclosure provides compounds and compositions for the treatment of sickle cell disease.

[0202] In one aspect, the disclosure provides compounds and compositions for the treatment of of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease In one aspect, the compounds and compositions described herein induce HbF (fetal hemoglobin; expressed by the gamma globin genes HBG1 and HBG2) and reduce HbA (adult hemoglobin; expressed by the beta globin gene HBB), thus inducing production of fetal hemoglobin and reducing the expression of the hemoglobin beta gene. It should be appreciated that induction of HbF and reduction of HbA allows for the treatment of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. Thus, in one aspect, the disclosure provides compounds and compositions for the treatment of sickle cell disease.

[0203] In some embodiments, a compound described herein is an irreversible covalent inhibitor of DCN-1 and / or DCN-2. In some embodiments, an irreversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN-1 and / or DCN-2. In some embodiments, an irreversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease. In some embodiments, a compound described herein is a reversible covalent inhibitor of DCN-1 and / or DCN-2. In some embodiments, a reversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN-1 and / or DCN-2. In some embodiments, a reversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease. In some embodiments, a compound described herein is a reversible inhibitor of DCN-1 and / or DCN-2. In some embodiments, a reversible inhibitor of 139335853366 CENC-015 / 01WO 360899-2048DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN-1 and / or DCN-2. In some embodiments, a reversible covalent of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease.

[0204] In one aspect, the disclosure provides irreversible covalent inhibitors of DCN-1 and / or DCN-2 for the treatment of a disease, disorder, or condition associated with DCN-1 and / or DCN-2. In some embodiments, the disclosure provides irreversible covalent inhibitors of DCN-1 and / or DCN-2 for the treatment of sickle cell disease. In some embodiments, the irreversible covalent inhibitors of DCN-1 and / or DCN-2 irreversibly covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the irreversible covalent inhibitors of DCN-1 and / or DCN-2 irreversibly covalently modify Cysll5 of DCN-1 and / or DCN-2.

[0205] In one aspect, the disclosure provides reversible covalent inhibitors of DCN-1 and / or DCN-2 for the treatment of a disease, disorder, or condition associated with DCN-1 and / or DCN-2. In some embodiments, the disclosure provides reversible covalent inhibitors of DCN-1 and / or DCN-2 for the treatment of sickle cell disease. In some embodiments, the reversible covalent inhibitors of DCN-1 and / or DCN-2 reversibly covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the reversible covalent inhibitors of DCN-1 and / or DCN-2 reversibly covalently modify Cysll5 of DCN-1 and / or DCN-2.

[0206] In one aspect, the disclosure provides reversible inhibitors of DCN-1 and / or DCN-2 for the treatment of a disease, disorder, or condition associated with DCN-1 or DCN-2. In one aspect, the disclosure provides reversible inhibitors of DCN-1 and / or DCN-2 for the treatment of sickle cell disease.

[0207] In some embodiments, the disclosure provides irreversible covalent inhibitors of DCN-1 and / or DCN-2, wherein the compound has a warhead that can irreversible covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the cysteine is Cysl 15 of DCN-1 and / or DCN-2. In some embodiments, the disclosure provides reversible covalent inhibitors of DCN-1 and / or DCN-2, wherein the compound has a warhead that can reversible covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the cysteine is Cysl 15 of DCN-1 and / or DCN-2.

[0208] In one aspect, the disclosure provides a DCN-1 that is covalently modified at Cysl 15. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-1 in a subject. In some embodiments, the disclosure provides methods and 140335853366 CENC-015 / 01WO 360899-2048compositions for covalently modifying DCN-1 Cys-115 in a subject. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-1 Cys-115 in a subject for the treatment of sickle cell disease.

[0209] In one aspect, the disclosure provides a DCN-2 that is covalently modified at Cysl 15. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-2 in a subject. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-2 Cys-115 in a subject. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-2 Cys-115 in a subject for the treatment of sickle cell disease.

[0210] In one aspect, the present disclosure provides a method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof a compound or composition thereof disclosed herein, or a pharmaceutically acceptable salt thereof. In another aspect, the present disclosure provides a method of inducing or increasing production of fetal hemoglobin. Such methods are useful, for example, in treating hemoglobin-related disorders including sickle cell disorders, diseases and conditions and thalassemia.

[0211] In some embodiments, the hemoglobinopathy is a sickle cell disorder or disease.

[0212] In some embodiments, the hemoglobinopathy is a thalassemia disorder or disease.

[0213] In one aspect, the present disclosure provides a method to increase red blood cell levels and / or hemoglobin levels in a subject in need thereof, treat or prevent an anemia in a subject in need thereof, treat sickle-cell disease in a subject in need thereof, or treat one or more complications of sickle-cell disease in a subject in need thereof, comprising administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof.

[0214] In one aspect, the present disclosure provides a method to increase fetal hemoglobin levels in a subject in need thereof, treat or prevent an anemia in a subject in need thereof, treat sickle-cell disease in a subject in need thereof, or treat one or more complications of sicklecell disease in a subject in need thereof, comprising administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof.

[0215] In some embodiments, the present disclosure provides a method for the treatment of a DCN-1 associated disease. In some embodiments, the present disclosure provides a method for 141335853366 CENC-015 / 01WO 360899-2048the treatment of a DCN-2 associated disease. In some embodiments, the present disclosure provides a method for the treatment of cancers, premalignant conditions (e.g., hyperplasia, metaplasia, and dysplasia), benign tumors, hyperproliferative disorders, and benign dysproliferative disorders. Such methods comprise the step of administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is characterized by overexpression ofDCN-1 and / or DCN-2.

[0216] In some embodiments, cancers and related disorders that can be treated or prevented by methods disclosed herein include, but are not limited, to the following: a squamous cell carcinoma, a metastatic squamous cell carcinoma, a non-small cell lung carcinoma, a uterine carcinosarcoma, an embryonal rhabdomyosarcoma, a glioblastoma, a medulloblastoma, an osteosarcoma, or an adrenocortical tumor. In some embodiments, the cancer and related disorders include a cancer of the lung, cervix, ovary, uterus, esophagus, prostate, or head and neck.

[0217] In some embodiments, the cancer of the lung includes a non-small cell lung cancer, including, but not limited to a squamous cell carcinoma, adenocarcinoma, or large cell-undifferentiated carcinoma.

[0218] In some embodiments, cancers and related disorders include a hematological malignancy such as a leukemia, a lymphoma, a myeloma, a multiple lymphoma, a B-cell nonHodgkin’s lymphoma, or an acute myeloid leukemia.

[0219] In some embodiments, the present disclosure provides a method for the treatment of a cancer, including, but not limited to, leukemia, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, polycythemia vera, Lymphoma, Hodgkin’s disease, non-Hodgkin’s disease, multiple myeloma, Waldenstrom’s macroglobulinemia, heavy chain disease, solid tumors, sarcomas and carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,142335853366 CENC-015 / 01WO 360899-2048hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms’ tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[0220] In some embodiments, the present disclosure provides a method for the treatment of leukemia, including, but not limited to, acute leukemia, acute lymphocytic leukemia; acute myelocytic leukemia, including, but not limited to, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia and myelodysplastic syndrome; chronic leukemia, including, but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas, including, but not limited to, Hodgkin's lymphoma, non-Hodgkin's lymphoma; myeloma, including, but not limited, to smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone and connective tissue sarcomas, including, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurilemmoma, rhabdomyosarcoma, synovial sarcoma; brain tumor, including, but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary brain lymphoma; breast cancer, including, but not limited to, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget's disease, and inflammatory breast cancer; adrenal cancer, including, but not limited to, pheochromocytom and adrenocortical carcinoma; thyroid cancer, including, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer, including, but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; pituitary cancers, including, but not limited to, Cushing's disease, prolactinsecreting tumor, acromegaly, and diabetes insipius; eye cancer, including, but not limited to, ocular 143335853366 CENC-015 / 01WO 360899-2048melanoma such as iris melanoma, choroidal melanoma, and cilliary body melanoma, and retinoblastoma; vaginal cancer, including, but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer, including, but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancer, including, but not limited to, squamous cell carcinoma, and adenocarcinoma; uterine cancer, including, but not limited to, endometrial carcinoma and uterine sarcoma; ovarian cancers, including, but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; esophageal cancer, including, but not limited to, squamous cancer, adenocarcinoma, adenoid cyctic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; stomach cancer, including, but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphom, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancer; rectal cancer; liver cancer, including, but not limited to, hepatocellular carcinoma and hepatoblastoma, gallbladder cancer, including, but not limited to, adenocarcinoma; cholangiocarcinoma, including, but not limited to, pappillary, nodular, and diffuse; lung cancer, including, but not limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma and small-cell lung cancer; testicular cancer, including, but not limited to, germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, and choriocarcinoma (yolk-sac tumor); prostate cancer, including, but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penal cancers; oral cancer, including, but not limited to, squamous cell carcinoma; basal cancers; salivary gland cancer, including, but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; pharynx cancer, including, but not limited to, squamous cell cancer, and verrucous; skin cancer, including, but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, and acral lentiginous melanoma; kidney cancer, including, but not limited to, renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and / or uterer); Wilms’ tumor; bladder cancer, including, but not limited to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, carcinosarcoma. In addition, cancer includes myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, mesothelioma, synovioma,144335853366 CENC-015 / 01WO 360899-2048hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinomas.

[0221] In some embodiments, the present disclosure provides a method for the treatment of liver injury. Without being limited to a specific mechanism, targeting neddylation provides a method for the treatment of liver fibrosis and liver injury. (See e.g., Zubiete-Franco et al. Hepatology 65 (2) 2017, 694-709). Thus, in some embodiments, the present disclosure provides a method for the treatment of hepatitis, Non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, cirrhosis, hemochromatosis, jaundice, autoimmune liver disorders, liver cancer, galactosemia, alpha-1 antitrypsin deficiency, Wilson disease, oxalosis, liver adenoma, Alagille syndrome, primary biliary cholangitis (PBC), and lysosomal acid lipase deficiency (LAL-D).

[0222] In some embodiments, the present disclosure provides a method for the treatment of heart disease. Without being limited to a specific mechanism, targeting neddylation, provides a method for the treatment of heart disease (See e.g., Kandala et al., Am. J. Cardiovasc. Dis 4, 2014, 140). Thus, in some embodiments, the present disclosure provides a method for the treatment of arrhythmia, heart failure, coronary artery disease, heart valve disease, congenital heart disease, angina, cardiomyopathy, pericarditis, peripheral artery disease, aortic aneurysm, aortic stenosis, deep vein thrombosis, Marfan syndrome and rheumatic heart disease.

[0223] In some embodiments, the present disclosure provides a method for the treatment of neurodegenerative diseases (See e.g., Villa et al., Eur J. Neurol. 16 (7) 2009, 870. Thus, in some embodiments, the present disclosure provides a method for the treatment of amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple system atrophy, tauopathies and prion diseases.

[0224] In some embodiments, the method optionally comprises co-administration of a second therapeutic agent. In some embodiments, the second therapeutic agent is hydroxyurea or a pharmaceutically acceptable salt thereof.

[0225] In one aspect, the present disclosure provides a method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a second agent such as hydroxyurea or a pharmaceutically acceptable salt thereof.

[0226] In some embodiments, the hemoglobinopathy is a sickle cell disorder or disease.

[0227] In some embodiments, the hemoglobinopathy is a thalassemia disorder or disease.145335853366 CENC-015 / 01WO 360899-2048

[0228] In some embodiments, the compound or pharmaceutically acceptable salt thereof and the hydroxyurea or a pharmaceutically acceptable salt thereof act synergistically.

[0229] In some embodiments, the compound or pharmaceutically acceptable salt thereof is selected from one of those shown in Table 1, or a pharmaceutically acceptable salt thereof.

[0230] In one aspect, the present disclosure provides a method of increasing efficacy and / or reducing toxicity of hydroxyurea treatment in a subject undergoing said treatment, comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the hydroxyurea treatment is for a hemoglobinopathy. In some embodiments, the hydroxyurea treatment is for sickle cell disease. In some embodiments, the hydroxyurea treatment is for a thalassemia disorder.

[0231] In some embodiments, the method further comprises the step of decreasing an amount of hydroxyurea being administered to the subject.

[0232] In some embodiments, the amount of hydroxyurea being administered is decreased by 10-90%.

[0233] In one aspect, the present disclosure provides a method of decreasing the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof, wherein the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of the hemoglobinopathy disorder or disease is less than the dose needed for treatment in the subject using hydroxyurea or a pharmaceutically acceptable salt thereof as a monotherapy.

[0234] In some embodiments, the dose of hydroxyurea or a pharmaceutically acceptable salt thereof co-administered with the compound or pharmaceutically acceptable salt thereof is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% relative to the dose needed for treatment in the subject using hydroxyurea or a pharmaceutically acceptable salt thereof as a monotherapy.

[0235] In some embodiments, the compound or pharmaceutically acceptable salt thereof is selected from one of those shown in Table 1, or a pharmaceutically acceptable salt thereof.

[0236] In some embodiments, the present disclosure provides a method to treat or prevent one or more complications of sickle cell disease including, for example, anemia, anemia crisis,146335853366 CENC-015 / 01WO 360899-2048splenomegaly, pain crisis, chest syndrome, acute chest syndrome, blood transfusion requirement, organ damage, pain medicine (management) requirement, splenic sequestration crises, hyperhemolytic crisis, vaso-occlusion, vaso-occlusion crisis, acute myocardial infarction, sicklecell chronic lung disease, thromboemboli, hepatic failure, hepatomegaly, hepatic sequestration, iron overload and complications of iron overload (e.g., congestive heart failure, cardiac arrhythmia, myocardial infarction, other forms of cardiac disease, diabetes mellitus, dyspnea, hepatic disease and adverse effects of iron chelation therapy), splenic infarction, acute and / or chronic D renal failure, pyelonephritis, aneurysm, ischemic stroke, intraparenchymal hemorrhage, subarachnoid hemorrhage, intraventricular hemorrhage, peripheral retinal ischemia, proliferative sickle retinopathy, vitreous hemorrhage, and / or priapism; comprising administering to a subject in need thereof a disclosed compound or pharmaceutically acceptable salt thereof, optionally in combination with a second therapeutic agent such as hydroxyurea or a pharmaceutically acceptable salt thereof.

[0237] In some embodiments, the compound or pharmaceutically acceptable salt thereof acts synergistically in combination with the second therapeutic agent, e.g., hydroxyurea or a pharmaceutically acceptable salt thereof.4. Combination Therapies

[0238] In one aspect, the compounds of the present disclosure are used advantageously in combination with a second therapeutic agent. Such a second therapeutic agent includes, in some embodiments, hydroxyurea or a pharmaceutically acceptable salt thereof.

[0239] In some embodiments, the disclosure provides methods for using a compound or combination therapy (for example, a disclosed compound or pharmaceutically acceptable salt thereof in combination with hydroxyurea or a pharmaceutically acceptable salt thereof) to treat or prevent vascular occlusion (vaso-occlusion) in a sickle-cell disease patient in need thereof as well as various complications associated with vaso-occlusion in a sickle-cell disease patient (e.g., vasoocclusion crisis, pain crisis, etc.). In some embodiments, the disclosure provides methods for using a disclosed compound or combination therapy to treat or prevent anemia in a sickle-cell disease patient in need thereof as well as various complications associated with anemia in a sickle-cell disease patient (e.g., aplastic crisis, hyperhemolytic crisis, etc.). In such methods, a disclosed compound or combination therapy can be used to increase red blood cell levels while reducing the need for red blood cell transfusions and / or iron chelation therapy, and thereby reduce morbidity 147335853366 CENC-015 / 01WO 360899-2048and mortality associated with iron accumulation in vulnerable tissues / organs. In such methods, a disclosed compound or combination therapy can also be used to reduce the need for other supportive therapies for treating sickle-cell disease [e.g., treatment with hydroxyurea, treatment with an EPO or other EPO agonist, and / or pain management (e.g., treatment with one or more of opioid analgesic agents, non-steroidal anti-inflammatory drugs, and / or corticosteroids)]. In part, a disclosed compound or combination therapy can be used in combination with existing supportive therapies for sickle-cell disease including, for example, transfusion of red blood cells, iron chelation therapy, hydroxyurea therapy, EPO or EPO agonist therapy, and / or pain management therapy. Optionally, a disclosed compound or combination therapy can be used to reduce the amount, duration, etc. of an existing supportive therapy for sickle-cell disease. For example, while transfusion of red blood cells and iron chelation therapy may help treat certain complications of sickle-cell disease, they sometimes result in adverse side effects. Therefore, in certain aspects, a disclosed compound or combination therapy can be used to reduce the amount of a second supportive therapy, e.g., reduce blood cell transfusion burden or reduce the dosage of a chelation therapeutic. In certain aspects, the disclosure provides uses of a disclosed compound or combination therapy (optionally in combination with one or more supportive therapies for sicklecell disease) for making a medicament for the treatment or prevention of sickle-cell disease, particularly one or more complications of sickle-cell disease as disclosed herein.5. Compositions

[0240] The present disclosure also provides compositions that comprise or deliver a compound as provided herein. In some embodiments, the present disclosure provides compositions comprising a compound provided herein with one or more other components.

[0241] In some embodiments, provided compositions comprise and / or deliver a compound described herein. In some embodiments, a provided composition is a pharmaceutical composition that comprises and / or delivers a compound provided herein and further comprises a pharmaceutically acceptable carrier.

[0242] Pharmaceutical compositions typically contain an active agent (e.g., a compound described herein) in an amount effective to achieve a desired therapeutic effect while avoiding or minimizing adverse side effects. In some embodiments, provided pharmaceutical compositions comprise a compound described herein and one or more carriers or excipients (e.g., fillers, disintegrants, lubricants, glidants, anti-adherents, and / or anti-statics, etc.) Provided pharmaceutical 148335853366 CENC-015 / 01WO 360899-2048compositions can be in a variety of forms including oral dosage forms, topical creams, topical patches, iontophoresis forms, suppository, nasal spray and / or inhaler, eye drops, intraocular injection forms, depot forms, as well as injectable and infusible solutions.

[0243] Provided pharmaceutical compositions can be prepared with any appropriate available technologies.

[0244] In some embodiments, provided compounds are formulated in a unit dosage form for ease of administration and uniformity of dosage. The expression “unit dosage form” as used herein refers to a physically discrete unit of an active agent (e.g., a compound described herein) for administration to a subject. Typically, each such unit contains a predetermined quantity of active agent. In some embodiments, a unit dosage form contains an entire single dose of the agent. In some embodiments, more than one unit dosage form is administered to achieve a total single dose. In some embodiments, administration of multiple unit dosage forms is required, or expected to be required, in order to achieve an intended effect. A unit dosage form may be, for example, a liquid pharmaceutical composition containing a predetermined quantity of one or more active agents, a solid pharmaceutical composition (e.g., a tablet, a capsule, or the like) containing a predetermined amount of one or more active agents, a sustained release formulation containing a predetermined quantity of one or more active agents, or a drug delivery device containing a predetermined amount of one or more active agents, etc.

[0245] Provided compositions may be administered in accordance with a dosing regimen (i.e., that includes a single dose or multiple doses separated from one another in time, administered via a particular route of administration) that is (e.g., has been demonstrated to be) effective for treating (e.g., delaying onset of and / or decreasing incidence and / or intensity of) a disease or disorder, for example as described herein.

[0246] The present disclosure also provides methods of preparing pharmaceutical compositions provided herein. In some embodiments, provided methods comprise (i) providing a provided compound or a pharmaceutically acceptable salt thereof; and (ii) formulating the compound with suitable excipients to give a pharmaceutical composition.6. General Methods of Providing the Present Compounds

[0247] The compounds of this invention may be prepared or isolated in general by synthetic and / or semi-synthetic methods known to those skilled in the art for analogous compounds and by methods described in detail in the Examples, herein.149335853366 CENC-015 / 01WO 360899-2048

[0248] In the schemes and chemical reactions depicted in the detailed description, Examples, where a particular protecting group (“PG”), leaving group (“LG”), or transformation condition is depicted, one of ordinary skill in the art will appreciate that other protecting groups, leaving groups, and transformation conditions are also suitable and are contemplated. Such groups and transformations are described in detail in March ’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M. B. Smith and J. March, 7thEdition, John Wiley & Sons, 2013, Comprehensive Organic Transformations, R. C. Larock, 3rdEdition, John Wiley & Sons, 2018, and Protective Groups in Organic Synthesis, P. G. M. Wuts, 5thedition, John Wiley & Sons, 2014, the entirety of each of which is hereby incorporated herein by reference.

[0249] As used herein, the phrase “leaving group” (LG) includes, but is not limited to, halogens (e.g., fluoride, chloride, bromide, iodide), sulfonates (e.g., mesylate, tosylate, benzenesulfonate, brosylate, nosylate, triflate), diazonium, and the like.

[0250] As used herein, the phrase “oxygen protecting group” includes, for example, carbonyl protecting groups, hydroxyl protecting groups, etc. Hydroxyl protecting groups are well known in the art and include those described in detail in Protective Groups in Organic Synthesis, P. G. M. Wuts, 5thedition, John Wiley & Sons, 2014, and Philip Kocienski, in Protecting Groups, Georg Thieme Verlag Stuttgart, New York, 1994, the entireties of which are incorporated herein by reference. Examples of suitable hydroxyl protecting groups include, but are not limited to, esters, allyl ethers, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of such esters include formates, acetates, carbonates, and sulfonates. Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxy acetate, 3 -phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethyl acetyl), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate, carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl. Examples of such silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers. Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxy carbonyl ethers or derivatives. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta- (trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers. Examples of arylalkyl ethers include 150335853366 CENC-015 / 01WO 360899-2048benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, and 2- and 4-picolyl.

[0251] Amino protecting groups are well known in the art and include those described in detail in Protective Groups in Organic Synthesis, P. G. M. Wuts, 5thedition, John Wiley & Sons, 2014, and Philip Kocienski, in Protecting Groups, Georg Thieme Verlag Stuttgart, New York, 1994, the entireties of which are incorporated herein by reference. Suitable amino protecting groups include, but are not limited to, aralkylamines, carbamates, cyclic imides, allyl amines, amides, and the like. Examples of such groups include t-butyloxycarbonyl (Boc), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxocarbonyl (Cbz), allyl, phthalimide, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), formyl, acetyl, chloroacetyl, di chloroacetyl, trichloroacetyl, phenylacetyl, trifluoroacetyl, benzoyl, and the like.

[0252] One of skill in the art will appreciate that various functional groups present in compounds of the invention such as aliphatic groups, alcohols, carboxylic acids, esters, amides, aldehydes, halogens, and nitriles can be interconverted by techniques well known in the art including, but not limited to reduction, oxidation, esterification, hydrolysis, partial oxidation, partial reduction, halogenation, dehydration, partial hydration, and hydration. See, for example, March ’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M. B. Smith, and J. March, 7thEdition, John Wiley & Sons, 2013, Comprehensive Organic Transformations, R. C. Larock, 3rdEdition, John Wiley & Sons, 2018, the entirety of each of which is incorporated herein by reference. Such interconversions may require one or more of the aforementioned techniques, and certain methods for synthesizing compounds of the invention are described below.

[0253] One of skill in the art will appreciate that various functional groups present in compounds of the invention such as aliphatic groups, alcohols, carboxylic acids, esters, amides, aldehydes, halogens, and nitriles can be interconverted by techniques well known in the art including, but not limited to reduction, oxidation, esterification, hydrolysis, partial oxidation, partial reduction, halogenation, dehydration, partial hydration, and hydration. Such groups and transformations are described in detail in March 's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M. B. Smith and J. March, 7thEdition, John Wiley & Sons, 2013, Comprehensive Organic Transformations, R. C. Larock, 3rdEdition, John Wiley & Sons, 2018, and Protective Groups in Organic Synthesis, P. G. M. Wuts, 5thedition, John Wiley & Sons, 2014, the entirety of each of which is hereby incorporated herein by reference. Such interconversions 151335853366 CENC-015 / 01WO 360899-2048may require one or more of the aforementioned techniques, and certain methods for synthesizing compounds of the invention are described below in the Exemplification.EXEMPLIFICATION

[0254] As depicted in the Examples below, exemplary compounds are prepared according to the following general procedures and used in biological assays and other procedures described generally herein. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein. Similarly, assays and other analyses can be adapted according to the knowledge of one of ordinary skilled in the art.Example 1: Synthesis of compoundsGeneral Synthetic Schemes

[0255] The compounds of Formula 1 may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and transformations that are familiar to those of ordinary skill in the art. The starting materials used herein are commercially available or may be prepared by routine methods known in the art, such as those methods disclosed in standard reference books. Preferred methods include, but are not limited to, those described below.

[0256] During any of the following synthetic sequences, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference.

[0257] Compounds of Formula 1, or their pharmaceutically acceptable salts, can be prepared according to the reaction Schemes discussed herein below. Unless otherwise indicated, the substituents in the Schemes are defined as above. Isolation and purification of the products is accomplished by standard procedures, which are known to a chemist of ordinary skill.

[0258] It will be understood by one skilled in the art that the various symbols, superscripts and subscripts used in the schemes, methods and examples are used for convenience of representation 152335853366 CENC-015 / 01WO 360899-2048and / or to reflect the order in which they are introduced in the schemes, and are not intended to necessarily correspond to the symbols, superscripts or subscripts in the appended claims. Additionally, one skilled in the art will recognize that in many cases, these compounds will be mixtures of stereoisomers that may be separated at various stages of the synthetic schemes using conventional techniques, such as, but not limited to, crystallization, normal phase chromatography, reversed phase chromatography and chiral chromatography, to afford single enantiomers. The schemes are representative of methods useful in synthesizing the compounds of the present invention. They are not to constrain the scope of the invention in any way.Scheme 1

[0259] Scheme 1 illustrates a generally applicable approach to the synthesis of intermediates of Formula F, which are versatile intermediates that may be further elaborated to the compounds of Formula 1. An amide of glycine of Formula A, wherein X is an optionally selected substituent and the aryl ring may contain further substituents as desired, is converted to an Erlenmeyer azlactone of Formula B through the elimination of water, which can be accomplished by a number of means known in the art. The azlactone of Formula B may then be subjected to a Knoevenagel condensation with an aldehyde of Formula RiCHO under appropriate conditions known in the art to provide a vinylidene azlactone of Formula C. This is treated with an enamine of Formula D, usually with heating, to provide the dihydropyridone derivative of Formula E. The enamine of 153335853366 CENC-015 / 01WO 360899-2048Formula D is typically a lower alkyl ester in which R is a methyl or ethyl group. It will be appreciated that two stereogenic centers are produced in this reaction and that the compound of Formula E so produced will likely contain a mixture of stereoisomers, and that these stereoisomers may be separated at various points in the synthetic sequence. Being an ester, the compound of Formula E may be saponified to provide the carboxylic acid intermediate of Formula F. The execution of these steps is detailed in the Examples that follow.Scheme 2

[0260] While the stereoisomers of the present invention may be separated at various points in the synthetic sequence, it is generally convenient to do so on carboxylic acid intermediates of Formula F as shown in Scheme 2 due to the many known methods and well-developed procedures in the chemical literature for the resolution of carboxylic acids. Resolution of a compound of Formula F will provide separated stereoisomers, usually single enantiomers, here represented as compounds of Formula Fa* and Fa**. It will be understood that any of these carboxylic acid derivatives of Formulas F, Fa*, or Fa** may be used in the synthetic sequences that follow.Scheme 3

[0261] Scheme 3 illustrates the transformation of the carboxylic acid of Formula F to a compound of Formula 1 by the formation of an amide with an amine of Formula R4R5NH, in which the substituents R4 and Rs may vary widely, as will be seen in the following Examples and in the 154335853366 CENC-015 / 01WO 360899-2048Table. The preparation of amides from carboxylic acids is well known in synthetic organic chemistry and an abundance of effective methods are known and exemplified in the Examples and Methods that follow.Scheme 4

[0262] Scheme 4 illustrates the transformation of the carboxylic acid of Formula F to a homologated carboxylic acid of Formula G, which may be performed in a variety of ways of which the Arndt - Eistert method is perhaps the most direct and well known. The resulting compound of Formula G may be converted to a compound of Formula 1 by the formation of an amide with an amine of Formula R4R5NH, in which the substituents R4 and Rs may vary widely, as will be seen in the Table. The preparation of amides from carboxylic acids is well known in synthetic organic chemistry and an abundance of effective methods are known and exemplified in the Examples and Methods that follow.Scheme 5

[0263] Scheme 5 illustrates the transformation of the carboxylic acid of Formula F to an amine of Formula H. This may be accomplished by well known functional group manipulations, and the 155335853366 CENC-015 / 01WO 360899-2048use of these transformations is represented in the Examples. The resulting amine of Formula H may then be converted into amide derivatives of Formula 1 by treatment with a carboxylic acid of Formula ReCChH or a carboxylic acid chloride of Formula ReCOCl, or the amine of Formula H may be converted into sulfonamide derivatives by treatment with a sulfonyl chloride of Formula ReSChCl. These latter transformations are illustrated in the accompanying Methods.

[0264] Scheme 6 illustrates the transformation of the carboxylic acid of Formula F to a bromide of Formula I by the application of the Hunsdiecker reaction. This is another well known reaction, and its application is provided in the Examples that follow. The bromide of Formula I is a versatile intermediate that may be transformed into a variety of further derivatives of Formula 1, in which the R? group shown can have many functional expressions and derivatives. The synthesis of these derivatives of Formula 1 may be accomplished by a category of reactions broadly known as cross coupling reactions, which permit a great diversity of R? groups to be introduced. In the Examples that follow, the use of the Suzuki - Miyaura reaction and the nickel-catalyzed cross electrophile coupling reaction are presented, as are the subsequent further functionalization of the R? groups. It will be apparent to one skilled in the art that many other couplings leading to other expressions of R? are possible.Scheme 7156335853366 CENC-015 / 01WO 360899-2048

[0265] Scheme 7 illustrates the transformation of the carboxylic acid of Formula F to a carbamate of Formula J by the application of the Curtius reaction. Alternatively, the transformation may be effected in additional steps by the application of the Lessen or Hofmann reactions. The carbamates of Formula J may contain any manner of groups Rs; however, for further synthetic transformations one skilled in the art will generally select Rs equal to tert-butyl, methyl, ethyl, or benzyl due to the many convenient procedures for their introduction and subsequent removal. Subsequent acylation of the compound of Formula J with a carboxylic acid of Formula ReCChH or a carboxylic acid chloride of Formula ReCOCl, followed by cleavage of the carbamate RsCCh radical, yields the compounds of Formula 1 shown. This sequence of transformations is illustrated in the accompanying Examples.

[0266] In the table presenting specific embodiments of this invention, the specific compounds of Formulas F, Fa*, Fa**, G, H, I and J that are used in each particular example are referred to as Reagent A. In many cases, particular advanced intermediates from the Examples will be employed as Reagent A. Likewise, the specific additional compound that is used in each particular example is referred to as Reagent B. In some cases, no additional Reagent B is indicated for simplicity; however, it will be clear from the Methods presented in the Table what additional reagents are employed, for example the use of cyanogen bromide as described in Method 3, or hydrogen chloride in Method 4.Experimental Procedures and Working Examples

[0267] The following illustrate the synthesis of various compounds of the present invention. Additional compounds within the scope of this invention may be prepared using the methods illustrated in these Examples, either alone or in combination with techniques generally known in the art.

[0268] It will be understood that the intermediate compounds of the invention depicted above are not limited to the particular enantiomer(s) shown but also include all stereoisomers and mixtures thereof.Experimental Procedures157335853366 CENC-015 / 01WO 360899-2048

[0269] Experiments were carried out with continuous stirring under inert atmosphere (nitrogen or argon). Commercial solvents and reagents were generally used without further purification, including anhydrous solvents where appropriate. Unless noted otherwise, all reactants were obtained commercially. All concentrations were conducted under reduced pressure using techniques well known to one skilled in the art. Solvent mixtures used for chromatography are expressed as volume ratios; for example, petroleum ether / ethyl acetate (3:1 ) means three volumes of petroleum ether were mixed with one volume of ethyl acetate to prepare the eluting solvent. Products were generally dried under vacuum before being carried on to further reactions or submitted for biological testing.

[0270] Mass spectrometry data is reported from either liquid chromatography-mass spectrometry (LCMS), atmospheric pressure chemical ionization (APCI) or gas chromatographymass spectrometry (GCMS) instrumentation. It will be noted that LCMS instruments are generally capable of returning positive ions resulting from the addition of a proton to the analyte, negative ions resulting from the loss of a proton from the analyte, or both. Depending on the chemical structure of the particular analyte, the positive or negative ion may be more abundant. Nuclear magnetic resonance (NMR) data were recorded on Bruker 300 MHz or 400 MHz instruments internally referenced to a tetramethylsilane (TMS) signal. Chemical shifts (d) and coupling constants (J) are expressed in parts per million and hertz, respectively.

[0271] Methods used for LCMS include the following:Method-A: Column: L-column3 C183.0*30 mm, 3um; Mobile Phase A: 5 mM NH4HCO3 in water; B: Acetonitrile; Flow Rate: 1.2 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.00 / 10.0, 1.4 / 95, 1.9 / 95, 1.91 / 10.Method-B: Column: HALO C18, 3.0*30 mm, 2 um; Mobile Phase A: Water / 0.05% TFA; B: Acetonitrile; Flow Rate: 1.5 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.01 / 5, 1.5 / 95, 1.9 / 95, 1.91 / 5.Method-C: Column: HPH-C18, 3.0*50 mm, 2.7 um; Mobile Phase A: Water / 0.05% NH4OH; B: Acetonitrile; Flow Rate: 1.2 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.50 / 55, 3.50 / 70, 4.00 / 95, 4.80 / 95, 4.81 / 5.158335853366 CENC-015 / 01WO 360899-2048Method-D: Column: CORTECS Cl 8+ 3.0*30 mm, 2.7 urn; Mobile Phase A: Water / 0.05% TFA; B: Acetonitrile; Flow Rate: 1.5 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.30 / 30, 1.80 / 60, 2.20 / 95, 2.80 / 95, 2.81 / 5.Method-E: Column: SB-Aq 4.6*50 mm, 1.8 um; Mobile Phase A: Water / 0.05% TFA; B:Acetonitrile; Flow Rate: 1.5 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.00 / 5, 0.30 / 40, 1.80 / 80, 2.20 / 95, 2.80 / 95, 2.81 / 5.Method-F: Column: SB-Aq 4.6*50 mm, 1.8 um; Mobile Phase A: Water / 0.05% TFA; B:Acetonitrile; Flow Rate: 1.5 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.00 / 5, 0.40 / 40, 3.20 / 70, 4.10 / 95, 4.80 / 95, 4.81 / 5.Method-G: Column: L-column3 C18, 3.0*50 mm, 3 um; Mobile Phase A: Water / 0.05% NFLOH; B: Acetonitrile; Flow Rate: 1.2 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.01 / 5, 2.00 / 95, 2.80 / 95, 2.81 / 5.Method-H: Column: HPH-C18, 4.6*100 mm, 2.7 um; Mobile Phase A: Water / 0.05% NH4OH; B: Acetonitrile; Flow Rate: 1.2 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.01 / 40, 5.50 / 70, 6.5 / 95, 7.50 / 95, 7.51 / 40,Method-L Column: L-column3 Cl 8, 3.0*50 mm, 3 um; Mobile Phase A: Water / 0.05% NH4OH; B: Acetonitrile; Flow Rate: 1.2 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.01 / 5, 0.50 / 50, 2.10 / 80, 2.60 / 95, 3.30 / 95, 3.31 / 5.Method-J: Column: L-column3 C183.0*30 mm, 3um; Mobile Phase A: 5 mMNELHCOs in water; B: Acetonitrile; Flow Rate: 1.2 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.00 / 10.0, 0.30 / 40, 1.80 / 70, 2.20 / 95, 2.90 / 95, 2.91 / 10.Method-K: Column: HALO C18, 3.0*30 mm, 2 um; Mobile Phase A: Water / 0.05% TFA; B: Acetonitrile; Flow Rate: 1.5 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.01 / 5, 2.00 / 40, 2.50 / 95, 2.80 / 95, 2.81 / 5.Method-L: Column: HPH-C18, 3.0*50 mm, 2.7 um; Mobile Phase A: Water / 0.05% NH4OH; B: Acetonitrile; Flow Rate: 1.2 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.01 / 5, 0.50 / 30, 2.10 / 60, 2.50 / 95, 2.80 / 95, 2.81 / 5.Method-M: Column: SB-Aq 4.6*50 mm, 1.8 um; Mobile Phase A: Water / 0.02% formic acid; B: Acetonitrile / 0.02% formic acid; Flow Rate: 1.5 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.00 / 5.0, 0.40 / 20, 3.00 / 50, 4.00 / 95.0, 4.80 / 95.0, 4.81 / 5.0.159335853366 CENC-015 / 01WO 360899-2048Method-N: Column: L-column3 Cl 83.0*30 mm, 3um; Mobile Phase A: 5 mMNl-UHCCh in water; B: Acetonitrile; Flow Rate: 1.2 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.00 / 10.0, 1.80 / 50, 2.30 / 95, 2.90 / 95, 2.91 / 10.Method-O: Column: Atlantis Premier BEH C18 AX, 4.6*50mm, 2.5 um; Mobile Phase A:Water / 0.05% NFUOH; B: Acetonitrile; Flow Rate: 1.2 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.01 / 5, 0.50 / 40, 2.10 / 70, 2.50 / 95, 2.80 / 95, 2.81 / 5.Method-P: Column: YMC-Triart C18, 3.0*50 mm, 3 um; Mobile Phase A: Water / 0.05% NFLOH; B: Acetonitrile; Flow Rate: 1.2 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.01 / 5, 0.80 / 45, 3.60 / 75, 4.00 / 90, 4.80 / 95, 4.81 / 5.Method-Q: Column: HALO 90A, PCS C18 3.0*30 mm, 2.7um; Mobile Phase A: Water / 0.02% formic acid; B: Acetonitrile / 0.02% formic acid; Flow Rate: 1.5 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.00 / 5.0, 1.50 / 95.0, 1.90 / 95.0, 1.91 / 5.0.Method-R: Column: Kinetex XB-C18, 3.0*30 mm, 1.7 um; Mobile Phase A: Water / 0.1% formic acid; B: Acetonitrile / 0.07% formic acid; Flow Rate: 1.5 mL / min.; Oven Temperature: 40 °C; Gradient program (B%): 0.00 / 5.0, 1.50 / 95.0, 1.90 / 95.0, 1.91 / 5.0.Method-S: Column: SB-Aq, 3.0*30mm, 1.8 um; Mobile Phase A: Water / 0.05% TFA; B:Acetonitrile; Flow Rate: 1.5 mL / min.; Oven Temperature: 40 °C, Gradient program (B%): 0.01 / 5, 1.5 / 95, 1.9 / 95, 1.91 / 5.

[0272] Purification by reverse phase HPLC was carried out under the following conditions unless otherwise specified:Method-A: column, C18 silica gel; mobile phase A, water (containing 0.1% formic acid), mobile phase B, MeCN (10% to 50% gradient in 10 min); detector, UV 254 nm.Method-B: column, XBridge Prep OBD C18 30*150 mm, 5pm; Mobile Phase A: Water (containing 10 mM NH4HCO3 and 0.05% NH4OH), Mobile Phase B: MeCN; Flow rate: 35 mL / min.; Gradient: isocratic 52%-60% lOmin; detector, 254nm and 220nm.

[0273] Methods used for chiral supercritical fluid chromatography include the following: Method-A: Column: (R, R)-WHELK CORE 3.0*50 mm,2.7um; Co-Solvent B: MeOH - DCM (1 / 1 v / v containing 10 mM NH3); Gradient (B): 10% to 50% in 2.0 min, hold 1.0 min at 50%. Flow rate: 3.0 ml / min; Column Temperature: 35 °C.160335853366 CENC-015 / 01WO 360899-2048Method-B: Column: Cellulose-SC 4.6*100 mm, 3.0 um; Co-Solvent B: MeOH - DCM (1 / 1 v / v containing 10mM NH3); Gradient (B): 0.01 / 10, 2.50 / 50, 3.70 / 50, 3.71 / 10; Flow rate: 3.0 ml / min; Column Temperature: 40 °C.Method-C: Column: CHIRALPAK IG-3 3.0*50 mm, 3um; Co-Solvent B: MeOH - DCM (1 / 1 v / v containing 20 mMNHs); Gradient (B): 10% to 50% in 2.0 min, hold 1.0 min at 50%. Flow rate: 3.0 ml / min; Column Temperature: 35 °C.Method-D: Column: CHIRALPAK IG-U, 3.0*50 mm, 1.6 um; Co-Solvent B: MeOH - DCM (1 / 1 v / v containing 20 mM NH3); Gradient (B): 10% to 50% in 2.0 min, hold 1.0 min at 50%. Flow rate: 3.0 ml / min; Column Temperature: 35 °C.

[0274] Methods used for chiral stationary phase HPLC include the following:Method-B: CHIRALPAK IH-34.6*100 mm, 3um, IH30CC-BT002; Mobile Phase A: n-Hexane - THF (4 / 1 v / v); B: MeOH; Cone, of Pump B: 2.0%; Flow rate: 1.0 ml / min; Column Temperature: 25 °C.

[0275] For syntheses referencing procedures in other Examples or Methods, reaction conditions (length of reaction and temperature) may vary. In general, reactions were followed by thin layer chromatography and / or liquid chromatography-mass spectrometry and subjected to work-up when appropriate. It will be recognized by one skilled in the art that purifications may vary between experiments: in general, sorbents, solvents and the solvent ratios used for eluants / gradients were chosen to provide appropriate Rrs or retention times. It will also be recognized by one skilled in the art that HPLC purifications may be effected in a variety of ways, including the use of normal stationary phases, reverse stationary phases, chiral stationary phases, and supercritical eluants. The appropriate choices of conditions for chromatographic and HPLC purifications will be discerned by one skilled in the art.

[0276] The following Preparations describe the preparation of certain intermediates used in the Methods and Examples that follow. The following Preparations, Methods and Examples are intended to illustrate particular embodiments of the invention and preparations thereto and are not intended to limit the specification, including the claims, in any manner.AbbreviationsUnless indicated otherwise, the following abbreviations have the indicated meanings:161335853366 CENC-015 / 01WO 360899-2048

[0277] Unless indicated otherwise, the following chemical formulas and acronyms have the indicated meanings:162335853366 CENC-015 / 01WO 360899-2048163335853366 CENC-015 / 01WO 360899-2048PreparationsPreparation 1: Synthesis of ethyl (Z)-3-(ethylamino)hex-2-enoate (1)

[0278] Ethylamine (about 70% in water, 97.6 g, 1.52 mol, 3.00 equiv.) was added in portions to a solution of ethyl 3 -oxohexanoate (80.0 g, 505 mmol, 1.00 equiv.) in water (800 mL) at about 0 °C. After about 16 h at about 25 °C, the mixture was extracted with EtOAc (3 x 300 mL). The combined EtOAc extracts were washed with brine (1x100 mL), dried (Na2SC>4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (10: 1) to afford the title compound 1 (83.0 g, 89% yield).2

[0279] 3-(Trifluoromethyl)benzoyl chloride (1000 g, 4.79 mol, 1.00 equiv.) was added over about 1 hto a solution of glycine (378 g, 5.03 mol, 1.05 equiv.) and sodium hydroxide (479 g, 12.0 mol, 2.5 equiv.) in a mixture of MeCN (6 L) and water (4 L) maintained at about -5 °C. After about 5 h further at about 25 °C, the mixture was acidified to about pH 6 with concentrated hydrochloric acid and extracted with EtOAc (2 x 2 L). The combined EtOAc extracts were washed with brine (164335853366 CENC-015 / 01WO 360899-20482x 2 L), dried (Na2SO4), filtered and concentrated. The residue was purified by trituration with petroleum ether (2 L), filtered and dried to give the title compound 2 (990 g, 84%).'HNMR (400 MHz, DMSO-t / e) 89.17 (t, J= 5.9 Hz, 1H), 8.25 - 8.15 (m, 2H), 7.97 - 7.90 (m, 1H), 7.75 (t, J= 7.8 Hz, 1H), 3.98 (d, J= 5.9 Hz, 2H). LCMS Calculated for C10H8F3NO3: 247.1; Observed: 248.2 [M+H]+.Preparation 3: Synthesis of 2-(3-(trifluoromethyl)phenyl)oxazol-5(4 7)-one (3)3

[0280] EDC (58.2 g, 0.303 mmol, 1.00 equiv.) was added in portions over about 30 min to a solution of compound 2 (75.0 g, 0.303 mol, 1.00 equiv.) in DCM (750 mL) at about 25 °C and stirring was continued for about 1 h further. Water (1 L) was added and the mixture, the phases separated, and the aqueous phase was extracted with DCM (2 x 500 mL). The combined DCM extracts were washed with brine (2 x 500 mL), dried (Na2SO4), filtered and concentrated to give the title compound 3 (60.0 g, 86%).1HNMR(400 MHz, DMSO-rL) 88.23 (d, J= 7.7 Hz, 1H), 8.15 (s, 1H), 8.05 (d, J= 7.9 Hz, 1H), 7.84 (t, J= 7.8 Hz, 1H), 4.62 (s, 2H). LCMS Calculated for C10H6F3NO2: 229.0; Observed: 230.1 [M+H]+.Preparation 4: Synthesis of (Z)-4-(4-fluorobenzylidene)-2-(3-(trifluoromethyl)phenyl)oxazol- 5(4 7)-one (4)4165335853366 CENC-015 / 01WO 360899-2048

[0281] A solution of compound 3 (60.0 g, 0.261 mol, 1.00 equiv.) and 4-fluorobenzaldehyde (32.5 g, 0.261 mmol, 1.00 equiv.) in DCM (600 mL) was treated with Activity 1 basic aluminum oxide (267 g, 0.261 mol, 10.0 equiv.), added in portions over about 10 min at about 25 °C and stirring was continued for about 30 min longer before the mixture was filtered. The filter was washed with EtOAc (2 x 2 L) and the combined filtrates were concentrated. The residue was purified by trituration with petroleum ether (0.5 L), filtered, and washed with additional petroleum ether (3 x 100 mL) to give after drying the title compound 4 (60 g, 68%).1HNMR(400 MHz, DM SO- r,) 88.43 - 8.34 (m, 3H), 8.29 (s, 1H), 8.09 (d, J= 7.8 Hz, 1H), 7.88 (t, J= 7.8 Hz, 1H), 7.41 (dd, J= 19.7, 11.0 Hz, 3H). LCMS Calculated for C17H9F4NO2: 335.1; Observed: 336.1 [M+H]+.Preparation 5: Synthesis of rac-ethyl (4R,5R)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylate (5)5

[0282] A solution of compound 1 (60.0 g, 324 mmol, 1.00 equiv.) and compound 4 (108 g, 324 mmol, 1.00 equiv.) in acetic acid (600 mL) was stirred at about 120 °C for about 24 h, then cooled and concentrated. The residue was taken up in EtOAc (300 mL) and adjusted to about pH 7 with 15% sodium carbonate solution. After phase separation, the aqueous phase was extracted with EtOAc (3 x 300 mL). The combined EtOAc phases were washed with brine (100 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1:1) to afford the title compound 5 (45.0 g, 27% yield).’HNMR (300 MHz, DMSO-cL) 8 8.52 (d, J= 6.8 Hz, 1H), 8.14 (q, J= 7.9 Hz, 2H), 7.90 (d, J = 7.9 Hz, 1H), 7.69 (t, J = 7.8 Hz, 1H), 7.16 - 6.92 (m, 4H), 5.13 (t, J= 7.1 Hz, 1H), 4.41 (d, = 7.4 Hz, 1H), 4.05 (qq, J= 7.5, 3.5 Hz, 3H), 3.60 (dq, J= 14.0, 6.7 Hz, 1H), 3.39 - 3.19 (m, 1H), 2.67166335853366 CENC-015 / 01WO 360899-2048(ddd, J= 14.3, 8.7, 6.1 Hz, 1H), 1.61 (p, J= 7.8 Hz, 2H), 1.20 (t, J= 6.9 Hz, 3H), 1.09 (t, J= 7.4 Hz, 3H), 1.03 (t, J= 7.3 Hz, 3H). LCMS Calculated for C27H28F4N2O4: 520.2; Observed: 521.3 [M+H]+.Preparation 6: Synthesis of rac-(4R,5R)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (6)

[0283] Sodium hydroxide (6.92 g, 172 mmol, 2.00 equiv.) was added to a solution of compound 5 (45.0 g, 86.4 mmol, 1.00 equiv.) in a mixture of water (225 mL) and acetonitrile (450 mb) and the mixture was heated at about 70 °C for about 16 h, then cooled before being acidified to about pH 5 with concentrated hydrochloric acid and extracted with EtOAc (3 x 1 L). The combined EtOAc extracts were washed with brine (500 mL), dried (Na2SO4), filtered and concentrated. The residue was triturated with ethyl ether (200 mL) and filtered. The precipitate was washed with additional ethyl ether (2 x 100 mL) and dried to give the title compound 6 (22 g, 52% yield).’H NMR (300 MHz, DMSO r,) 8 12.43 (s, 1H), 8.48 (d, J= 6.7 Hz, 1H), 8.19 - 8.08 (m, 2H), 7.91 (d, J = 7.8 Hz, 1H), 7.70 (t, J = 7.8 Hz, 1H), 7.08 (t, J = 8.8 Hz, 2H), 6.98 (dd, J = 8.7, 5.6 Hz, 2H), 5.07 (t, J= 7.0 Hz, 1H), 4.40 (d, J= 7.3 Hz, 1H), 4.09 - 3.96 (m, 1H), 3.569 - 3.3 l(m, 2H), 2.63 (s, 1H), 1.67 - 1.51 (m, 2H), 1.18 (t, J= 6.9 Hz, 3H), 1.01 (t, J= 7.3 Hz, 3H). LCMS Calculated for C25H24F4N2O4: 492.2; Observed: 491.2 [M-H] ".Preparation 7. Separation of enantiomers (4R,5R)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (7) and (4S,5S)-1-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (8)167335853366 CENC-015 / 01WO 360899-2048

[0284] Compound 3 (22 g) was purified by prep-HPLC under the following conditions (Column: XA-CHIRAL ART Cellulose-SB, 3*25 cm, 5 pm; Mobile Phase A: CO2, Mobile Phase B: 2-propanol (containing 0.1% TFA); Flow rate: 80 mL / min; Gradient (B%): isocratic 20% B; Column Temperature (°C): 35; Back Pressure (bar): 100; Wave Length: 220 nm; RT l(min): 2.5; RT 2(min): 3.0; Sample Solvent: 2-propanol; Injection Volume: 2 mb) to afford the title compounds 7 (10 g, 45% yield) and 8 (9.0 g, 41% yield).Data for 7:'H NMR (300 MHz, DMSO- s) 8 12.43 (s, 1H), 8.48 (d, J= 6.7 Hz, 1H), 8.19 - 8.08 (m, 2H), 7.91 (d, J= 7.8 Hz, 1H), 7.70 (t, J= 7.8 Hz, 1H), 7.08 (t, J= 8.8 Hz, 2H), 6.98 (dd, J= 8.7, 5.6 Hz, 2H), 5.07 (t, J= 7.0 Hz, 1H), 4.40 (d, J = 7.3 Hz, 1H), 4.09 - 3.96 (m, 1H), 3.56 (dd, J= 14.1, 6.9 Hz, 2H), 2.63 (s, 1H), 1.59 (d, J= 7.0 Hz, 1H), 1.18 (t, J= 6.9 Hz, 3H), 1.01 (t, J= 7.3 Hz, 3H). LCMS Calculated for C25H24F4N2O4: 492.2; Observed: 491.2 [M-H] ’. Purity (Method D): 99.3% atRT 1.100 min. Optical rotation: [a]o = -199.3o, (c = 0.1, MeOH, 25 °C).Data for 8:'H NMR (300 MHz, DMSO r,) 8 12.44 (s, 1H), 8.51 (d, J= 6.8 Hz, 1H), 8.22 - 8.07 (m, 2H), 7.97 - 7.84 (m, 1H), 7.70 (t, J= 7.8 Hz, 1H), 7.14 - 7.04 (m, 2H), 6.99 (ddd,, / = 8.7, 5.6, 2.6 Hz, 2H), 5.08 (t, J= 7.0 Hz, 1H), 4.40 (d, J = 7.2 Hz, 1H), 4.02 (dt, J= 14.0, 7.1 Hz, 1H), 3.56 (dt, J = 13.6, 6.9 Hz, 1H), 3.41 (dt, J= 16.3, 7.9 Hz, 1H), 2.75 - 2.57 (m, 1H), 1.76- 1.49 (m, 2H), 1.19 (t, J= 6.9 Hz, 3H), 1.02 (t, J= 13 Hz, 3H). LCMS Calculated for C25H24F4N2O4: 492.2; Observed: 493.1 [M+H]+. Purity (Method B): 98.8% atRT 1.882 min. Optical rotation: [a]o= +234.3°, (c = 0.1, MeOH, 25 °C).168335853366 CENC-015 / 01WO 360899-2048Preparation 8: Synthesis of tert-butyl ((lS,2R)-2-((4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxamido)cyclopentyl)carbamate (9)9

[0285] A solution of compound 8 (100 mg, 0.20 mmol, 1.00 equiv.), DIEA (79 mg, 0.61 mmol, 3.00 equiv.), and HATU (93 mg, 0.24 mmol, 1.20 equiv.) in DMF (2 mL) was kept at about 25 °C for about 20 min, after which tert-butyl ((lS,2R)-2-aminocyclopentyl)carbamate (CAS 445479-01-6, 49 mg, 0.24 mmol, 1.20 equiv.) was added. After about 1 h, water (30 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). The combined EtOAc extracts were washed with brine (3 x 20 mL), dried (Na2SO4), filtered and concentrated to give the title compound 9 (110 mg) which was used without further purification.LCMS Calculated for C35H42F4N4O5: 674.3; Observed: 675.4 [M+H] LPreparation 9: Synthesis of (4S,5S)-N-((lR,2S)-2-aminocyclopentyl)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxamide hydrochloride (10)10

[0286] A solution of compound 9 (110 mg, 0.16 mmol, 1.00 equiv.) inDCM (2 mL) was treated with a solution of HC1 (4.0 M in 1,4-dioxane, 0.16 mL, 4.00 equiv.) and stirred at about 25169335853366 CENC-015 / 01WO 360899-2048°C for about 3 h, then concentrated to afford the title compound 10 hydrochloride (85 mg), which was used without further purification.LCMS Calculated for C30H34F4N4O3: 574.3; Observed: 575.2 [M+H]+.Preparation 10: Synthesis of tert-butyl (3RS)-3-cyano-4-[(4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-[3-(trifluoromethyl)benzamido]-4,5-dihydropyridine-3-carbonyl]piperazine-l-carboxylate (11)[00287J TCFH (CAS 94790-35-9, 113 mg, 0.41 mmol, 2.00 equiv.) was added to a solution of compound 8 (100 mg, 0.20 mmol, 1.00 equiv.) and N-methylimidazole (50 mg, 0.61 mmol, 3.00 equiv.) in MeCN (1.5 mL) at about 25 °C. After about 10 min, tert-butyl (3RS)-3-cyanopiperazine-1 -carboxylate (CAS 859518-35-7, 51 mg, 0.24 mmol, 1.20 equiv.) was added. After about 1 h further at about 25 °C, the mixture was concentrated. The residue was purified by silica gel column chromatography, eluted with di chloromethane / methanol (12:1) to afford the title compound 11 (80 mg, 57% yield), which was used without further purification.Preparation 11: Synthesis of N-((3S,4S)-5-((RS)-2-cyanopiperazine-l -carbonyl)- l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (12)170335853366 CENC-015 / 01WO 360899-2048

[0288] A solution of compound 11 (80 mg, 0.12 mmol, 1.00 equiv.) and benzenesulfonic acid (22 mg, 0.14 mmol, 1.20 equiv.) in DCM (1 mL) was heated at about 40 °C for about 1 h, then concentrated. The residue was purified by prep-HPLC (Method-B) to afford the title product 12 N-[(3S,4S)-5-[(2S)-2-cyanopiperazine-l -carbonyl]- 1 -ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-3,4-dihydropyridin-3-yl]-3-(trifluoromethyl)benzamide (19 mg, 28% yield).Preparation 12: Synthesis of rac-2-((4R,5R)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridin-3-yl)acetic acid (13)

[0289] A solution of compound 6 (1.20 g, 2.43 mmol, 1.00 equiv.) and thionyl chloride (1.45 g, 12.1 mmol, 5.00 equiv.) in CHCl3 (12 mL) was heated at about 60 °C for about 1 h, then cooled and concentrated. The residue was dissolved in MeCN (5 mL) and the solution was added dropwise to a mixture of (trimethylsilyl)diazomethane (556 mg, 4.87 mmol, 2.00 equiv.) in acetonitrile (12.0 mL). The mixture was then treated with water (10 mL), Et3N (0.490 g, 4.87 mmol, 2.00 equiv.) and silver(I) acetate (610 mg, 3.65 mmol, 1.50 equiv.) and kept at about 25 °C for about 2 h, then filtered. The filter was washed with MeCN (3 x 10 mL) and the combined filtrates were concentrated. The residue was purified by reversed-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase A, water (containing 0.05% formic acid), mobile phase B, MeCN (20% to 50% gradient in 15 min); detector, UV 254 nm to give the title compound 13 (160 mg, 13% yield).LCMS Calculated for C26H26F4N2O4: 506.2; Observed: 507.3 [M+H]+.Preparation 13: Synthesis of rac-N-((3R,4S)-5-bromo-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (14)171335853366 CENC-015 / 01WO 360899-2048

[0290] A solution of compound 6 (6.00 g, 12.2 mmol, 1.00 equiv.), lithium acetate (0.96 g, 14.6 mmol, 1.20 equiv.) and NBS (4.34 g, 24.4 mmol, 2.00 equiv.) in a mixture of DMF (90 mL) and water (10 mL) was heated at about 110 °C for about 30 min, then cooled to about 25 °C and diluted with water (200 mL). After extraction with EtOAc (3 x 100 mL), the combined EtOAc extracts were washed with brine (100 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography eluted with a gradient of ethyl acetate in petroleum ether (0% to 10% ethyl acetate) to afford the title compound 14 (5.1 g, 79% yield). LCMS Calculated for C24H23BrF4N2O2: 526.1 (79Br isotope). Observed: 527.2 [M+H]+(79Br isotope).Preparation 14: Synthesis of rac-di ethyl 2-((4R,5R)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridin-3-yl)malonate (15)

[0291] A mixture of compound 14 (1.20 g, 2.28 mmol, 1.00 equiv), tris(dibenzylideneacetone)dipalladium(0) (10 mg, 0.01 mmol, 0.005 equiv.), tri-tert-butylphosphine tetrafluoroborate (7 mg, 0.025 mmol, 0.011 equiv.) and K2CO3 (881 mg, 6.37 mmol, 2.80 equiv.) in diethyl malonate (20 mL) was heated for about 3 h at about 150 °C, then cooled to about 25 °C, diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The 172335853366 CENC-015 / 01WO 360899-2048combined EtOAc extracts were washed with brine (50 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography eluted with a gradient of ethyl acetate in petroleum ether (10% to 20% ethyl acetate) to give the title compound 15 (270 mg, 20% yield).Preparation 15: Synthesis of Sodium rac-2-((4R,5R)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridin-3-yl)acetate (16)

[0292] A solution of compound 15 (130 mg, 0.21 mmol, 1.00 equiv.) and NaOH (34 mg, 0.86 mmol, 4.00 equiv.) in EtOH (4 mL) and water (1 mL) was heated for about 4 h at about 60 °C, then concentrated in vacuum to afford the title compound 16 sodium salt (85 mg), which was used without further purification.LCMS Calculated for C26H26F4N2O4: 506.2; Observed: 507.3 [M+H]+.Preparation 16: Synthesis of rac-N-((3R,4R)-l-ethyl-4-(4-fluorophenyl)-5-(hydroxymethyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (17)17

[0293] To a solution of compound 13 (3.00 g, 6.09 mmol, 1.00 equiv.) and Et3N (1.23 g, 12.2 mmol, 2.00 equiv.) in THF (30 mL) was added isobutyl chloroformate (1.0 g, 7.31 mmol, 1.20173335853366 CENC-015 / 01WO 360899-2048equiv.) dropwise at about 25 °C. After about 1 h, NaBH4 (0.58 g, 15.2 mmol, 2.50 equiv.)was added and the reaction mixture was stirred at about 25 °C overnight. The mixture was diluted with water and extracted with EtOAc (2 x 30 mL). The combined EtOAc extracts were washed with brine (2 x 30 mL), dried (Na2SC>4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1:1) to yield the title compound 17 (1.20 g, 41% yield).LCMS Calculated for C25H26F4N2O3: 478.2; Observed: 479.3 [M+H]+.Preparation 17: Synthesis of rac-N-((3R,4R)-5-((l,3-dioxoisoindolin-2-yl)methyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (18)18

[0294] Diethyl azodicarboxylate (0.87 g, 5.02 mmol, 2.00 equiv.) was added slowly to a solution of compound 17 (1.20 g, 2.51 mmol, 1.00 equiv.), phthalimide (0.550 g, 3.76 mmol, 1.50 equiv.) and triphenylphosphine (0.99 g, 3.76 mmol, 1.50 equiv.) in THF (15 mL) at about 0 °C, and the reaction mixture was kept at that temperature for about 1 h. Water was added and the mixture was extracted with EtOAc (2 x 15 mL). The combined EtOAc extracts were washed with brine (2 x 10 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by reverse phase flash column chromatography under the following conditions (column, C18 silica gel; mobile phase, MeCN in Water (containing 0.1% NH4OH), 5% to 50% MeCN gradient in 10 min; detector, UV 254 nm) to give the title compound 18 (700 mg, 46% yield).LCMS Calculated for C33H29F4N3O4: 607.2; Observed: 608.4 [M+H]+.Preparation 18: Synthesis of rac-N-((3R,4R)-5-(aminomethyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (19)174335853366 CENC-015 / 01WO 360899-204819

[0295] A solution of compound 18 (500 mg, 0.823 mmol, 1.00 equiv.) and hydrazine (53 mg, 1.65 mmol, 2.00 equiv.) in EtOH (5.0 mL) was heated at about 80 °C overnight, then cooled and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1: 1) to afford the title compound 19 (300 mg, 76% yield).LCMS Calculated for C25H27F4N3O2: 477.2; Observed: 478.3 [M+H]+.Preparation 19: Synthesis of rac -tert-butyl ((4R,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridin-3-yl)carbamate (20)

[0296] A solution of compound 6 (8.50 g, 17.3 mmol, 1.00 equiv) in / c / 'Z-butanol (80 mL) was treated with Et3N (34.9 g, 345 mmol, 20.0 equiv.), followed by the dropwise addition of diphenylphosphoryl azide (7.12 g, 25.9 mmol, 1.50 equiv.). The reaction mixture was heated at about 80 °C for about 16 h, then cooled and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1:1) to afford the title compound 20 (5.9 g, 60% yield).LCMS Calculated for C29H33F4N3O4: 563.2; Observed: 564.1 [M+H]+.175335853366 CENC-015 / 01WO 360899-2048Preparation 20: Synthesis of rac-N-((3R,4S)-5-(3-chloropropanamido)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (21)

[0297] A solution of compound 20 (200 mg, 0.36 mmol, 1.00 equiv.) and acryloyl chloride (64 mg, 0.71 mmol, 2 equiv.) in toluene (2 mL) was heated at about 90 °C for about 16 h, then cooled and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1:1) to afford the title compound 21 (100 mg, 51% yield). LCMS Calculated for C27H28CIF4N3O3 553.2 (35C1 isotope); Observed: 554.2 [M+H]+(35C1 isotope).Preparation 21: Synthesis of rac-N-((3R,4S)-5-acrylamido-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (22)22

[0298] A solution of compound 21 (100 mg, 0.18 mmol, 1.00 equiv.) and K2CO3 (100 mg, 0.72 mmol, 4.00 equiv.) in MeCN (1 mL) was heated at about 40 °C for about 16 h, then cooled and filtered. The filter was washed with EtOAc (3 x 4 mL) and the combined filtrates were concentrated. The residue was purified by reverse phase HPLC to afford the title product 22 rac-N-((3R,4S)-5-acrylamido-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (31 mg, 33% yield).176335853366 CENC-015 / 01WO 360899-2048Preparation 22: Synthesis of rac -tert-butyl ((4R,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridin-3-yl)(methacryloyl)carbamate (23)

[0299] A solution of compound 21 (150 mg, 0.27 mmol, 1.00 equiv.) in DMF (2 mL) was treated with NaH (60% in oil, 19 mg, 0.80 mmol, 3.00 equiv.) at about 0 °C for about 30 min, after which methacryloyl chloride (42 mg, 0.40 mmol, 1.50 equiv.) was added. The reaction was continued at about 0 °C for about 2 h, then was diluted with water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined EtOAc extracts were washed with brine (2 x 10 mL), dried (Na2SC>4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (5:1) to afford the title compound 23 (65 mg, 39% yield).LCMS Calculated for C33H37F4N3O5: 631.3; Observed: 632.4 [M+H]+.Preparation 23: Synthesis of rac-N-((3R,4S)-l-ethyl-4-(4-fluorophenyl)-5-methacrylamido-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (24)

[0300] A solution of compound 23 (50 mg, 0.08 mmol, 1.00 equiv.) and HC1 (4 M in 1,4-dioxane, 40 pL) in DCM (1 mL) was stirred at about 25 °C for about 2 h. After neutralization to 177335853366 CENC-015 / 01WO 360899-2048about pH 7 with saturated aqueous NaHCO3, the mixture was diluted with MeCN (3 mL) and purified by reversed-phase flash chromatography (Method-B) to give the title product 24 rac-N-((3R,4S)-l-ethyl-4-(4-fhiorophenyl)-5-methacrylamido-2-oxo-6-propyl-l, 2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (11 mg, 27% yield).Preparation 24: Synthesis of 5-(l-hydroxy-2-(tetrahydro-2H-pyran-4-yl)ethylidene)-2,2-dimethyl-l,3-dioxane-4, 6-dione (25)25

[0301] A mixture of tetrahydropyranyl-4-acetic acid (100 g, 694 mmol, 1.00 equiv.), Meldrum’s acid (127 g, 1040 mmol, 1.50 equiv.) and DCC (214 g, 1.04 mol, 1.50 equiv.) in DCM (1 L) was stirred for about 12 h at about 25 °C, then filtered through diatomaceous earth and the filtrate was evaporated. The residue was dissolved in EtOAc and washed with 1 M hydrochloric acid (3 x 500 mL) and brine (1 x 500 mL). The EtOAc phase was dried (Na2SO4), filtered and concentrated to give the title compound 25 (200 g), which was used without further purification.LCMS Calculated for C13H18O6: 270.1; Observed: 271.2 [M+H]+.Preparation 25: Synthesis of ethyl 3-oxo-4-(tetrahydro-2H-pyran-4-yl)butanoate (26)26

[0302] A solution of compound 25 (200 g, 740 mmol, 1.00 equiv.) in ethanol (2 L) was heated for about 12 h at about 80 °C, then cooled and concentrated. The residue was purified by silica gel column chromatography eluted with a gradient of ethyl acetate in petroleum ether (20% to 35% ethyl acetate) to afford ethyl the title compound 26 (125 g, 79% yield).LCMS Calculated for C11H18O4: 214.1; Observed: 215.2 [M+H]+.178335853366 CENC-015 / 01WO 360899-2048Preparation 26: Synthesis of ethyl (Z)-3-(ethylamino)-4-(tetrahydro-2H-pyran-4-yl)but-3-enoate (27)27

[0303] Ethylamine (44.1 g, 980 mmol, 3.00 equiv.) was added to a cold (about 0 °C) solution of compound 26 (70.0 g, 327 mmol, 1.00 equiv.) in a mixture of MeCN (630 mL) and water (70 mL). After about 12 h at about 0 °C, the mixture was concentrated and the residue was purified by silica gel column chromatography eluted with a gradient of ethyl acetate in petroleum ether (10% to 30% ethyl acetate) to yield the title compound 27 (43.5 g, 55% yield).LCMS Calculated for C13H23NO3: 241.2; Observed: 242.2 [M+H]+.Preparation 27: Synthesis of rac-ethyl (4R,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-((tetrahydro-2H-pyran-4-yl)methyl)-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylate (28)28

[0304] Compound 27 (21.0 g, 87.0 mmol, 1.00 equiv.), compound 4 (29.1 g, 87.0 mmol, 1.00 equiv.), and acetic acid (5.23 g, 87.0 mmol, 1.00 equiv.) were dissolved in chlorobenzene (500 mb) and heated at about 110 °C for about 3 h. After cooling, water (200 mb) was added and the mixture was extracted with EtOAc (3 x 100 mb). The combined EtOAc extracts were washed with brine (300 mb), dried (Na2SC>4), filtered concentrated. The residue was purified by silica gel column chromatography eluted with a gradient of ethyl acetate in petroleum ether (20% to 50% ethyl acetate) to provide the title compound 28 (20.8 g, 41% yield).179335853366 CENC-015 / 01WO 360899-2048LCMS Calculated for C30H32F4N2O5: 576.2; Observed: 577.2 [M+H]+Preparation 28: Synthesis of rac-ethyl (4R,5R)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-((tetrahydro-2H-pyran-4-yl)methyl)-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylate (29)29

[0305] DBU (10.9 g, 72.1 mmol, 2.00 equiv.) was added to a solution of compound 28 (20.8 g, 36.1 mmol, 1.00 equiv.) in MeCN (350 mL). The reaction mixture was heated at about 80 °C for about 16 h, then cooled and concentrated. The residue was purified by silica gel column chromatography, eluted with a gradient of ethyl acetate in petroleum ether (0% to 50% ethyl acetate) to yield the title compound 29 (12.0 g, 58% yield).LCMS Calculated for C30H32F4N2O5: 576.2; Observed: 577.2 [M+H]+.Preparation 29: Synthesis of rac-(4R,5R)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-((tetrahydro-2H-pyran-4-yl)methyl)-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (30)180335853366 CENC-015 / 01WO 360899-2048

[0306] Lithium hydroxide monohydrate (1.99 g, 47.4 mmol, 2.3 equiv.)was added to a solution of compound 29 (12.0 g, 20.8 mmol, 1.00 equiv.) in a mixture of THF (80 mL) and water (40 mL). After heating at about 70 °C for about 48 h, the mixture was cooled and acidified to about pH 2 to 3 with 1 M hydrochloric acid. After extraction with EtOAc (3 x 50 mL), the combined EtOAc extracts were washed with brine (50 mL), dried (Na2SC>4), filtered and concentrated. The residue was purified by silica gel column chromatography eluted with a gradient of ethyl acetate in petroleum ether (70% to 90% ethyl acetate) to afford compound 30 (3.8 g, 33% yield).LCMS Calculated for C28H28F4N2O5: 548.2; Observed: 549.3 [M+H]+.Preparation 30: Synthesis of (4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-((tetrahydro-2H-pyran-4-yl)methyl)-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (31) and (4R,5R)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-((tetrahydro-2H-pyran-4-yl)methyl)-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (32)31 32

[0307] Compound 30 (3.80 g, 6.93 mmol) was separated by chiral SFC under the following conditions: CHIRALPAK IA, 3*25 cm, 5 pm; Mobile Phase A: CO2, Mobile Phase B: 2-propanol (containing 0.1% formic acid); Flow rate: 80 mL / min; Gradient: isocratic 25% B; Column Temperature (°C): 35; Back Pressure (bar): 100; Wave Length: 220 nm; RT1 (min): 2.6; RT2 (min): 3.5; Sample Solvent: 2-propanol; Injection Volume: 4 mL to give the title products 31 (4R, 5R)- 1 -ethyl -4-(4-fluorophenyl )-2-(oxan-4-yl m ethy l)-6-oxo-5 - [3 -(trifluoromethyl)-benzamido]-4,5-dihydropyridine-3-carboxylic acid (1.6 g, 42% yield) and 32 (4R,5R)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-((tetrahydro-2H-pyran-4-yl)methyl)-5-(3-(trifluoromethyl)-benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (1.4 g, 37% yield).

[0308] Data for 31181335853366 CENC-015 / 01WO 360899-2048¹H NMR (400 MHz, DMSO-d₆) δ 12.57 (s, 1H), 8.48 (d, J = 6.6 Hz, 1H), 8.18 - 8.08 (m, 2H), 7.93 - 7.90 (m, 1H), 7.71 (t, J= 7.8 Hz, 1H), 7.13 - 7.06 (m, 2H), 7.03 - 6.97 (m, 2H), 5.07 (t, J = 6.9 Hz, 1H), 4.49 (d, J= 7.3 Hz, 1H), 4.25 -4.11 (m, 1H), 4.08 - 3.99 (m, 1H), 3.92 - 3.75 (m, 1H), 3.55 - 3.43 (m, 1H), 3.34 - 3.23 (m, 2H), 2.02 - 1.98 (m, 2H), 1.80 - 1.58 (m, 3H), 1.42 -1.27 (m, 2H), 1.18 (t, J= 7.4 Hz, 3H). LCMS Calculated for C28H28F4N2O5: 548.2; Observed: 549.3 [M+H]+. Purity (Method-A): 97.32% atRT 0.770 min. Chiral SFC (Method-A): 98.06% at RT 0.28 min. Optical rotation: [a]D = -139.18° (c = 0.1, MeOH, 25 °C).

[0309] Data for 32'H NMR (400 MHz, DMSO-t / 6) 6 12.59 (s, 1H), 8.48 (d, J = 6.6 Hz, 1H), 8.17 - 8.07 (m, 2H), 7.92 (d, J= 7.9 Hz, 1H), 7.75 - 7.67 (m, 1H), 7.12 - 7.05 (m, 2H), 7.02 - 6.97 (m, 2H), 5.07 (t, J = 7.0 Hz, 1H), 4.49 (d, J= 7.3 Hz, 1H), 4.25 -4.11 (m, 1H), 4.08 - 3.99 (m, 1H), 3.91 - 3.78 (m, 1H), 3.55 - 3.42 (m, 1H), 3.36 - 3.30 (m, 2H), 2.02 - 1.97 (m, 2H), 1.81 - 1.57 (m, 3H), 1.41 -1.27 (m, 2H), 1.18 (t, J = 7.1 Hz, 3H). LCMS Calculated for C28H28F4N2O5: 548.2. Observed: 549.3 [M+H] Purity (Method-A): 90.56% atRT 0.809 min. Chiral SFC (Method-A): 99.04% at RT 0.46 min. Optical rotation: [a]o = +128.9° (c = 0.1, MeOH, 25 °C).Preparation 31: Synthesis of ethyl (Z)-3-(ethylamino)-4-phenylbut-2-enoate (33)

[0310] A solution of ethyl 3-oxo-4-phenylbutanoate (25.0 g, 121.0 mmol, 1.00 equiv.) and ethylamine (2 M in THF, 187 mL, 485 mmol, 4.00 equiv.) in tetrahydrofuran (200 mL) was stirred at about 25 °C for about 4 h, then concentrated and the residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1: 1) to afford the title compound 33 (22 g, 78% yield).LCMS Calculated for C14H19NO2: 233.1; Observed: 234.2 [M+H]+.Preparation 32: Synthesis of rac-ethyl (4R,5R)-2-benzyl-l-ethyl-4-(4-fluorophenyl)-6-oxo-5-[3-(trifluoromethyl)benzamido]-4,5-dihydropyridine-3-carboxylate (34)335853366 CENC-015 / 01WO 360899-2048

[0311] A solution of compound 33 (22.0 g, 94.3 mmol, 1.00 equiv.) and compound 4 (31.6 g, 94.3 mmol, 1.00 equiv.) in acetic acid (250 mL) was heated at about 120 °C for about 16 h, then cooled and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (5:1) to afford the title compound 34 (18 g, 34% yield). LCMS Calculated for C31H28F4N2O4: 568.2; Observed: 569.2 [M+H]+.Preparation 33: Synthesis of rac-(4R,5R)-2-benzyl-l-ethyl-4-(4-fluorophenyl)-6-oxo-5-[3-(trifluoromethyl)benzamido]-4,5-dihydropyridine-3-carboxylic acid (35)

[0312] Sodium hydroxide (2.53 g, 63.3 mmol, 2.00 equiv.) was added to a solution of compound 34 (18.0 g, 31.6 mmol, 1.00 equiv.) in a mixture of THF (180 mL) and water (60 mL). The reaction mixture was heated at about 70 °C for about 48 h, then cooled and adjusted to about pH 4 with concentrated hydrochloric acid. After extraction with EtOAc (2 x 200 mL), the combined EtOAc extracts were washed with brine (2 x 200 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1: 1) to give the title compound 35 (3.0 g, 18% yield).183335853366 CENC-015 / 01WO 360899-2048LCMS Calculated for C29H24F4N2O4: 540.2; Observed: 541.2 [M+H]+.Preparation 34: Synthesis of (4S,5S)-2-benzyl-l-ethyl-4-(4-fluorophenyl)-6-oxo-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (36) and (4R,5R)-2-benzyl-l-ethyl-4-(4-fluorophenyl)-6-oxo-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (37)36 37

[0313] Compound 35 (3.0 g, 5.55 mmol) was purified by preparative chiral SFC under the following conditions (Column: XA-CHIRAL ART Cellulose-SC, 3*25cm, 5um; Mobile Phase A:CO2, Mobile Phase B: MeOH (containing 0.1% of 2 M NH3 in MeOH solution); Flow rate: 80 mL / min; Gradient (B%): isocratic 20% B; Column Temperature (°C): 35; Back Pressure (bar): 100; Wave Length: 220 nm; RT l(min): 2.8; RT 2(min): 3.4; Sample Solvent: MeOH; Injection Volume: 2.5 mL) to yield the title products 36 (4S,5S)-2-benzyl-l-ethyl-4-(4-fluorophenyl)-6-oxo-5-[3-(trifluoromethyl)benzamido]-4,5-dihydropyridine-3-carboxylic acid (1.2 g, 40% yield) and 37 (4R,5R)-2-benzyl-l-ethyl-4-(4-fluorophenyl)-6-oxo-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (1.6 g, 55% yield).

[0314] Data for 361HNMR (400 MHz, DMSO-t / e) 5 8.40 - 8.33 (m, 2H), 8.17 - 8.08 (m, 2H), 7.91 (d, J= 7.8 Hz, 1H), 7.70 (t, J = 7.8 Hz, 1H), 7.40 - 7.31 (m, 3H), 7.23 (tt, J = 6.0, 3.1 Hz, 1H), 7.08 (d, J = 7.2 Hz, 4H), 5.29 (d, J= 16.1 Hz, 1H), 5.09 (t, J= 7.0 Hz, 1H), 4.63 (d, J= 7.3 Hz, 1H), 4.05 - 3.96 (m, 1H), 3.90 - 3.76 (m, 1H), 3.35 - 3.27 (m, 1H), 1.01 (t, J= 7.0 Hz, 3H). LCMS Calculated for C29H24F4N2O4: 540.2; Observed: 541.2 [M+H]+. Optical rotation: [a]D= 61.32° (c = 0.1, MeOH, 25 °C).

[0315] Data for 37184335853366 CENC-015 / 01WO 360899-2048¹H NMR (400 MHz, DMSO-d₆) δ 8.41 - 8.31 (m, 2H), 8.16 - 8.08 (m, 2H), 7.94 - 7.88 (m, 1H), 7.70 (t, J= 7.9 Hz, 1H), 7.38 - 7.30 (m, 3H), 7.23 (dt, J= 6.0, 3.4 Hz, 1H), 7.07 (d, J= 7.3 Hz, 4H), 5.40 - 5.31 (m, 1H), 5.06 (t, J= 6.9 Hz, 1H), 4.65 (d, J= 7.3 Hz, 1H), 4.05 - 3.76 (m, 2H), 3.37 - 3.25 (m, 1H), 1.10 - 0.95 (m, 3H). LCMS Calculated for C29H24F4N2O4: 540.2; Observed: 541.2 [M+H]+. Optical rotation: [a]D= -79.99° (c = 0.1, MeOH, 25 °C).Preparation 35: Synthesis of rac-N-((3R,4R)-l-ethyl-4-(4-fluorophenyl)-5-(hydroxymethyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (38)

[0316] To a solution of compound 6 (2.75 g, 5.31 mmol, 1.00 equiv.) and EtsN (2.5 mL, 18 mmol, 3.40 equiv.) in THF (45 mL) was added ethyl chloroformate (1.5 mL, 15 mmol, 2.83 equiv.) at about 0 °C and the reaction mixture was stirred at about 25 °C for about 2 h. The reaction mixture was filtered through diatomaceous earth and the fdter was washed with THF (3 x 10 mL). The combined fdtrates were cooled to about 0 °C. Sodium borohydride (1.2 g, 30 mmol, 5.66 equiv.) was added and the reaction mixture was kept at about 25 °C for about 16 h, after which the mixture was diluted with water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined EtOAc extracts were washed with brine (2 x 50 mL), dried (Na2SC>4), filtered and concentrated. The residue was purified by silica gel column chromatography eluted with a gradient of ethyl acetate in petroleum ether (40% to 70% ethyl acetate) to afford the title compound 38 (2.0 g, 75% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.25 (d, J= 6.4 Hz, 1H), 8.10 - 8.07 (m, 2H), 7.90 (d, J= 7.6 Hz, 1H), 7.69 (t, J= 7.6 Hz, 1H), 7.09 - 7.05 (m, 2H), 7.01 - 6.98 (m, 2H), 4.97 (t, J= 7.2 Hz, 1H), 4.86 (t, J= 5.2 Hz, 1H), 4.23 - 4.19 (m, 1H), 4.12 (d, J= 7.6 Hz, 1H), 4.03 - 3.97 (m, 1H), 3.74- 3.69 (m, 1H), 3.40 - 3.34 (m, 1H), 2.60 - 2.57 (m, 1H), 2.36 - 2.34 (m, 1H), 1.51 - 1.48 (m, 2H), 1.18 - 1.12 (m, 3H), 1.00 - 0.97 (m, 3H). LCMS Calculated for C25H26F4N2O3: 478.2; Observed: 479.26 [M+H]+.185335853366 CENC-015 / 01WO 360899-2048Preparation 36: Synthesis of rac-A-((37?,47?)-5-(azidomethyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl- 1,2, 3, 4-tetrahydropyri din-3 -yl)-3-(trifluoromethyl)benzamide (39):39

[0317] Compound 38 (1.6 g, 3.3 mmol, 1.0 equiv.) in THF (35 mL) was treated with diphenylphosphoryl azide (1.50 mL, 6.6 mmol, 2.0 equiv.) followed by DBU (1.00 mL, 6.6 mmol, 2.0 equiv.) at about 25 °C and the reaction mixture was heated at about 80 °C for about 16 h. After cooling, water (50 mL) was added, and the mixture was extracted with EtOAc (2 x 50 mL). The combined EtOAc extracts were washed with brine (2 x 50 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography eluted with a gradient of ethyl acetate in petroleum ether (10% to 50% ethyl acetate) to give the title compound 39 (1.2 g, 67% yield).¹H NMR (400 MHz, DMSO-d₆) δ 8.29 (br s, 1H), 8.10 - 8.07 (m, 2H), 7.89 (d, J= 7.6 Hz, 1H), 7.69 (t, J = 8.0Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 7.31 - 7.26 (m, 1H), 7.11 - 7.07 (m, 1H), 7.03 -7.00 (m, 1H), 5.03 (t, J= 6.8 Hz, 1H), 4.25 (d, J= 13.6 Hz, 1H), 4.09 - 4.04 (m, 1H), 3.97 - 3.89 (m, 2H), 3.42 - 3.37 (m, 1H), 2.69 - 2.61 (m, 1H), 2.44 - 2.36 (m, 1H), 1.59 - 1.57 (m, 1H), 1.49 - 1.42 (m, 1H) 1.17 (t, J = 6.0 Hz, 3H), 1.01 (t, J = 7.2 Hz, 3H). LCMS Calculated for C25H25F4N5O2: 503.2; Observed: 504.3 [M+H]+.Preparation 37: Synthesis of rac-N-((3R,4R)-5-(aminomethyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo- 6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (40):335853366 CENC-015 / 01WO 360899-2048

[0318] A solution of compound 39 (1.2 g, 2.2 mmol, 1.0 equiv.) in a mixture of THF (25 mL) and water (6 mL) was treated with tri-n-butylphosphine (3.0 g, 7.4 mmol, 3.4 equiv.) at about 25 °C and kept at that temperature for about 16 h. Water (30 mL) was added and the mixture was extracted with EtOAc (2 x 50 mL). The combined EtOAc extracts were washed with brine (2 x 30 mL), dried (Na2SO4), filtered, and concentrated. The residue purified by column chromatography using neutral alumina adsorbent eluted with a gradient of methanol in dichloromethane (5 % to 8% methanol). This was then followed by preparative HPLC purification to provide the title compound 40 (0.8 g, 70% yield).¹H NMR (400 MHz, DMSO-d₆) δ 8.21 (d, J= 6.8 Hz, 1H), 8.11 - 8.07 (m, 2H), 7.90 (d, J= 7.6 Hz, 1H), 7.69 (t, J= 7.6 Hz, 1H), 7.09 - 7.00 (m, 4H), 4.98 - 4.95 (m, 2H), 4.15 (d, J= 7.6 Hz, 1H), 4.03 - 3.97 (m, 1H), 3.47 (d, J= 13.6 Hz, 1H), 3.39 - 3.30 (m, 1H), 2.92 (d, J= 14.0 Hz, 1H), 2.62 - 2.50 (m, 1H), 2.37 - 2.30 (m, 1H), 1.94 (s, 1H), 1.58 - 1.42 (m, 2H), 1.13 (t, J = 7.2 Hz, 3H), 0.99 (t, J= 7.2 Hz, 3H). LCMS Calculated for C25H27F4N3O2: 477.2; Observed: 476.1 [M-H]. Purity (Method B): 99.83 % at RT 2.36 min.Preparation 38: Separation of N-((3R,4S)-5-bromo-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (41) and N-((3S,4R)-5-bromo-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl- 1,2,3, 4-tetrahydropyri din-3 -yl)-3-(trifluoromethyl)benzamide (42)

[0319] Compound 14 (5.1 g) was purified by preparative chiral SFC under the following conditions (Column, XA-CHIRALPAK IG, 5*30 cm, 10 pm; Mobile Phase A: CO2, Mobile Phase B: MeOH; Flow rate: 150 mL / min; Gradient (B%): isocratic 50% B; Column Temperature (°C): 35; BackPressure (bar): 100; Wave Length: 220 nm; RT l(min): 3.74; RT 2(min): 5.26; Sample Solvent: MeOH; Injection Volume: 9.0 mL) to afford the title products 41 N-((3R,4S)-5-bromo- 187335853366 CENC-015 / 01WO 360899-20481 -ethyl -4-(4-fluorophenyl)-2-oxo-6-propyl-l, 2, 3, 4-tetrahydropyridin-3-yl)-3-(tri fluoromethyl)-benzamide (1.45 g, 48% yield) and 42 N-((3S,4R)-5-bromo-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (1.5 g, 50% yield).

[0320] Data for 41:¹H NMR (400 MHz, DMSO-d₆) δ 8.53 (d, J= 6.9 Hz, 1H), 8.14 - 8.06 (m, 2H), 7.91 (dd, J= 7.6, 1.8 Hz, 1H), 7.69 (t, J= 7.8 Hz, 1H), 7.20 - 7.10 (m, 2H), 7.10 - 7.00 (m, 2H), 5.29 (t, J= 7.3 Hz, 1H), 4.19 (d, J= 7.6 Hz, 1H), 4.13 -4.00 (m, 1H), 3.52 - 3.39 (m, 1H), 2.81 - 2.69 (m, 1H), 2.60 - 2.51 (m, 1H), 1.71 - 1.49 (m, 2H), 1.17 (t, J= 7.0 Hz, 3H), 1.04 (t, J = 7.3 Hz, 3H). LCMS Calculated for C24H23BrF4N2Ch: 526.1 (79Br isotope). Observed: 527.1 [M+H]+(79Br isotope). Purity (Method-A): 100% at RT 1.486 min. Chiral SFC (Method-B): 100% at RT 1.510 min. Optical rotation: [a]o= -204.9°, (c=0.1, MeOH, 25 °C)

[0321] Data for 42:¹H NMR (400 MHz, DMSO-d₆) δ 8.53 (d, J= 6.8 Hz, 1H), 8.14 - 8.06 (m, 2H), 7.91 (d, J= 7.8 Hz, 1H), 7.69 (t, J= 7.8 Hz, 1H), 7.20 - 7.09 (m, 2H), 7.09 - 6.99 (m, 2H), 5.29 (t, J= 7.2 Hz, 1H), 4.19 (d, J = 7.6 Hz, 1H), 4.13 -4.00 (m, 1H), 3.52 - 3.39 (m, 1H), 2.81 - 2.69 (m, 1H), 2.60 - 2.51 (m, 1H), 1.70 - 1.47 (m, 2H), 1.17 (t, J= 7.0 Hz, 3H), 1.04 (t, J = 7.3 Hz, 3H). LCMS Calculated for C24H23BrF4N2O2: 526.1 (79Br isotope). Observed: 527.1 [M+H]+(79Br isotope). Purity (Method-A): 100% at RT 1.478 min. Chiral SFC (Method-B): 100% at RT 0.893 min. Optical rotation: [U]D= +182.9°, (c=0.1, MeOH, 25 °C).Preparation 39: Synthesis of tert-butyl 3-((4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridin-3-yl)azetidine-l-carboxylate (43)

[0322] A solution of NiCh (25 mg, 0.19 mmol, 2.0 equiv.), pyridine-2-carboximidamide hydrochloride (15 mg, 0.1 mmol, 1.0 equiv.) and tert-butyl 3 -iodoazetidine- 1 -carboxylate (27 mg,188335853366 CENC-015 / 01WO 360899-20480.1 mmol, 1.00 equiv.) in DMA (1.00 mL) was heated for about 3 h at about 40 °C, after which compound 42 (50 mg, 0.1 mmol, 1.00 equiv.) and zinc (19 mg, 0.29 mmol, 3.0 equiv.) were added. The mixture was heated at about 60 °C for about 12 h, then cooled concentrated. The residue was purified by silica gel column chromatography eluted with a gradient of ethyl acetate in petroleum ether (0% to 20%) to afford the title compound 43 (28 mg, 46% yield).LCMS Calculated for C32H37F4N3O4: 603.3. Observed: 604.2 [M+H]+.Preparation 40: Synthesis of N-((3S,4S)-5-(azetidin-3-yl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide hydrochloride (44)44

[0323] Compound 43 (28 mg, 0.05 mmol, 1.00 equiv.) was dissolved in HC1 (4 M in 1,4-dioxane, 1.0 mL) and allowed to remain for about 1 h at about 25 °C. Concentration yielded the title compound 44 hydrochloride (25 mg), which was used without further purification.Preparation 41: Synthesis of tert-butyl 3-((4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5- (3-(trifluoromethyl)benzamido)- 1,4,5, 6-tetrahydropyridin-3-yl)-2,5-dihydro-lH-pyrrole-l-carboxylate (45)189335853366 CENC-015 / 01WO 360899-2048

[0324] A mixture of compound 42 (200 mg, 0.38 mmol, 1.00 equiv ), tert-butyl 3-(4,4,5,5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)-2,5-dihydro-lH-pyrrole-l -carboxylate (CAS 212127-83-8, 223 mg, 0.76 mmol, 2.00 equiv.), PdC12(dtbpf) (12 mg, 0.02 mmol, 0.05 equiv.) and K2CO3 (157 mg, 1.14 mmol, 3.00 equiv.) in a mixture of 1,4-dioxane (1.6 mL) and water (0.4 mL) was heated at about 90 °C for about 3 h, then cooled. Water (30 mL) was added and the mixture was extracted with EtOAc (2 x 30 mL). The combined EtOAc extracts were washed with brine (100 mL), dried (Na2SC>4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (3: 1) to afford the title compound 45 (200 mg, 86% yield).8.41 (d, J = 6.9 Hz, 1H), 8.16 (d, J = 2.9 Hz, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.91 (dd, J= 7.7, 1.6 Hz, 1H), 7.70 (t, J = 7.8 Hz, 1H), 7.15 - 7.02 (m, 4H), 5.67 (dd, J= 4.8, 2.6 Hz, 1H), 5.09 (td, J= 7.0, 3.5 Hz, 1H), 4.14-4.06 (m, 2H), 3.96 - 3.89 (m, 2H), 3.88-3.82 (m, 1H), 3.40 - 3.32 (m, 1H), 2.73 - 2.60 (m, 1H), 2.44 - 2.33 (m, 1H), 1.45 - 1.40 (m, 4H), 1.39-1.35 (m, 9H), 1.18 (t, J= 7.1 Hz, 3H), 0.99 (t, J= 7.3 Hz, 3H).LCMS Calculated for C33H37F4N3O4: 615.3. Observed: 616.2 [M+H]+.Preparation 42: Synthesis of N-((3S,4S)-5-(2,5-dihydro-lH-pyrrol-3-yl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide hydrochloride (46)

[0325] Compound 45 (42 mg, 0.07 mmol, 1 equiv.) was dissolved in HC1 (4 M in 1,4-dioxane, 1.0 mL) and kept for about 1 h at about 25 °C, then concentrated to give the title compound 46 hydrochloride (40 mg), which was used without further purification.LCMS Calculated for C28H29F4N3O2: 515.2; Observed: 516.2 [M+H]+.190335853366 CENC-015 / 01WO 360899-2048Preparation 43: Synthesis of tert-butyl 3-((4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)- 1,4, 5, 6-tetrahydropyri din-3 -yl)pyrrolidine-l -carboxylate (47)

[0326] A solution of compound 45 (190 mg, 0.31 mmol, 1.00 equiv.) in MeOH (10.0 mL) was hydrogenated over a 10% palladium on carbon catalyst (39 mg) at about 25 °C under one atmosphere of hydrogen pressure for about 12 h. The reaction mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1: 1) to afford the title compound 47 (150 mg, 78% yield).LCMS Calculated for C33H39F4N3O4: 617.3; Observed: 618.3 [M+H]+.Preparation 44: Synthesis ofN-((3S,4S)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-5-(pyrrolidin- 3-yl)-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide hydrochloride (48)48

[0327] Compound 47 (140 mg, 0.23 mmol, 1.00 equiv.) was dissolved in HC1 (4 M in 1,4-di oxane, 3.0 mL) and kept for about 1 h at about 25 °C, then concentrated to give the title compound 48 hydrochloride (80 mg, 63% yield), which was used without further purification. LCMS Calculated for C28H31F4N3O2: 517.2. Observed: 518.2 [M+H]+.191335853366 CENC-015 / 01WO 360899-2048Preparation 45: Synthesis of tert-butyl (4'S,5'S)-r-ethyl-4l-(4-fluorophenyl)-6l-oxo-2l-propyl-5'- (3-(trifluoromethyl)benzamido)-r,4',5,5',6,6'-hexahydro-[3,3'-bipyridine]-l(2H)-carboxylate (49)49

[0328] A mixture of compound 42 (250 mg, 0.47 mmol, 1.00 equiv.), tert-butyl 3-(4,4,5,5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)-5,6-dihydro-2H-pyridine-1-carboxylate (CAS 885693-20-9, 293 mg, 0.95 mmol, 2.00 equiv.), PdCh(dppf) (17 mg, 0.024 mmol, 0.05 equiv.) and K2CO3 (196 mg, 1.42 mmol, 3.00 equiv.) in a mixture of 1,4-dioxane (2 mL) and water (2 mL) was heated at about 90 °C overnight, then cooled. Water (20 mL) was added and the mixture was extracted with EtOAc (2 x 30 mL). The combined EtOAc extracts were washed with brine (20 mL), dried (Na2SC>4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1:1) to yield the title compound 49 (290 mg, 98% yield).1HNMR(400 MHz, DMSO- G 58.36 (d, J= 6.7 Hz, 1H), 8.14 (s, 1H), 8.11 (d, J= 7.8 Hz, 1H), 7.99 - 7.88 (m, 1H), 7.70 (t, J= 7.8 Hz, 1H), 7.15 - 7.00 (m, 4H), 5.66 - 5.57 (m, 1H), 5.06 (t, J = 6.9 Hz, 1H), 4.11 (dt, J= 14.2, 7.0 Hz, 1H), 3.86 (d, J= 7.2 Hz, 1H), 2.63 -2.52 (m, 1H), 2.39 - 2.28 (m, 1H), 2.17 - 2.02 (4, 2H), 1.56 (s, 1H), 1.51 - 1.22 (m, 12H), 1.18 (t, J= 7.1 Hz, 4H), 0.97 (t, J = 7.3 Hz, 3H).LCMS Calculated for C34H39F4N3O4: 629.3; Observed: 630.3 [M+H]+.Preparation 46: Synthesis of N-((4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-l,r,2',4,5,5',6,6'-octahydro-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide hydrochloride (50)192335853366 CENC-015 / 01WO 360899-2048

[0329] Compound 49 (55 mg, 0.09 mmol, 1.00 equiv.) was dissolved in HC1 (4 M in 1,4-dioxane, 1.0 mL) and kept at about 25 °C for about 1 h, then concentrated to afford the title compound 50 hydrochloride (45 mg), which was used without further purification.LCMS Calculated for C29H31F4N3O2: 529.2; Observed: 530.2 [M+H]+.Preparation 47: Synthesis of tert-butyl 3-((4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido) -l,4,5,6-tetrahydropyridin-3-yl)piperidine-l-carboxylate (51)51

[0330] A solution of compound 49 (290 mg, 0.46 mmol, 1.00 equiv.) in MeOH (10.0 mL) was hydrogenated over a 10% palladium on carbon catalyst (59 mg) at about 25 °C under one atmosphere of hydrogen pressure for about 1 h. The reaction mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1: 1) to give the title compound 51 (105 mg, 36% yield).LCMS Calculated for C34H41F4N3O4: 631.3. Observed: 632.3 [M+H]+.Preparation 48: Synthesis of N-((3S,4S)-l-ethyl-4-(4-fluorophenyl)-2-oxo-5-(piperidin-3-yl)-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (52)193335853366 CENC-015 / 01WO 360899-2048

[0331] Compound 51 (100 mg, 0.16 mmol, 1.00 equiv.) was dissolved in HC1 (4 M in 1,4-dioxane, 2 mL) and kept at about 25 °C for about 1 h, then concentrated to afford the title compound 52 hydrochloride (100 mg), which was used without further purification.LCMS Calculated for C29H33F4N3O2: 531.3. Observed: 532.2 [M+H]+.Preparation 49: Synthesis of tert-butyl 6-((4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridin-3-yl)-2,3-dihydro-4H-l,4-oxazine-4-carboxylate (53)53

[0332] A solution of compound 42 (80 mg, 0.15 mmol, 1.00 equiv.), K2CO3 (63 mg, 0.46 mmol, 3.00 equiv.), tert-butyl 2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-5,6-dihydro-oxazine-4-carboxylate (CAS 2223055-83-0, 94 mg, 0.30 mmol, 2.00 equiv.), and PdCh(dppf) (6 mg, 0.008 mmol, 0.05 equiv.) in a mixture of 1,4-dioxane (0.4 mL) and water (0.1 mL) was heated at about 90 °C for about 3 h, then cooled and filtered. The filtrate was concentrated and the residue was purified by silica gel column chromatography, eluted with ethyl acetate to give the title compound 53 (120 mg).LCMS Calculated for C33H37F4N3O5: 631.3; Observed: 632.2 [M+H]+.194335853366 CENC-015 / 01WO 360899-2048Preparation 50: Synthesis of tert-butyl 2-((4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridin-3-yl)morpholine-4-carboxylate (54)54

[0333] A solution of compound 53 (110 mg, 0.17 mmol, 1.00 equiv.) in EtOAc (10 mL) was hydrogenated over a 10% palladium on carbon catalyst (20 mg) under one atmosphere of hydrogen pressure at about 25 °C for about 1 h. The mixture was filtered, and the filter was washed with EtOAc (3 x 10 mL). Concentration of the filtrates provide the title compound 54 (43 mg, 39% yield).LCMS Calculated for C33H39F4N3O5: 633.3; Observed: 634.3 [M+H]+.Preparation 51: Synthesis of N-((3S,4S)-l-ethyl-4-(4-fluorophenyl)-5-(morpholin-2-yl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (55)55

[0334] A mixture of compound 54 (40 mg, 0.06 mmol, 1.00 equiv.) and TFA (0.7 mL) in DCM (2.0 mL) was stirred at about 25 °C for about 1 h, then concentrated to give the title compound 55 trifluoroacetate (69 mg), which was used without further purification.LCMS Calculated for C28H31F4N3O3: 533.2; Observed: 534.3 [M+H]+.195335853366 CENC-015 / 01WO 360899-2048Preparation 52: Synthesis ofN-((3S,4S)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-5-(lH-pyrazol-4-yl)-l,2,3,4-tetrahydropyridin-3-yl)-3(trifluoromethyl)benzamide (56)

[0335] A solution of compound 42 (105 mg, 0.20 mmol, 1.00 equiv.), K2CO3 (83 mg, 0.60 mmol, 3.00 equiv.), tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole-l-carboxylate (CAS 552846-17-0, 117 mg, 0.40 mmol, 2.00 equiv.) and PdCh(dtbpf) (7 mg, 0.01 mmol, 0.05 equiv.) in a mixture of 1,4-dioxane (0.8 mL) and water (0.2 mL) was heated at about 90 °C for about 3 h, then cooled. Water (20 mL) was added and the mixture was extracted with EtOAc (3 x 10 mL). The combined EtOAc extracts were washed with brine (1 x 10 mL), dried (Na2SC>4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1: 1) to afford the title compound 56 (100 mg, 98% yield).LCMS Calculated for C27H26F4N4O2: 514.2; Observed: 513.2 [M-H] ’.Preparation 53: Synthesis of rac-N-((3R,4R)-l-ethyl-4-(4-fluorophenyl)-5-(2-nitrophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (57)196335853366 CENC-015 / 01WO 360899-2048

[0336] A solution of compound 14 (4.00 g, 7.58 mmol, 1.00 equiv.), 2-nitrophenylboronic acid (CAS 5570-19-4, 1.39 g, 8.34 mmol, 1.10 equiv.). K2CO3 (2.62 g, 19.0 mmol, 2.50 equiv.) and PdCh(dppf) (554 mg, 0.76 mmol, 0.100 equiv.) in a mixture of 1,4-dioxane (30 mL) and water (3.0 mL) was heated at about 90 °C overnight, then cooled and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1:1) to give the title compound 57 (2.7 g, 62% yield).Preparation 54: Synthesis of rac-N-((3R,4R)-5-(2-aminophenyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (58)58

[0337] A solution of compound 57 (2.7 g, 4.74 mmol, 1.00 equiv.) in MeOH (25 mL) was hydrogenated over a 10% palladium on carbon catalyst (0.05 g) at about 25 °C for about 2 h. The mixture was filtered, the filter was washed with DCM (3 x 5 mL) and the combined filtrates were concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1:1) to afford the title compound 58 (2.0 g, 78% yield).1HNMR (300 MHz, DMSO-cL) d 8.43 - 8.20 (m, 1H), 8.15 - 8.00 (m, 2H), 7.90 (d, J= 7.8 Hz, 1H), 7.69 (t, J= 7.8 Hz, 1H), 7.13 - 7.00 (m, 4H), 6.98 - 6.62 (m, 2H), 6.61 - 6.30 (m, 2H), 5.59 - 5.17 (m, 1H), 4.77 (d, J= 150.9 Hz, 2H), 4.29 - 3.36 (m, 3H), 2.45 - 2.08 (m, 2H), 1.69 - 1.35 (m, 2H), 1.31 - 1.16 (m, 3H), 0.95 - 0.67 (m, 3H). LCMS Calculated for C30H29F4N3O2: 539.2; Observed: 540.3 [M+H]+.Preparation 55: Synthesis of (Z)-4-(cyclopropylmethylene)-2-(3-(trifluoromethyl)-phenyl)oxazol-5(4H)-one (59)197335853366 CENC-015 / 01WO 360899-2048

[0338] A mixture of compound 3 (300 g, 1.31 mol, 1.00 equiv.), Activity 1 basic aluminum oxide (2.00 kg, 19.6 mol, 15.0 equiv.) and cyclopropanecarbaldehyde (82.6 g, 1.18 mol, 0.900 equiv.) in CHCI3 (3 L) was stirred at about 25 °C for about 1 h. The mixture was filtered, the filter was washed with DCM (6 x 500 mL), and the combined filtrates were concentrated. The residue was triturated with petroleum ether (100 mL), filtered and dried to give the title compound 59 (93 g, 28% yield).LCMS Calculated for C14H11F3NO2: 281.1; Observed: 282.1 [M+H]+.Preparation 56: Synthesis of rac-ethyl (4R,5R)-4-cyclopropyl-l-ethyl-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylate (60)

[0339] A mixture of compound 1 (26.0 g, 140 mmol, 1.00 equiv.) and compound 59 (43.4 g, 154 mmol, 1.10 equiv.) in acetic acid (260 mL) was heated at about 110 °C for about 16 h, then cooled and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1:1) to yield the title compound 60 (12.0 g, 18% yield). LCMS Calculated for C24H29F3N2O4: 466.2; Observed: 467.1 [M+H]+.Preparation 57: Synthesis of rac-(4R,5R)-4-cyclopropyl-l-ethyl-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (61)198335853366 CENC-015 / 01WO 360899-204861

[0340] A solution of compound 60 (2.50 g, 5.35 mmol, 1.00 equiv.) in a mixture of water (10 mL) and EtOH (10 mL) was treated with aqueous sodium hydroxide (2 M, 5.35 mL, 10.7 mmol, 2.00 equiv.) and heated at about 70 °C for about 16 h. After cooling, the mixture was adjusted to about pH 6 with 2 M aqueous hydrochloric acid and extracted with EtOAc (3 x 30 mL). The combined EtOAc extracts were washed with brine (3 x 20 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1: 1) to afford the title compound 61 (620 mg, 26% yield).LCMS Calculated for C22H25F3N2O4: 438.2; Observed: 439.2 [M+H]+.Preparation 58: Separation of (4R,5R)-4-cyclopropyl-l-ethyl-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (62) and (4S,5S)-4-cyclopropyl- 1 -ethyl-6-oxo-2-propyl-5-(3-(tri fluoromethyl)benzamido)-l, 4,5,6-tetrahydropyridine-3-carboxylic acid (63)

[0341] Compound 61 was separated by chiral SFC under the following conditions (Column: (R, R)-WHELK-01, 50*4.6mm, 3.5um; Mobile Phase A: CO2, Mobile Phase B: MeOH (containing 0.1% 2 M NH3 in MeOH solution); Flow rate: 150 mL / min; Gradient: isocratic 50% B; Column Temperature (°C): 35; Back Pressure (bar): 100; Wave Length: 220 nm; RT l(min): 3.6; RT 2(min): 4.85; Sample Solvent: MeOH; Injection Volume: 3.0 mL) to afford the title products 63 (4S,5S)-4-cyclopropyl-l-ethyl-6-oxo-2-propyl-5-(3-(trifluoromethyl)-benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (120 mg, 32% yield) and 62 (4R,5R)-4-cyclopropyl-l-ethyl-199335853366 CENC-015 / 01WO 360899-20486-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylic acid (120 mg, 32% yield).[003421 Data for 62’HNMR (400 MHz, DMSO-cL) d 8.84 (d, J= 7.6 Hz, 1H), 8.28 (d, J= 2.2 Hz, 1H), 8.22 (d, J = 7.8 Hz, 1H), 7.94 (d, J= 7.8 Hz, 1H), 7.74 (t, J = 7.8 Hz, 1H), 4.86 (dd, J=7.6, 5.9 Hz, 1H), 4.10 - 3.97 (m, 1H), 3.45 - 3.32 (m, 2H), 2.83 (dd, J= 7.6, 5.9 Hz, 1H), 2.44 - 2.32 (m, 1H), 1.57 -1.33 (m, 2H), 1.10 (t, J= 7.0 Hz, 3H), 0.93 (t, J= 7.3 Hz, 3H), 0.75 - 0.62 (m, 1H), 0.49 - 0.38 (m, 1H), 0.27 -0.11 (m, 2H), 0.04 (s, 1H). LCMS Calculated for C22H25F3N2O4: 438.2; Observed: 439.2 [M+H]+. Purity (Method-A): 98.14% at RT 0.695 min. Chiral SFC (Method-A): 95.06% at RT 1.33 min. Optical rotation: [a]o= -66.6° (c = 0.1, MeOH, 25 °C).

[0343] Data for 63'HNMR (400 MHz, DMSO-rL) d 8.83 (d, J= 7.6 Hz, 1H), 8.28 (d, J= 2.3 Hz, 1H), 8.22 (d, J = 7.8 Hz, 1H), 7.93 (d, J= 7.8 Hz, 1H), 7.74 (t, J = 7.8 Hz, 1H), 4.85 (dd, J=7.6, 5.9 Hz, 1H), 4.10 - 3.97 (m, 1H), 3.46 - 3.34 (m, 2H), 2.83 (dd, J= 7.6, 6.0 Hz, 1H), 2.43 - 2.31 (m, 1H), 1.83 -1.32 (m, 2H), 1.10 (t, J= 7.0 Hz, 3H), 0.93 (t, J= 7.3 Hz, 3H), 0.75 - 0.62 (m, 1H), 0.49 - 0.37 (m, 1H), 0.27 - 0.13 (m, 2H), 0.05 (s, 1H). LCMS Calculated for C22H25F3N2O4: 438.2; Observed: 439.2 [M+H]+. Purity (Method-A): 96.3% at RT 0.700 min. Chiral SFC (Method-A): 97.60% at RT 1.52 min. Optical rotation: [a]o= 62.3° (c = 0.1, MeOH, 25 °C).Preparation 59: Synthesis of ethyl (2Z)-4-(benzyloxy)-3-(ethylamino)but-2-enoate (64)64

[0344] Ethyl 4-(benzyloxy)-3-oxobutanoate (10.0 g, 42.0 mmol, 1.00 equiv.), ethylamine hydrochloride (2.90 g, 63.0 mmol, 1.50 equiv.), and Et3N (8.60 g, 85.0 mmol, 2.00 equiv.) were dissolved in EtOH (100 mL) and maintained at about 25 °C for about 4 h. After concentration, the residue was diluted with water (100 mL) and extracted with EtOAc (3 x 50 mL). The combined EtOAc extracts were washed with brine (3 x 100 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / petroleum ether (1:1) to afford the title compound 64 (10 g, 89% yield).LCMS Calculated for C15H21NO3: 263.2; Observed: 264.2 [M+H]+.200335853366 CENC-015 / 01WO 360899-2048Preparation 60: Synthesis of rac-ethyl (4R,5R)-2-((benzyloxy)methyl)-l-ethyl-4-(4-fluorophenyl)-6-oxo-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxylate (65)

[0345] A solution of compound 4 (5.10 g, 15.2 mmol, 1.00 equiv.) and compound 64 (6.00 g, 22.8 mmol, 1.50 equiv.) in acetic acid (20 mL) was heated at about 140 °C for about 14 h, then cooled and adjusted to about pH 7 by the addition of saturated aqueous NaHCO3. After extraction with EtOAc (3 x30 mL), the combined EtOAc extracts were washed with brine (2x 50 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1: 1) to provide the title compound 65 (1.5 g, 16% yield).LCMS Calculated for C32H30F4N2O5: 598.2; Observed: 599.3 [M+H]+.Preparation 61: Synthesis of rac-(4R,5R)-2-((benzyloxy)methyl)-l-ethyl-4-(4-fluorophenyl)-6-oxo-5-(3-(trifluoromethyl)benzami do)-l, 4, 5, 6-tetrahydropyridine-3 -carboxylic acid (66)66

[0346] A solution of compound 65 (1.30 g, 2.20 mmol, 1.00 equiv.) and lithium hydroxide monohydrate (78 mg, 1.86 mmol, 0.85 equiv.) in a mixture of THF (7.0 mL), MeOH (7.0 mL),201335853366 CENC-015 / 01WO 360899-2048and water (0.7 mL) was heated at about 30 °C for about 4 h. After cooling, the mixture was acidified with 2 M aqueous hydrochloric acid solution and extracted with DCM (3 x 20 mL). The combined DCM extracts were washed with brine (2 x 30 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with dichloromethane / methanol (10:1) to afford the title compound 66 (400 mg, 32% yield).LCMS Calculated for C30H26F4N2O5: 570.2; Observed: 569.2 [M-H] ’.Preparation 62: Synthesis of tert-butyl (S)-7-((4RS,5RS)-2-((benzyloxy)methyl)-l-ethyl-4-(4-fluorophenyl)-6-oxo-5-(3-(tri fluoromethyl)benzamido)- 1,4,5, 6-tetrahy dropyridine-3-carboxamido)-5-azaspiro[2.4]heptane-5-carboxylate (67)67

[0347] A solution of compound 66 (800 mg, 1.40 mmol, 1.00 equiv.) and DIEA (543 mg, 4.21 mmol, 3.00 equiv.) in DMF (8.0 mL) was treated with HATU (639 mg, 1.68 mmol, 1.20 equiv.) and kept at about 0 °C for about 10 min. Tert-butyl (7S)-7-amino-5-azaspiro[2.4]heptane-5-carboxylate (CAS 1638744-35-0, 357 mg, 1.68 mmol, 1.20 equiv.) was added and the mixture kept for about 1 h at about 0 °C before being purified by reverse phase FTPLC under the following conditions (Column: YMC-Actus Triart C18 Column, 50*250 mm, 5pm; Mobile Phase A: Water(containing lOmmol / L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 90mL / min; Gradient: 45% B to 75% B in 10 min; wavelength: 254nm / 220nm) to yield the title compound 67 (750 mg, 70% yield).LCMS Calculated for C41H44F4N4O6: 764.3; Observed: 765.3 [M+H]+.Preparation 63: Synthesis of tert-butyl (S)-7-((4RS,5RS)-l-ethyl-4-(4-fluorophenyl)-2-methyl-6-oxo-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxamido)-5-azaspiro[2.4]heptane-5-carboxylate (68)202335853366 CENC-015 / 01WO 360899-204868

[0348] A solution of compound 67 (200 mg, 0.26 mmol, 1.00 equiv.) in MeOH (10 mL) was hydrogenated over a 10% palladium on carbon catalyst (42 mg) at about 25 °C under one atmosphere of hydrogen pressure for about 1 h. The reaction mixture was filtered and the filtrate was concentrated to afford the title compound 68 (140 mg, 81% yield), which was used without further purification.LCMS Calculated for C34H38F4N4O5: 658.3; Observed: 659.2 [M+H]+.Preparation 64: Synthesis of tert-butyl ((lR,2S)-2-((4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)- 1,4,5, 6-tetrahydropyridine-3-carboxamido)cyclopentyl)carbamate (69)69

[0349] A solution of compound 8 (100 mg, 0.20 mmol, 1.00 equiv.), DIEA (79 mg, 0.61 mmol, 3.00 equiv.), and HATU (93 mg, 0.24 mmol, 1.20 equiv.) in DMF (2 mL) was kept at about 25 °C for about 20 min, after which tert-butyl ((lR,2S)-2-aminocyclopentyl)carbamate (CAS 721395-15-9, 49 mg, 0.24 mmol, 1.20 equiv.) was added. When the reaction was completed, water (30 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). The combined EtOAc extracts were washed with brine (3 x 20 mL), dried (Na2SO4), filtered and concentrated to give the title compound 69 (110 mg) which was used without further purification.203335853366 CENC-015 / 01WO 360899-2048LCMS Calculated for C35H42F4N4O5: 674.3; Observed: 675.4 [M+H]+.Preparation 65: Synthesis of (4S,5S)-N-((lS,2R)-2-aminocyclopentyl)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carboxamide (70)70

[0350] A solution of compound 69 (110 mg, 0.16 mmol, 1.00 equiv.) inDCM (2 mL) was treated with a solution of HC1 (4.0 M in 1,4-dioxane, 0.16 mL, 4.00 equiv.) and stirred at about 25 °C for about 3 h, then concentrated to afford the title compound 70 hydrochloride (85 mg), which was used without further purification.LCMS Calculated for C30H34F4N4O3: 574.3; Observed: 575.2 [M+H]l.Preparation 66: Separation of N-((3S,4S)-5-(aminomethyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (71) and N-((3R,4R)-5-(aminomethyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl- 1,2,3, 4-tetrahydropyridin-3-yl)-3- (trifluoromethyl)benzamide (72)

[0351] Compound 19 (370 mg) was purified by preparative chiral SFC under the following conditions (Column: Lux Cellulose-42.12*25 cm, 5 pm; Mobile Phase A: CO2, Mobile Phase B:204335853366 CENC-015 / 01WO 360899-2048MeOH (containing 0.1% 2 M ammonia in MeOH); Flow rate: 80mL / min; Gradient (B%): isocratic 20% B; Column Temperature (°C): 35; Back Pressure (bar): 100; wavelength: 254 nm; RT1 (min): 3.60; RT2 (min): 4.60; Sample Solvent: MeOH; Injection Volume: 1.5 mL) to afford the title compound 71 (80 mg) and the title compound 72 (80 mg).71 Optical rotation: [a]o = 184.0°, (c = 0.1, MeOH, 25 °C)72 Optical rotation: [a]o = -179.6°, (c = 0.1, MeOH, 25 °C)Preparation 67: Synthesis of (3-chlorobenzoyl)glycine (73)

[0352] A solution of glycine (4.72 g, 62.8 mmol, 1.00 equiv.) in MeCN (60 mL) and water (40 mL) containing NaOH (6.28 g, 157 mmol, 2.50 equiv.) was treated with 3-chlorobenzoyl chloride (11.0 g, 62.8 mmol, 1.00 equiv.) added dropwise over about 1 h at about 0 °C. After the addition was complete, the mixture was stirred at about 25 °C for about 5 h further, then then acidified to about pH 6 with concentrated HC1. After extraction with EtOAc (2 x 200 mL), the combined EtOAc extracts were washed with brine (2 x 200 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by trituration with petroleum ether (200 mL). The solid was filtered, washed with petroleum ether (3 x 100 mL), and dried to give the title compound 73 (10 g, 75% yield).LCMS Calculated for C9H8CINO3: 213.0 (35C1 isotope); Observed: 214.2 [M+H]+(35C1 isotope).Preparation 68: Synthesis of 2-(3-chlorophenyl)oxazol-5(4H)-one (74)205335853366 CENC-015 / 01WO 360899-2048

[0353] A mixture of 73 (5.00 g, 23.4 mmol, 1.00 equiv.) and EDC (3.63 g, 23.4 mmol, 1.00 equiv.) in DCM (50 mL) was kept at about 25 °C for about 1 h, then diluted with water (50 mL). After separation of the DCM phase, the aqueous phase was extracted with DCM (2 x 25 mL). The combined DCM solutions were washed with brine (2 x 25 mL), dried (Na2SO4), filtered and concentrated to provide 74 (4.5 g,96% yield), which was used without further purification.LCMS Calculated for C9H6CINO2: 195.0 (33C1 isotope); Observed: 196.3 [M+H]+(35C1 isotope).Preparation 69: Synthesis of (Z)-2-(3-chlorophenyl)-4-(4-fluorobenzylidene)oxazol-5(4H)-one (75)

[0354] A solution of 74 (4.5 g, 23.0 mmol, 1.00 equiv.) and 4-fluorobenzaldehyde (2.86 g, 23.0 mmol, 1.00 equiv.) in DCM (55 mL) was treated with Activity 1 basic aluminum oxide (23.5 g, 230 mmol, 10 equiv.) at about 25 °C and kept for about 30 min. The mixture was filtered, and the filter was washed with EtOAc (2 x 250 mL). The combined filtrates were concentrated, and the residue was purified by trituration with petroleum ether (50 mL). The solid was filtered, washed with petroleum ether (3 x 30 mL), and dried to afford the title compound 75 (2.10 g, 30% yield), which was used without further purification.LCMS Calculated for C16H9ClFNO2: 301.0 (35C1 isotope); Observed: 302.2 [M+H]+(35C1 isotope).Preparation 70: Synthesis of rac-ethyl (4R,5R)-5-(3-chlorobenzamido)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-l,4,5,6-tetrahydropyridine-3-carboxylate (76)206335853366 CENC-015 / 01WO 360899-204876

[0355] A solution of 1 (1.29 g, 6.96 mmol, 1.00 equiv.) and 75 (2.10 g, 6.96 mmol, 1.00 equiv.) in 2-methyl-2-propanol (20 mL) was treated with tin(II) chloride (0.13 g, 0.69 mmol, 0.100 equiv.) and heated at about 80 °C overnight. After cooling, the mixture was concentrated and the residue was purified by silica gel column chromatography, eluted with petroleum ether - ethyl acetate (3: 1) to afford the title compound 76 (300 mg, 9% yield).58.26 (d, J= 6.7 Hz, 1H), 7.86 (t, J= 1.9 Hz, 1H), 7.78 (d, J = 7.7 Hz, 1H), 7.65 - 7.58 (m, 1H), 7.49 (t, J= 7.9 Hz, 1H), 7.09 (t, J= 8.8 Hz, 2H), 7.02 - 6.94 (m, 2H), 5.08 (t, J= 7.0 Hz, 1H), 4.39 (d, J= 7.4 Hz, 1H), 4.14 - 3.97 (m, 2H), 3.64 - 3.53 (m, 1H), 3.32 - 3.22 (m, 1H), 2.71 -2.60 (m, 1H), 1.61 (s, 2H), 1.26 - 1.14 (m, 4H), 1.14- 0.98 (m, 6H). LCMS Calculated for C26H28CIFN2O4: 486.2 (35C1 isotope); Observed: 487.2 [M+H]+(35C1 isotope).Preparation 71: Synthesis of rac-(4R,5R)-5-(3-chlorobenzamido)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-l,4,5,6-tetrahydropyridine-3-carboxylic acid (77)77

[0356] Sodium hydroxide solution (2 M, 0.62 mL, 2.00 equiv.) was added to a solution of 76 (300 mg, 0.62 mmol, 1.00 equiv.) in EtOH (3.0 mL) and water (1.50 mL) and the solution was heated at about 80 °C for about 1 h. After cooling, the mixture was acidified to about pH 6 with 207335853366 CENC-015 / 01WO 360899-2048concentrated HC1 and extracted with EtOAc (4 x 10.0 mL). The combined EtOAc extracts were washed with brine (3 x 10.0 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with DCM - methanol (10: 1) to yield the title compound 77 (87 mg, 31% yield).LCMS Calculated for C24H24CIFN2O4: 458.1 (35C1 isotope); Observed: 459.2 [M+H]+(35C1 isotope).Preparation 72: Synthesis of tert-butyl (7S)-7-[(4RS,5RS)-5-(3-chlorobenzamido)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-4,5-dihydropyridine-3-amido]-5-azaspiro[2.4]heptane-5-carboxylate (78)78

[0357] A solution of 77 (87 mg, 0.20 mmol, 1.00 equiv.) and DIEA (51 mg, 0.39 mmol, 2.00 equiv.) in DCM (1.00 mL) was treated with HATU (150 mg, 0.39 mmol, 2.00 equiv.) at about 25 °Cfor about 10 min, followed by the addition of tert-butyl (7S)-7-amino-5-azaspiro[2.4]heptane-5-carboxylate (CAS 1638744-35-0, 50 mg, 0.24 mmol, 1.00 equiv.). The reaction mixture was stirred at about 25 °C for about 2 h, then concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether - ethyl acetate (1:1) to give the title compound 78 (110 mg, 85% yield).LCMS Calculated for C35H42CIFN4O5: 652.3 (35C1 isotope); Observed: 653.3 [M+H]+(35C1 isotope).Preparation 73: Synthesis of (4RS,5RS)-N-[(7S)-5-azaspiro[2.4]heptan-7-yl]-5-(3-chlorobenzamido)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-4,5-dihydropyridine-3-carb oxami de (79)208335853366 CENC-015 / 01WO 360899-2048

[0358] A solution of 78 (110 mg, 0.17 mmol, 1.00 equiv.) and benzenesulfonic acid (33 mg, 0.21 mmol, 1.20 equiv.) in DCM (1.0 mL) was heated at about 40 °C for about 4 h, then cooled and concentrated. The residue was purified by preparative TLC (DCM - MeOH (10:1)) to afford the title compound 79 benzenesulfonate (70 mg, 74% yield).LCMS Calculated for C30H34CIFN4O3: 552.2 (35C1 isotope); Observed: 553.5 [M +H]+(35C1 isotope).Preparation 74: Synthesis of tert-butyl (2S,3S)-2-carbamoyl-3-methoxypyrrolidine-l-carboxylate (80)

[0359] To a solution of (2S,3S)-l-(tert-butoxycarbonyl)-3-methoxypyrrolidine-2-carboxylic acid (CAS 1932362-84-9, 200 mg, 0.82 mmol, 1.00 equiv.) and 4-methylmorpholine (90.7 mg, 0.896 mmol, 1.10 equiv.) in THF (5 mL) was added isobutyl chloroformate (122 mg, 0.896 mmol, 1.10 equiv.) with cooling to about -15 °C. After about 30 min at that temperature, NH4OH (30%, 81 pL, 1.222 mmol, 1.5 equiv.) was added. After a further 2 h at about 25 °C, the mixture was concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether - ethyl acetate (1:1) to afford the title compound 80 (150 mg, 75% yield).Preparation 75: Synthesis of (2S,3S)-3-methoxypyrrolidine-2-carboxamide (81)209335853366 CENC-015 / 01WO 360899-204881

[0360] A mixture of 80 (150 mg, 0.61 mmol, 1.00 equiv.) and HC1 (4 M in 1,4-dioxane, 1 mL) was stirred at about 25 °C for about 1 h, then concentrated to give 81 hydrochloride (120 mg), which was used without further purification.Preparation 76: Synthesis of tert-butyl (S)-(l -amino- l-oxopropan-2-yl)(methyl)carbamate (82)|-Boc1(.. tabs-NH2O82

[0361] A mixture of N-(tert-butoxycarbonyl)-N-methyl-L-alanine (CAS 16948-16-6, 13.0 g, 64 mmol, 1.00 equiv.), DMF (200 mL), HATU (48.6 g, 128 mmol, 2.0 equiv.), HOBt (4.30 g, 32.0 mmol, 0.500 equiv.), DIEA (41.3 g, 320 mmol, 5.00 equiv.) and NH4CI (5.13 g, 96.0 mmol, 1.50 equiv.) was stirred at about 25 °C for about 2 h, then diluted with water (300 mL) at about 0 °C and extracted with EtOAc (3 x 200 mL). The combined EtOAc extracts were washed with brine (3 x 200 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether - ethyl acetate (3:1) to afford the title compound 82 (13.0 g, 85% yield).Preparation 77: Synthesis of tert-butyl (S)-(l-cyanoethyl)(methyl)carbamate (3002)3002

[0362] A solution of 82 (5.00 g, 24.7 mmol, 1.00 equiv.) in THF (100 mL) and pyridine (7.80 g, 98.9 mmol, 4.00 equiv.) was cooled to about 0 °C and treated with TFAA (10.4 g, 49.4 mmol, 2.00 equiv.) added dropwise over about 10 min. The reaction mixture was then stirred at about 25 °C for about 2 h further. After concentration, the residue was taken up in water (20 mL) and 210335853366 CENC-015 / 01WO 360899-2048extracted with EtOAc (3 x 20 mL). The combined EtOAc extracts were washed with brine (2 x 20 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether - ethyl acetate (3:1) to afford the title compound 3002 (3.00 g, 66% yield).Preparation 78: Synthesis of (S)-2-(methylamino)propanenitrile (84)\NH,,.(absX84

[0363] A solution of 3002 (500 mg, 2.70 mmol, 1.00 equiv.) in DCM (10 mL) and 2,6-dimethylpyridine (872 mg, 8.1 mmol, 3.0 equiv.) was treated with iodotrimethylsilane (1.1 g, 5.4 mmol, 2.0 equiv.) at about 0 °C for about 1 h, then concentrated to give the title compound 84 hydriodide (500 mg), which was used without further purification.Preparation 79: Synthesis of (R)-2-(methylamino)propanenitrile (85)NHX85

[0364] This compound was prepared similarly to 84, starting with N-(tert-butoxycarbonyl)-N-methyl-D-alanine (CAS 19914-38-6).Preparation 80: Synthesis of tert-butyl (R)-4-carbamoylthiazolidine-3-carboxylate (86)86

[0365] A solution of (R)-3-(tert-butoxycarbonyl)thiazolidine-4-carboxylic acid (CAS 51077-16-8, 14.0 g, 60 mmol, 1.00 equiv.) in THF (140 mL) was treated with CDI (13.6 g, 84 mmol, 1.40 equiv.) at about 25 °C for about 2 h, after which it was cooled to about 0 °C and NH4OH (20 mL)211335853366 CENC-015 / 01WO 360899-2048was added. After about 30 min, the mixture was extracted with DCM (3 x 100 mL). The combined DCM extracts were washed with 2 M HCl (3 x 100 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with petroleum ether - ethyl acetate (1: 1) to afford the title compound 86 (13.0 g, 93%).Preparation 81: Synthesis of (R)-thiazolidine-4-carboxamide hydrochloride (87)87

[0366] A solution of 86 (581 mg, 2.50 mmol, 1,00 equiv.) in DCM (6.00 mL) was treated with HC1 (4 M in 1,4-di oxane, 6.0 mL) at about 25 °C for about 2 h, then concentrated. The residue was purified by trituration with MTBE (20 mL). The solid was filtered, washed with MTBE (3 x 10 mL) and dried to give the title compound 87 hydrochloride (500 mg), which was used without further purification.LCMS Calculated for C4H8N2OS: 132.0; Observed: 132.2 [M+H]+.Preparation 82: Synthesis of (R)-3-((4S,5S)-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-(3-(trifluoromethyl)benzamido)-l,4,5,6-tetrahydropyridine-3-carbonyl)thiazolidine-4-carboxamide (88)88

[0367] A solution of 8 (100 mg, 0.203 mmol, 1.00 equiv.) in MeCN (1.0 mL) was treated with N-methylimidazole (50 mg, 0.61 mmol, 3.00 equiv.) and TCFH (85 mg, 0.30 mmol, 1.50 equiv.) at about 25 °C for about 5 min, followed by the addition of 87 (51 mg, 0.30 mmol, 1.50 equiv.) and DIEA (105 mg, 0.81 mmol, 4.00 equiv.). After about 14 h at about 25 °C, the reaction mixture 212335853366 CENC-015 / 01WO 360899-2048was purified by reverse phase flash chromatography under the following conditions (column, Cl 8 silica gel; mobile phase, MeCN in water (containing 0.1% NH4OH), 30% to 70% gradient in 15 min; detector, UV 254 nm) to give the title compound 88 (78 mg, 63% yield).LCMS Calculated for C29H30F4N4O4S: 606.2; Observed: 607.2 [M+H]+.Preparation 83: Synthesis of N-((3S,4S)-5-((R)-4-cyanothiazolidine-3-carbonyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (89)89

[0368] A solution of 88 (78 mg, 0.13 mmol, 1.00 equiv.) in DCM (1.0 mL) was treated with Et3N (52 mg, 0.52 mmol, 4.00 equiv.) followed by the addition of TFAA (81 mg, 0.39 mmol, 3.00 equiv.) at about 0 °C. After about 2 h at about 0 °C, water (2.00 mL) was added, and the mixture was extracted with DCM (2 x 2.0 mL). The combined DCM extracts were washed with NaHCO3 (l x 2.0 mL), dried (Na2SC>4), filtered and concentrated to afford the title compound 89 (68 mg), which was used without further purification.LCMS Calculated for C29H28F4N4O3S: 588.2; Observed: 589.2 [M+H]+.Preparation 84: Synthesis of N-((3S,4S)-5-((RS)-4-cyano-l,l-dioxidothiazolidine-3-carbonyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl- 1,2,3, 4-tetrahydropyri din-3 -yl)-3- (trifluoromethyl)benzamide (213335853366 CENC-015 / 01WO 360899-204890

[0369] A solution of 89 (75 mg, 0.13 mmol, 1 equiv.) in DCM (1 mL) was treated with m-CPBA (66 mg, 0.38 mmol, 3 equiv.) at about 25 °C for about 4 h. Saturated sodium sulfite aqueous solution (1 mL) was added, and the pH was adjusted to about pH 9 with K2CO3 solution. The mixture was extracted with dichloromethane (3 x 1 mL) and the combined DCM extracts were washed with brine (3 x 1 mL), dried (Na2SO4), filtered and concentrated. The residue was purified by reverse phase HPLC (Method-B) to give the title product 90.Preparation 85: Synthesis of tert-butyl ((lS,2R)-2-(methylamino)cyclopentyl)carbamate (91)91

[0370] A solution of tert-butyl ((lS,2R)-2-aminocyclopentyl)carbamate (CAS 445479-01-6, 60 mg, 0.30 mmol, 1.00 equiv.) and 37% aqueous formaldehyde solution (9 mg, 0.11 mmol, 0.33 equiv,) in MeOH (1.0 mL) was hydrogenated over a 20% palladium on carbon catalyst (10 mg) at about 25 °C under one atmosphere of hydrogen pressure for about 1 h. The reaction mixture was filtered, and the filter was washed with MeOH (3 x 5 mL). The combined filtrates were concentrated to afford the title compound 91 (80 mg), which was used without further purification.Preparation 86: Synthesis of tert-butyl (R)-2-((methylamino)methyl)azetidine-l -carboxylate (92)Boc92

[0371] A solution of tert-butyl (2R)-2-(aminomethyl)azetidine-l -carboxylate (CAS 887626-82-6, 100 mg, 0.54 mmol, 1.00 equiv.) and 37% aqueous formaldehyde solution (44 mg, 0.54 mmol, 1.00 equiv.) in MeOH (4 mL) was hydrogenated over a 10% palladium on carbon catalyst (10 mg) at about 25 °C under one atmosphere of hydrogen pressure for about 2 h. The reaction mixture was filtered, the filter washed with MeOH, and the filtrate was concentrated to afford the title compound 92, which was used without further purification.LCMS Calculated for C10H20N2O2: 200.15; Observed: 201.2 [M+H]+.214335853366 CENC-015 / 01WO 360899-2048Methods

[0372] The Methods set forth hereinbelow are intended only to exemplify various aspects and embodiments of the invention and are not intended to limit the scope of the claimed invention in any way. It will be apparent to one skilled in the art that the Methods described below may be modified in various ways, for example by changing reaction solvents or volumes, by substituting similar reagents to those described, or by substituting similar catalysts to those described.Method 1

[0373] The acylation of an amine to produce an amide product is one of most frequently performed transformations in organic chemistry. It is frequently conducted by treating a mixture of the amine substrate with the intended carboxylic acid with a so-called “activating agent”, of which many are known and widely used. These reagents are so commonly used by those skilled in the art that they are frequently referred to by abbreviations of their chemical names, such as EDC, DCC, BOP, HATU, CDI, T3P, TCFH, and DIC. Commonly a reaction compatible base is added to neutralize any acidic by-products, as well as to neutralize the amine salt if the amine is provided to the reaction in the form of salt, such as a hydrochloride salt for example. Reaction compatible bases are most commonly inexpensive tertiary amines and again are so commonly used by those skilled in the art that they are frequently referred to by abbreviations of their chemical names, such as TEA, DIEA, NMM, NMI, and Py. The reader is referred to the list of Abbreviations in this document to learn what the chemical names are that these abbreviations stand for. A nucleophilic catalyst or co-reagent such as N-hydroxybenzotriazole, N-hydroxysuccinimide, N-hydroxy-2-pyridone, or 4-(dimethylamino)pyridine may also be added to advantage in some cases. While it is very common to combine all the reactants simultaneously, one may also teat the carboxylic acid with the activating agent first, after which the amine partner is added later. In the case of some activating agents, including CDI, TCFH and 2-chloro-l -methylpyridinium iodide (the latter also known as Mukaiyama’s reagent), it is important that the amine partner be added later because the amine partner can react with the activating agent to form unwanted by-products and reduced yields. Dichloromethane and DMF are the most frequently used solvents due to their polar and aprotic nature and their general applicability, but a great many solvents may be employed effectively.215335853366 CENC-015 / 01WO 360899-2048

[0374] As an example of the use of HATU as an activating agent, a solution of (4S,5S)-1-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-[3-(trifluoromethyl)benzamido]-4,5-dihydropyridine-3-carboxylic acid (90 mg, 0.18 mmol, 1.10 equiv.) in dichloromethane (1.0 mL) was treated with HATU (76 mg, 0.20 mmol, 1.20 equiv.) and DIEA (43 mg, 0.33 mmol, 2.00 equiv.) at room temperature for 10 min under nitrogen atmosphere followed by the addition of 2-[(cyanomethyl)[3-(dimethylamino)propyl]amino]acetonitrile (30 mg, 0.17 mmol, 1.00 equiv.) at about 25 °C and kept for about for 30 min. After concentration, the residue was purified by preparative HPLC to afford (4S,5S)-N-(cyanomethyl)-N-[3-(dimethylamino)-propyl]-l-ethyl-4-(4-fluorophenyl)-6-oxo-2-propyl-5-[3-(trifluoromethyl)benzamido]-4,5-dihydropyridine-3-carboxamide. The use of HATU as an activating agent will be referred to as Method 1 in the subsequent tables. For clarity, the similar use of T3P as the activating agent will be referred to as Method IB in the subsequent tables. Similarly, the use of 2-chloro-l -methylpyridinium iodide as the activating agent will be referred to as Method 1C in the subsequent tables.As an example of the use of TCFH as an activating agent, in which case it is important that the amine partner be added after the reaction between TCFH and the acid component has completed, the reader is referred to Preparation 10 in this document. The use of TCFH as an activating agent will be referred to as Method ID in the subsequent tables, due to the more specialized procedure surrounding its use.Method 2

[0375] Another frequently employed method to acylate an amine to produce an amide product is performed by treating the amine substrate with the intended acid halide, most frequently an acyl chloride or sulfonyl chloride. A reaction compatible base is added to neutralize the acid formed as a by-product, as well as to neutralize the amine salt if the amine is provided to the reaction in the form of salt, such as a hydrochloride salt for example. As in Method 1, the reaction compatible bases are most commonly inexpensive tertiary amines and generally are the same as those used in Method 1, including TEA, DIEA, NMM, NMI, and Py. Dichloromethane is very frequently used as solvent due to its polar and aprotic nature, and compatibility with the reactive acyl and sulfonyl halides, but other reaction compatible solvents may be employed effectively. As an example, a solution of N-((3S,4S)-5-(azetidin-3-yl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide hydrochloride (50 mg, 0.10 mmol, 1.00216335853366 CENC-015 / 01WO 360899-2048equiv.) and DIEA (39 mg, 0.30 mmol, 3.00 equiv.) in dichloromethane (2.0 mL) was treated with chloroacetyl chloride (14 mg, 0.12 mmol, 1.20 equiv.) with cooling to about 0 °C. After about 1 h at about 0 °C, water (1.0 mL) was added. The dichloromethane was separated and concentrated, and the residue was purified by preparative HPLC to afford N-((3S,4S)-5-(l-(2-chloroacetyl)azetidin-3-yl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide.Method 3

[0376] Many compounds of this invention contain a cyanamide functional group as part of their structure. While there are numerous ways by which cyanamides may be prepared, the reaction of an amine with cyanogen bromide is of particular utility because of the ease with which the reaction is carried out. The reaction is conducted in the presence of a base to consume the hydrogen bromide generated as a byproduct. Sodium carbonate and potassium carbonate are particularly useful, while sodium bicarbonate may at times be used, as may tertiary amine bases. Suitable solvents are chosen for their ability to dissolve the intended reactants and resist the action of cyanogen bromide, with dichloromethane and tetrahydrofuran being common choices. As an example, cyanogen bromide (27 mg, 0.25 mmol, 1.20 equiv.) was added to a mixture of N-((3S,4S)-5-(aminomethyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (100 mg, 0.21 mmol, 1.00 equiv.) and sodium carbonate (44 mg, 0.42 mmol, 2.00 equiv.) in tetrahydrofuran (2.0 mL) at about 25 °C. After about 1 h, the mixture was concentrated and the residue was purified by reverse phase flash chromatography to afford N-((3S,4S)-5-(cyanamidomethyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide.Method 4

[0377] The tert-butoxycarbonyl (BOC) protecting group is a very common and popular protecting group for amines in organic chemistry, due to the ease with which it may be placed on a particular amine and the ease with which it may be removed by treatment with a strong acid. While many strong acids can effect the cleavage reaction, it is most common to use strong acids 217335853366 CENC-015 / 01WO 360899-2048that are volatile, particularly hydrogen chloride or trifluoroacetic acid, in which case the amine product of the reaction may be isolated as the salt of the acid by simple evaporation of the mixture. Reaction compatible solvents are those that are resistant to the acidic conditions, and frequently selected for ease of evaporation, with di chloromethane and 1,4-di oxane being especially commonly chosen. In the context of this invention, the removal of the tert-butoxycarbonyl (BOC) protecting group is required in many of the synthetic sequences. Preparation 9 is a typical example of this transformation.

[0378] For clarity, the similar use of trifluoroacetic acid to cleave the tert-butoxycarbonyl (BOC) protecting group will be referred to as Method 4B in the subsequent tables.Method 5

[0379] Certain embodiments of the present invention contain a nitrile group, that upon inspection will be discerned by one skilled in the art to be derived from an amino acid. While a great many of these nitriles are now offered for sale, in some cases it may be necessary to synthesize them from the amino acid, typically from an amino acid in which the amine group is protected with a tert-butoxycarbonyl (BOC) protecting group. This is generally carried out in two steps. In the first step, the carboxylic acid is converted to a carboxylic primary amide. This may be done in many ways, however, in the chemistry of amino acids and peptide synthesis the so-called mixed anhydride method has always been popular. A mixed anhydride is prepared by the reaction of the carboxylic acid with a simple chloroformate ester, such is isobutyl chloroformate or ethyl chloroformate, in the presence of a suitable tertiary amine base, such as TEA, DIEA, or NMM. The mixed anhydride so formed is then treated with the amine partner, which for the production of a primary amide is ammonia. The ammonia is most easily introduced in the form of a saturated solution of ammonia gas in water, and large excesses of ammonia are generally taken. For example, a solution of (lR,5R)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (10.0 g, 44.0 mmol, 1.00 equiv.) and triethylamine (8.91 g, 88.0 mmol, 2.00 equiv.) in tetrahydrofuran (100 mL) was treated with isobutyl chloroformate (9.01 g, 66.0 mmol, 1.50 equiv.), added dropwise with cooling to about 0 °C. Once the addition was complete, the reaction mixture was kept at about 0 °C for about 10 min longer before concentrated ammonium hydroxide solution (30.8 g, 880 mmol, 20.0 equiv.) was added over about 1 min. After about 5 min, the mixture was extracted with ethyl acetate (2 x 100 mL) and the combined ethyl acetate extracts 218335853366 CENC-015 / 01WO 360899-2048were washed with brine (2 x 100 mL), dried (Na2SO4), filtered and concentrated to give tert-butyl (lR,5R)-3-carbamoyl-2-azabicyclo[3.1,0]hexane-2-carboxylate.Method 6

[0380] In the second step of the synthesis of a nitrile from a carboxylic acid, including a protected amino acid, the intermediate primary amide is dehydrated to afford the nitrile. Many reagents are capable of removing the elements of water from a primary amide. In the context of this invention, trifluoroacetic anhydride is a particularly convenient reagent for this purpose. It is common to add a suitable base, often a tertiary amine base, such as TEA, DIEA, or NMM, to neutralize the trifluoroacetic acid formed as a byproduct. Reaction compatible solvents are those that are resistant to the acidic conditions, and frequently selected for ease of evaporation, with di chloromethane and 1,4-di oxane being especially commonly chosen. For example, trifluoracetic anhydride (56 mg, 0.27 mmol, 2.00 equiv.) was added to a solution ofN-((3S,4S)-5-((lR,3S,5R)-3-cyano-2-azabicyclo[3.1.0]hexane-2-carbonyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)-benzamide (80 mg, 0.13 mmol, 1.00 equiv.) and triethylamine (54 mg, 0.53 mmol, 4.00 equiv.) in dichloromethane (2.0 mL) at about 0 °C, then kept at about 25 °C for about 30 min before being concentrated. The residue was purified by preparative HPLC to afford N-((3R,4R)-5-((lR,3S,5R)-3-cyano-2-azabicyclo[3.1.0]hexane-2-carbonyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide.Method 7

[0381] Some compounds of this invention contain a N-methyl cyanamide functional group as part of their structure. Such compounds may be thought of as being prepared in either of two ways, either by the reaction of a suitable N-methyl amine with cyanogen bromide as described previously, or by the methylation of a suitable N-H cyanamide. The methylation approach is frequently selected when the desired N-methyl amine is not available. The selected N-H cyanamide is treated with a methylating agent, typically iodomethane, and a reaction compatible base, such as sodium carbonate or potassium carbonate. Suitable solvents are chosen for their 219335853366 CENC-015 / 01WO 360899-2048ability to dissolve the intended reactants, with di chloromethane, acetonitrile and tetrahydrofuran being common choices. As an example, a mixture of N-((3S,4S)-5-(cyanamidomethyl)-l-ethyl-4-(4-fluorophenyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide (50 mg, 0.10 mmol, 1.00 equiv.), iodomethane (17 mg, 0.12 mmol, 1.20 equiv.), and potassium carbonate (28 mg, 0.20 mmol, 2.00 equiv.) in DMF (1.0 mL) was kept at about 25 °C for about 4 h, then the solution was purified by reverse phase flash chromatography to afford N-((3S,4S)-1-ethyl-4-(4-fluorophenyl)-5-((N-methylcyanamido)methyl)-2-oxo-6-propyl-l,2,3,4-tetrahydropyridin-3-yl)-3-(trifluoromethyl)benzamide.Method 8

[0382] It will be recognized that many compounds of the present invention have the potential to form multiple stereoisomers. In some cases, the formation of stereoisomers may be controlled by the use of starting materials that are single enantiomers. In other cases, it may be expedient to partially or entirely separate the various stereoisomers after the completion of synthetic transformations. Depending on the nature of the stereoisomer mixture at hand in any particular case, this may be accomplished by chromatography using achiral or chiral stationary supports and a variety of processes are of potential utility, including the use of preparative thin layer chromatography, flash column chromatography, HPLC, or SFC, to name a few. The selection of a chromatographic method, solid support, and mobile phase(s) appropriate for a particular instance will be discerned by one skilled in the art. It will also be recognized that such separations will be possible under multiple conditions and the selection of a particular set of conditions does not suggest that separation under other conditions is impossible.Dihydropyridone DPG5 Table

[0383] In the Table that follows presenting specific embodiments of this invention, the specific compounds of Formulas F, Fa*, Fa**, G, H, I and J that are used in each particular example are referred to as Reagent A. In most cases, particular advanced intermediates from the Examples will be employed as Reagent A and are identified by their compound numbers from the Examples. Likewise, any specific additional compound that is used in each particular example is referred to as Reagent B. The Reagent B compounds may be intermediates prepared in the Preparations section of this specification, or they may be commercially available. Where commercially available, they are identified by their Chemical Abstracts Service (CAS) numbers. In some cases,220335853366 CENC-015 / 01WO 360899-2048no additional Reagent B is indicated for simplicity; however, it will be clear from the Methods presented in the Table what additional reagents are employed, for example the use of cyanogen bromide as described in Method 3, or hydrogen chloride in Method 4.

[0384] The synthetic transformations that are necessary to produce the specific embodiments from Reagents A and B are referred to as Methods, and general procedures for these Methods have been presented. In this Table, the Methods are listed in the order in which they are performed, and the selection of the order of these steps will be discerned by one skilled in the art.

[0385] Certain embodiment examples of this invention require the synthesis of particular intermediates by procedures beyond those Methods presented. In these cases, the preparation of the intermediates required have been presented in the Preparations section of this specification. In some cases, these intermediates will be well advanced along the synthetic pathways shown in the Schemes and require only one or two further steps to provide the compound of that specific embodiment. In such cases, those advanced intermediates are referred to as Reagent A in the table for simplicity as noted previously.221335853366 CENC-015 / 01WO 360899-2048222335853366 CENC-015 / 01WO 360899-2048223335853366 CENC-015 / 01WO 360899-2048224335853366 CENC-015 / 01WO 360899-2048225335853366 CENC-015 / 01WO 360899-2048226335853366 CENC-015 / 01WO 360899-2048227335853366 CENC-015 / 01WO 360899-2048228335853366 CENC-015 / 01WO 360899-2048229335853366 CENC-015 / 01WO 360899-2048230335853366 CENC-015 / 01WO 360899-2048231335853366 CENC-015 / 01WO 360899-2048232335853366 CENC-015 / 01WO 360899-2048233335853366 CENC-015 / 01WO 360899-2048234335853366 CENC-015 / 01WO 360899-2048235335853366 CENC-015 / 01WO 360899-2048236335853366 CENC-015 / 01WO 360899-2048237335853366 CENC-015 / 01WO 360899-2048238335853366 CENC-015 / 01WO 360899-2048239335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048241335853366 CENC-015 / 01WO 360899-2048242335853366 CENC-015 / 01WO 360899-2048243335853366 CENC-015 / 01WO 360899-2048244335853366 CENC-015 / 01WO 360899-2048245335853366 CENC-015 / 01WO 360899-2048246335853366 CENC-015 / 01WO 360899-2048247335853366 CENC-015 / 01WO 360899-2048248335853366 CENC-015 / 01WO 360899-2048249335853366 CENC-015 / 01WO 360899-2048250335853366 CENC-015 / 01WO 360899-2048251335853366 CENC-015 / 01WO 360899-2048252335853366 CENC-015 / 01WO 360899-2048253335853366 CENC-015 / 01WO 360899-2048254335853366 CENC-015 / 01WO 360899-2048255335853366 CENC-015 / 01WO 360899-2048256335853366 CENC-015 / 01WO 360899-2048257335853366 CENC-015 / 01WO 360899-2048258335853366 CENC-015 / 01WO 360899-2048259335853366 CENC-015 / 01WO 360899-2048260335853366 CENC-015 / 01WO 360899-2048261335853366 CENC-015 / 01WO 360899-2048262335853366 CENC-015 / 01WO 360899-2048263335853366 CENC-015 / 01WO 360899-2048264335853366 CENC-015 / 01WO 360899-2048265335853366 CENC-015 / 01WO 360899-2048266335853366 CENC-015 / 01WO 360899-2048267335853366 CENC-015 / 01WO 360899-2048268335853366 CENC-015 / 01WO 360899-2048269335853366 CENC-015 / 01WO 360899-2048270335853366 CENC-015 / 01WO 360899-2048271335853366 CENC-015 / 01WO 360899-2048272335853366 CENC-015 / 01WO 360899-2048273335853366 CENC-015 / 01WO 360899-2048274335853366 CENC-015 / 01WO 360899-2048275335853366 CENC-015 / 01WO 360899-2048276335853366 CENC-015 / 01WO 360899-2048277335853366 CENC-015 / 01WO 360899-2048278335853366 CENC-015 / 01WO 360899-2048279335853366 CENC-015 / 01WO 360899-2048280335853366 CENC-015 / 01WO 360899-2048281335853366 CENC-015 / 01WO 360899-2048282335853366 CENC-015 / 01WO 360899-2048283335853366 CENC-015 / 01WO 360899-2048284335853366 CENC-015 / 01WO 360899-2048285335853366 CENC-015 / 01WO 360899-2048286335853366 CENC-015 / 01WO 360899-2048287335853366 CENC-015 / 01WO 360899-2048288335853366 CENC-015 / 01WO 360899-2048289335853366 CENC-015 / 01WO 360899-2048290335853366 CENC-015 / 01WO 360899-2048291335853366 CENC-015 / 01WO 360899-2048292335853366 CENC-015 / 01WO 360899-2048293335853366 CENC-015 / 01WO 360899-2048294335853366 CENC-015 / 01WO 360899-2048295335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048298335853366 CENC-015 / 01WO 360899-2048299335853366 CENC-015 / 01WO 360899-2048300335853366 CENC-015 / 01WO 360899-2048301335853366 CENC-015 / 01WO 360899-2048302335853366 CENC-015 / 01WO 360899-2048303335853366 CENC-015 / 01WO 360899-2048304335853366 CENC-015 / 01WO 360899-2048305335853366 CENC-015 / 01WO 360899-2048306335853366 CENC-015 / 01WO 360899-2048307335853366 CENC-015 / 01WO 360899-2048308335853366 CENC-015 / 01WO 360899-2048309335853366 CENC-015 / 01WO 360899-2048310335853366 CENC-015 / 01WO 360899-2048311335853366 CENC-015 / 01WO 360899-2048312335853366 CENC-015 / 01WO 360899-2048313335853366 CENC-015 / 01WO 360899-2048314335853366 CENC-015 / 01WO 360899-2048315335853366 CENC-015 / 01WO 360899-2048316335853366 CENC-015 / 01WO 360899-2048317335853366 CENC-015 / 01WO 360899-2048318335853366 CENC-015 / 01WO 360899-2048319335853366 CENC-015 / 01WO 360899-2048320335853366 CENC-015 / 01WO 360899-2048321335853366 CENC-015 / 01WO 360899-2048322335853366 CENC-015 / 01WO 360899-2048323335853366 CENC-015 / 01WO 360899-2048324335853366 CENC-015 / 01WO 360899-2048325335853366 CENC-015 / 01WO 360899-2048326335853366 CENC-015 / 01WO 360899-2048327335853366 CENC-015 / 01WO 360899-2048328335853366 CENC-015 / 01WO 360899-2048329335853366 CENC-015 / 01WO 360899-2048330335853366 CENC-015 / 01WO 360899-2048331335853366 CENC-015 / 01WO 360899-2048332335853366 CENC-015 / 01WO 360899-2048333335853366 CENC-015 / 01WO 360899-2048334335853366 CENC-015 / 01WO 360899-2048335335853366 CENC-015 / 01WO 360899-2048336335853366 CENC-015 / 01WO 360899-2048337335853366 CENC-015 / 01WO 360899-2048338335853366 CENC-015 / 01WO 360899-2048339335853366 CENC-015 / 01WO 360899-2048340335853366 CENC-015 / 01WO 360899-2048341335853366 CENC-015 / 01WO 360899-2048342335853366 CENC-015 / 01WO 360899-2048343335853366 CENC-015 / 01WO 360899-2048344335853366 CENC-015 / 01WO 360899-2048345335853366 CENC-015 / 01WO 360899-2048346335853366 CENC-015 / 01WO 360899-2048347335853366 CENC-015 / 01WO 360899-2048348335853366 CENC-015 / 01WO 360899-2048349335853366 CENC-015 / 01WO 360899-2048350335853366 CENC-015 / 01WO 360899-2048351335853366 CENC-015 / 01WO 360899-2048352335853366 CENC-015 / 01WO 360899-2048353335853366 CENC-015 / 01WO 360899-2048354335853366 CENC-015 / 01WO 360899-2048355335853366 CENC-015 / 01WO 360899-2048356335853366 CENC-015 / 01WO 360899-2048357335853366 CENC-015 / 01WO 360899-2048358335853366 CENC-015 / 01WO 360899-2048359335853366 CENC-015 / 01WO 360899-2048360335853366 CENC-015 / 01WO 360899-2048361335853366 CENC-015 / 01WO 360899-2048362335853366 CENC-015 / 01WO 360899-2048363335853366 CENC-015 / 01WO 360899-2048364335853366 CENC-015 / 01WO 360899-2048365335853366 CENC-015 / 01WO 360899-2048366335853366 CENC-015 / 01WO 360899-2048367335853366 CENC-015 / 01WO 360899-2048368335853366 CENC-015 / 01WO 360899-2048369335853366 CENC-015 / 01WO 360899-2048370335853366 CENC-015 / 01WO 360899-2048371335853366 CENC-015 / 01WO 360899-2048372335853366 CENC-015 / 01WO 360899-2048373335853366 CENC-015 / 01WO 360899-2048374335853366 CENC-015 / 01WO 360899-2048375335853366 CENC-015 / 01WO 360899-2048376335853366 CENC-015 / 01WO 360899-2048377335853366 CENC-015 / 01WO 360899-2048378335853366 CENC-015 / 01WO 360899-2048379335853366 CENC-015 / 01WO 360899-2048380335853366 CENC-015 / 01WO 360899-2048381335853366 CENC-015 / 01WO 360899-2048382335853366 CENC-015 / 01WO 360899-2048383335853366 CENC-015 / 01WO 360899-2048384335853366 CENC-015 / 01WO 360899-2048385335853366 CENC-015 / 01WO 360899-2048386335853366 CENC-015 / 01WO 360899-2048387335853366 CENC-015 / 01WO 360899-2048388335853366 CENC-015 / 01WO 360899-2048389335853366 CENC-015 / 01WO 360899-2048390335853366 CENC-015 / 01WO 360899-2048391335853366 CENC-015 / 01WO 360899-2048392335853366 CENC-015 / 01WO 360899-2048393335853366 CENC-015 / 01WO 360899-2048394335853366 CENC-015 / 01WO 360899-2048395335853366 CENC-015 / 01WO 360899-2048396335853366 CENC-015 / 01WO 360899-2048397335853366 CENC-015 / 01WO 360899-2048398335853366 CENC-015 / 01WO 360899-2048399335853366 CENC-015 / 01WO 360899-2048400335853366 CENC-015 / 01WO 360899-2048401335853366 CENC-015 / 01WO 360899-2048402335853366 CENC-015 / 01WO 360899-2048403335853366 CENC-015 / 01WO 360899-2048404335853366 CENC-015 / 01WO 360899-2048405335853366 CENC-015 / 01WO 360899-2048406335853366 CENC-015 / 01WO 360899-2048407335853366 CENC-015 / 01WO 360899-2048408335853366 CENC-015 / 01WO 360899-2048409335853366 CENC-015 / 01WO 360899-2048410335853366 CENC-015 / 01WO 360899-2048Example 2: HBG1 Nanostring Assay

[0386] A Nanostring Assay was performed to evaluate the ability of the compounds to induce expression of the fetal hemoglobin gene HBG1 in cells. The data are shown as EC50, with stronger inducers having a lower EC50 value and higher YMax.CD34 culture and sample preparation

[0387] Mobilized peripheral blood (mPB) derived CD34+ hematopoietic stem and progenitor cells (HSPCs) were thawed and plated at 500,000 cells / ml on day of cell thaw (day -4) in StemSpan (StemCell Tech, 09600) complete media supplemented with 1% StemSpan CC100 (StemCell Tech, 02690), and 0.2% human recombinant thrombopoietin (StemCell Tech, 02822). Forty eight hours later (day -2), the cells were passaged at a density of 200,000 cells / ml (lOOul / well in 96well culture plate) in complete expantion media. The cells were plated at 200,000 cells / ml on day 0 and day3, 400,000 cells / ml on day 5 in phase 1 erythroid differentiation containing StemSpan with 2.5U / mL of EPO (R& D systems, 287-TC-500), 0.5 mg / mL of Holo-Transferrin (Sigma, T0665-500MG), lx Glutamine (Gluta-Max) (Gibco, 35050-061), 5 pL / mL Lipid Mixture (Sigma, L0288-100ML), 50 ng / mL SCF (R& D Systems, 255-SV-050), 10 ng / mL IL-3 (R& D Systems, 203-IL010) and 10 ng / mL Insulin (Sigma, I9278-5ML) all 200pl per well in 96 well culture plate. Cells were then passaged at 500,000 cells / ml and 200pl per well on day 7 in phase 2 Erythroid differentiation (Phase 1 erythroid differentiation removing IL-3) until collection day (Day 10). The culture conditions were used for both control DMSO as well as experimental treatments.

[0388] For all cell pasagings, cells were centrifuged at 300g for 8 minutes at room temperature and cell number were normalized by MANTIS and Integra VIAFLO 384. All the compounds are diluted in DMSO and added to complete media by Formulatrix FAST and mixed starting from day -2. Cells were counted by Luna cell counter with AOPI Staining Solution (Nexcelom Bioscience, CS2-0106-25mL) on day-2. Cells were counted by BD FACSCelesta Flow Cytometer with CountBright™ Plus Absolute Counting Beads (Thermal Fisher Scientific, C36995) and SYTOX AADvanced™ Ready Flow™ Reagent (Invitrogen, R37173) for other passages. Cells were cultured at 37°C and 5% CO2. DMSO concentration was kept at 0.1% to minimize any effects to the cells by the vehicle. Due to the insolubility of positive control, it was freshly made every 6 weeks with stock concentration at 3mM while stock concentration for other compounds are lOmM.411335853366 CENC-015 / 01WO 360899-2048Compound plates were kept at room temptureture to protect from light to avoid multiple freeze and thaw cycle.

[0389] On the collection day (Day 10), 100K cells were collected and stored at -80 °C. For direct hybridization for Nanostring, 100K cell pellet was lyzed in 25 uL ofRLT (QIAGEN, 79216) with lx P -Mercaptoethanol (Gibco, 21985-023) and shaked at 300-500 RPM for 5 minutes at room temperature. Cell lysate was stored in -80°C after lysis.Hybridization and imaging

[0390] All hybridizations were done in a total volume of 15 pL (3 pL of RNA lysate added to master mix of 12 pL probe A / B, capture probe / reporter probes, proteinase K and attenuation oligos suspended in hybridization buffer). Samples were hybridized at 67 °C for 22 hr. Following hybridization, the tripartide complexes were purified, immobilized by nCounter Prep Station and imaged by Digital Analyzer (nCounter MAX / FLEX Analysis System), to generate digital counts of barcodes corresponding to each target in the multiplexed reaction. Labeled barcodes obtained from unamplified extracts were counted at 555 images or field of view (FOV). The barcode counts for each sample were recorded in Reporter Code Count (RCC) files that are imported into nSolver analysis software (provided with CodeSet by NS) for quality control evaluation.Quality control (QC) metrics and data analysis

[0391] The quality control (QC) metric included limit of detection QC by checking for wells with less than 100 total counts for positive controls.

[0392] Hybridization signals were normalized against the ERCC positive controls and CodeSet Content (housekeeping gene). Briefly, this involved first calculating a sample-specific scaling factor by calculating arithmetic mean of geomeans of all ERCC positive controls with counts more than zero in all samples. Then this arithmetic mean was divided by the geometric mean of each lane to generate a lane-specific normalization factor. All negative controls and targetspecific signal values were then normalized by multiplying counts values with their samplespecific scaling factor. The acceptable range for scaling factors is 0.3-3.0. For housekeeping gene(s) normalization, first calculating the arithmetic mean of geometric means of selected housekeeping genes for each lane for all samples. Then this arithmetic mean was divided by the geometric mean of each lane to generate a lane-specific normalization factor followed by multiplying the counts for every gene by its lane-specific normalization factor. The acceptable range for housekeeping genes normalization scaling factors is 0.1-10.412335853366 CENC-015 / 01WO 360899-2048

[0393] HBG1 dose-response curves, %Emax and EC50 values were generated by Dotmatic...

Claims

1. CLAIMS1. A compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein:Ring A is phenyl or a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;R1is a Ci-6 aliphatic group, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- 6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R1is optionally substituted with halogen, -CN, - C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, - N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, -NRS(O)2R, phenyl, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;R2is hydrogen or an optionally substituted group selected from Ci-6 aliphatic or a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring;each occurrence of R3is independently a halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, - S(O)R, -S(O)2R, -S(O)2N(R)2, -NRS(O)2R, or an optionally substituted Ci-6 aliphatic;R4is phenyl, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 3- 8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered 432335853366 CENC-015 / 01WO 360899-2048monocyclic heteroaromatic ring having 1 -4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a Ci-6 aliphatic; wherein R4is optionally substituted with p instances of R7;R5is a substituent comprising a warhead group;R6is hydrogen or an optionally substituted Ci-6 aliphatic group;each occurrence of R7is independently a halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, - S(O)R, -S(O)2R, -S(O)2N(R)2, -NRS(O)2R, or an optionally substituted C1-6 aliphatic; each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;n is 0, 1, 2, 3, 4, or 5; andp is 0, 1, 2, 3, 4, or 5.

2. The compound of claim 1, wherein R3is L2-Y, whereinL2is a covalent bond or a bivalent optionally substituted C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O)—, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2 —, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched, hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2 or -OR group; and additionally one or two methylene units of L2are optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered 433335853366 CENC-015 / 01WO 360899-2048bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COOR, -CN, -CON(R)2, -CONRCN, -NRCN, NO2, -N(R)2, optionally substituted Ci-s aliphatic, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide.

3. The compound of claim 1 or 2, wherein R5is L2-Y, whereinL2is a covalent bond or a bivalent optionally substituted C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O)—, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2 —, -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2or -OR group; and additionally one or two methylene units of L2are optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COORf, -CN, -CONRf2, -CONRfCN, -NRfCN, NO2, -NRf2, Ci-s aliphatic optionally substituted with halogen, NO2, or CN, or an optionally substituted ring selected from 434335853366 CENC-015 / 01WO 360899-2048a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide; and wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

4. The compound of any one of claims 1 to 3, wherein R5is L2-Y, whereinL2is a covalent bond or a bivalent C2-10 straight or branched hydrocarbon chain wherein one, two or three methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2— — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2— -C(O)-, — OC(O) —, or — C(O)O —; C2-10 straight or branched hydrocarbon chain is optionally substituted with 1, 2, 3, or 4 independently selected halogen atoms and optionally substituted with one -CN, -NR2 or -OR group; and additionally one methylene unit of L2is optionally replaced by a ring435335853366 CENC-015 / 01WO 360899-2048Y is hydrogen, halogen, -COORf, -CN, -CONRf2, -CONRfCN, -NRfCN, NO2, -NRf2, epoxide, Ci-8 aliphatic optionally substituted with halogen, NO2, or CN, or a ring selected fromHh lf,, and ' — ' wherein -L -Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, C2-6 alkynyl group, sulfonyl group, or epoxide; wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

5. The compound of any one of claims 1 to 4, wherein R5is selected from one of those shown in Table 1c, Table Id, Table le, Table If, or Table 1g.

6. The compound of any one of claims 1 to 5, wherein R5is selected from436335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-2048335853366 CENC-015 / 01WO 360899-20487. The compound of any one of claims 1 to 6, wherein Ring A is phenyl.

8. The compound of any one of claims 1 to 7, wherein R1is selected from propyl, methyl,benzyl,9. The compound of any one of claims 1 to 8, wherein R2is ethyl.

10. The compound of any one of claims 1 to 9, wherein R3is selected from Cl, F or -CF3.440335853366 CENC-015 / 01WO 360899-204811. The compound of any one of claims 1 to 10, wherein R4is selected fromcyclopropyl and phenyl.

12. The compound of any one of claims 1 to 11, wherein R6is hydrogen.

13. The compound of any one of claims 1 to 12, wherein R7is F.

14. The compound of any one of claims 1 to 6, wherein the compound is of Formula Ila, Formula lib, Formula lie or Formula lid:lie lidor a pharmaceutically acceptable salt thereof.

15. The compound of any one of claims 1 to 6, wherein the compound is of Formula Illa, Formula Illb, Formula IIIc or Formula Hid:441335853366 CENC-015 / 01WO 360899-2048IIIc Hidor a pharmaceutically acceptable salt thereof.

16. The compound of any one of claims 1 to 6, wherein the compound is of Formula IVa.Formula IVb, Formula IVc or Formula IVd:IVc IVdor a pharmaceutically acceptable salt thereof.442335853366 CENC-015 / 01WO 360899-204817. The compound of any one of claims 1 to 6, wherein the compound is of Formula Va, Formula Vb, Formula Vc or Formula Vd:or a pharmaceutically acceptable salt thereof.

18. The compound of any one of claims 1 to 6, wherein the compound is of Formula Via,or a pharmaceutically acceptable salt thereof.443335853366 CENC-015 / 01WO 360899-204819. The compound of any one of claims 1 to 6, wherein the compound is of Formula Vila, Formula Vllb, Formula Vile or Formula Vlld:or a pharmaceutically acceptable salt thereof.

20. The compound of any one of claims 1 to 6, wherein the compound is of Formula Villa, Formula VUIb, Formula VIIIc or Formula VUId:VIIIc VUIdor a pharmaceutically acceptable salt thereof.444335853366 CENC-015 / 01WO 360899-204821. A compound selected from one of those shown in Table 1, or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising the compound of any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

23. A method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof the compound of any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof.

24. The method of claim 23, wherein the hemoglobinopathy is a sickle cell disorder or disease.

25. The method of claim 23, wherein the hemoglobinopathy is a thalassemia disorder or disease.

26. A method of modulating the activity of DCN-1 and / or DCN-2, comprising the step of contacting DCN-1 and / or DCN-2 with the compound of any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof.445335853366 CENC-015 / 01WO 360899-2048